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ABSTRACT 
Introduction 
Coronary	 blood	 flow	 (CBF)	 is	 principally	 controlled	 by	 changes	 in	 coronary	vascular	resistance	(CVR).	Low	CVR	helps	to	maintain	myocardial	perfusion	in	the	presence	of	epicardial	stenosis,	therefore	factors	that	impair	the	reduction	of	CVR	will	have	a	direct	effect	on	CBF	leading	to	either	a	narrower	“effective”	perfusion	pressure	 range	 or	 reduced	 ability	 to	 compensate	 for	 increased	 demand	 on	myocardial	contraction.	There	are	several	mechanisms	which	may	be	important	in	the	control	CVR	in	humans	including	both	endothelial	dependent	production	of	NO	and	reduction	of	the	simple	anion	inorganic	nitrite	(a	metabolite	of	NO)	back	to	NO	(via	several	putative	mechanisms).	The	synthesis	of	NO	by	both	nitric	oxide	synthase	(NOS)	and	the	reduction	of	nitrite	in	the	coronary	circulation	has	been	the	 subject	 of	 many	 animal	 and	 human	 clinical	 studies.	 Reduced	 systemic	endothelial	 dependent	 production	 of	 NO	 has	 an	 association	 with	 worse	cardiovascular	 outcomes	 in	 humans,	 the	 number	 of	 potential	 mechanisms	 are	large	and	perhaps	central	is	the	effect	on	CVR.	The	reduction	of	nitrite	to	NO	is	seen,	in	some	ways,	to	be	the	perfect	compensatory	mechanism,	particularly	when	endothelial	function	is	impaired.	It	is	easy	to	hypothesise	that	this	stoichiometric	balance	of	NO	production	might	be	responsible	for	the	perfect	regulation	of	CVR	and	thus	CBF.		
Methods 
This	thesis	investigates	the	influence	and	effect	of	both	endothelial	production	of	NO	and	the	reduction	of	nitrite	to	NO	on	CVR	in	man.		
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First,	an	observational	study	assessing	the	impact	of	these	mechanisms	in	patients	undergoing	percutaneous	coronary	 intervention	(PCI),	 in	 the	treatment	of	both	non-ST-elevation	 myocardial	 infarction	 and	 stable	 angina.	 Specifically,	 the	metabolites	of	NO	were	measured	from	aortic	root	to	coronary	sinus	together	with	the	associated	CVR	both	before	and	after	PCI.	
Second,	using	a	systemic	infusion	of	sodium	nitrite	(NaNO2)	in	NSTEMI	patients	to	assess	 the	 effect	 of	 nitrite	 reduction	 on	 CVR	 during	 PCI.	 The	 systemic	 nitrite	concentration	was	 increased	8-fold	 in	 the	 same	experimental	 conditions	as	 the	observational	study.		
Third,	beyond	CVR	control	the	influence	of	NO	and	nitrite	was	also	assessed	in	terms	of	platelet	reactivity	and	systemic	inflammatory	cytokines	in	the	NSTEMI	cohort	both	with	and	without	NaNO2	infusion.	
Results  
NSTEMI	 patients	 have	 a	 net	 increase	 in	 NO	 metabolites	 across	 the	 coronary	circulation	 unlike	 healthy	 controls	 (historical	data)	 and	 stable	 angina	 patients.	This	net	increase	is	lost	following	PCI	and	is	associated	with	a	significant	rise	in	CVR.	 Stable	 angina	 patients	 appear	 to	 compensate	 with	 increase	 collateral	circulation	and	not	NO	synthesis.	An	8-fold	increase	in	nitrite	concentration	has	no	effect	on	CVR	or	platelet	reactivity	in	NSTEMI	patients.	
Conclusions 
In	 NSTEMI	 patients	 a	 net	 aorta	 to	 coronary	 sinus	 NO	 synthesis	 appears	 to	 be	important	 to	 maintain	 a	 low	 CVR	 and	 thus	 CBF	 when	 haemodynamically	significant	epicardial	disease	is	present.	After	the	epicardial	disease	is	treated	this	
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net	 increase	 in	NOx	(Nitric	Oxide	metabolites),	 is	lost	and	 is	associated	with	an	acute	increase	in	CVR.	Stable	angina	patients	have	no	net	increase	in	NOx	across	the	coronary	circulation	and	after	revascularisation	have	no	change	in	CVR,	this	may	reflect	an	alternate	mechanism	of	compensation	and	microvascular	perfusion	maintained	by	 collateral	 circulation	as	evident	by	 the	 increase	CFI.	Despite	 the	perfect	environment	for	the	reduction	of	nitrite	to	NO	we	saw	no	influence	of	an	8-fold	 increase	 in	 serum	nitrite	 concentration	on	CVR	 in	patients	with	NSTEMI	either	before	or	after	PCI,	suggesting	that	nitrite	reduction	to	NO	plays	no	role	in	CBF	regulation	in	NSTEMI	patients.	Nitrite	reduction	depends	on	conditions	that	are	 found	predominantly	 in	 the	 capillary	 bed	 or	 venules,	 thus	 any	mechanism	would	 need	 to	 rely	 on	 a	 feedback	 mechanism	 to	 signal	 back	 to	 the	 arterioles	(where	much	of	resistance	change	is	created).	Despite	hypotheses	by	others	that	this	may	occur	by	the	close	arrangement	of	venules	to	arterioles,	this	appears	not	to	 be	 the	 case	 in	 NSTEMI	 patients.	 Other	 clinically	 relevant	 and	 important	mechanisms	also	appear	to	be	unaffected	by	this	increase	in	serum	nitrite,	residual	platelet	function	and	cytokine	concentrations	at	24	hours.	
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P	Percutaneous	Coronary	Intervention	(PCI)	Platelet	Function	Testing	(PFT)	Potassium	Hexacyanoferrate	(K3Fe3+(CN)6)	Protein	Kinase	A	(PKA)	Proximal	Coronary	Pressure	(Pa)	P-Selectin	Glycoprotein	Ligand-1	(PSGL-1)		
R	Reactive	Oxygen	Species	(ROS),	Red	Blood	Cells	(RBC)	
S	S-Nitrosohaemoglobin	(Hbsno)	S-Nitrosohaemoglobin	(Snohb)	Sodium	Hydroxide	(NaOH	ST	Elevation	Myocardial	Infarction	(STEMI)	Stable	Angina	(SA)	Strain	Gauge	Plethysmography	(SGP)	Superoxide	Dismutase	Group	of	Enzymes	(SOD)	
T	Thrombin	Receptor	Activating	Peptide	(TRAP)	Thrombin	Receptor	Activating	Peptide	6	(TRAP-6)	Thromboxane	A2		(TXA2)	Tumour	Necrosis	Factor	(TNF)	
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Transforming	Growth	Factor	Β	(TGF-Β)	Transit	Time	At	Rest	(Tm	Rest)		
	
V	Vanadium	III	Chloride	(VCl3).	Voltage	Dependent	Calcium	Channels	(VDCC)	Von	Willibrand	Factor	(VwF)	 	
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Chapter 1: General introduction 
Autoregulation of coronary blood flow in health and disease 
The	 coronary	 circulation	 is	 unique	 in	 that	 it	 perfuses	 the	 organ	 that	 creates	systemic	perfusion	pressure.	Physiological,	pathological	and	other	interventions	that	 alter	 the	 heart	 and/or	 systemic	 circulation	 effect	 coronary	 blood	 flow	 by	altering	 the	 metabolic	 demands	 placed	 on	 the	 heart.	 1	 The	 mechanisms	 that	control	 coronary	 blood	 flow	 are	 complex	 and	 multifaceted,	 another	 layer	 of	complexity	 is	 achieved	 when	 we	 study	 these	 mechanisms	 in	 different	physiological	and	pathological	states.	As	conditions	change,	so	does	the	emphasis	or	influence	of	any	one	mechanism	of	coronary	blood	flow	control.			
	
Even	in	the	21st	century	where	we	can	influence	coronary	disease	with	a	multitude	of	pharmacological	and	interventional	treatments,	relatively	little	is	known	about	the	basic	mechanisms	of	coronary	blood	flow	control	in	human	pathological	states.	
	
This	thesis	focuses	on	one	aspect	of	coronary	blood	flow	and	its	influence	in	the	context	of	two	disease	states	(stable	angina	and	acute	coronary	syndrome).	
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Oxygen extraction, perfusion pressure and coronary vascular resistance: 
influence on coronary blood flow 
Oxygen extraction 
The	heart	primarily	depends	on	aerobic	metabolism	for	production	of	adenosine	triphosphate	 (ATP)	 and	 its	 ongoing	 heavy	 demands	 for	 continued	 function	throughout	life.	Under	resting	conditions	the	heart	can	extract	as	much	as	70	to	80%	of	the	oxygen	delivered	to	it	by	the	coronary	circulation,	compared	with	30	to	40%	in	skeletal	muscle.	Overall	oxygen	consumption	per	gram	of	tissue	is	20	fold	higher	than	skeletal	muscle.	1,2	
	
This	 highly	 efficient	 oxygen	 extraction	 is	 made	 possible	 by	 a	 high	 capillary	network	density	in	comparison	to	skeletal	muscle	(3000	to	4000	capillaries/mm2	vs.	 600-1000	 capillaries/mm2	 respectively).	 3,4	 Unsurprisingly	 because	 of	 the	almost	maximal	oxygen	 extraction	 at	 rest	 there	 is	 almost	 no	 change	 in	 oxygen	extraction	during	light	exercise	in	humans	5	and	a	tendency	towards	only	slightly	increased	extraction	during	moderate	to	heavy	exercise.	6,7	This	almost	maximal	oxygen	extraction	makes	 the	heart	 almost	 completely	dependent	on	 increasing	coronary	blood	flow	(CBF)	during	exercise.	This	 increase	 in	CBF	is	seen	 in-vivo	with	 four	to	 five-fold	and	above	 increases	 in	 flow	during	heavy	exercise	(mean	flow	of	280	ml	280	ml.min-1.100g-1	).	1,8,9	
Myocardial perfusion pressure  
The	gradient	of	pressure	across	the	coronary	bed	(perfusion	pressure),	together	with	the	total	coronary	vascular	resistance,	governs	CBF.	However,	because	the	
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coronary	bed	 is	 embedded	 in	 the	 contracting	myocardium	 the	 simple	aortic	 to	venous	pressure	drop	does	not	equate	to	effective	perfusion	pressure.	1	Because	of	 myocardial	 contraction	 in	 systole	 the	 majority	 of	 epicardial	 coronary	 flow	occurs	 during	 diastole.	 The	 aortic	 pressure	 -	 and	 thus	 the	 radial	 pressure	generated	by	myocardial	contraction	–	govern	diastolic	pressure	gradients	across	the	myocardium.	 This	 diastolic	pressure	 (or	 backflow	pressure)	 is	higher	 than	right	atrial	pressure	and	is	commonly	referred	to	as	the	zero	flow	pressure	(Pf=0).	During	exercise,	healthy	dogs	have	been	shown	to	increase	both	their	aortic	inflow	pressure	and	effective	zero	flow	pressure	(which	opposes	coronary	flow)	by	10-20mmHg.	 10	 This	 suggest	 that	 during	 exercise	 the	 effective	 perfusion	 pressure	gradient	does	not	change	and	thus	any	increase	in	CBF	must	be	proportional	to	a	reduction	in	coronary	vascular	resistance	(CVR).	
	
Canty	et	al	11	showed	that	in	awake	dogs	CBF	remains	remarkably	constant	over	a	range	of	perfusion	pressure	(the	auto-regulatory	range),	below	the	lower	limit	of	this	 range	 (~	40mmHg)	CBF	would	drop	 rapidly	with	very	 small	reductions	 in	perfusion	 pressure	 down	 to	 no	 flow	once	 the	 zero	 flow	 pressure	was	 reached	(Pf=0).		The	lower	limit	of	this	auto-regulatory	perfusion	pressure	is	raised	by	a	number	 of	 factors	 that	 change	 oxygen	 extraction	 requirements.	 These	 factors	would	 include	 increased	 heart	 rate	 (and	 decreased	 diastolic	 pressure	 time),	Increase	systolic	blood	pressure	leading	to	increased	contractility	and	radial	wall	stress;	or	reductions	in	oxygen	supply	such	as	anaemia	and	hypoxia.	12,13	These	increases	in	oxygen	demand	or	decreases	in	oxygen	delivery	increase	resting	flow	and	 thus	 raise	 the	 lower	 limit	 of	 the	 auto-regulatory	 perfusion	 range;	 this	
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translates	into	ischaemia	at	higher	perfusion	pressures.	(Figure	1:	Autorgulation	of	coronary	blood	flow	-	relationship	between	coronary	pressure	and	resistance)	
	
Figure 1: Autorgulation of coronary blood flow - relationship between coronary pressure and resistance 
Autoregulation of CBF in terms of perfusion pressure and coronary vascular resistance at rest (left panel) 
and stress (right panel). Red lines correspond to CBF (y-axis) and describe its relationship to coronary 
pressure (x –axis) being constant when in the autoregulatory range. The blue line represents maximal 
vasodilation (or lowest CVR). At rest when the coronary pressure drops below its lower autoregulatory 
limit CVR is at its lowest and coronary flow drops rapidly, this would lead to ischaemia. During stress 
(increased HR, increased systolic BP, increased contractility, increased oxygen demand) the lower 
pressure limit of the autoregulatory range increases (here to 60mmHg as an example), thus CBF falls at 
high pressures. This may be further compounded by factors that reduce the ability of the 
microvasculature to maximally dilate ( LVH, microvascular disease, increased preload / Pf=0).  Reprinted 
from Canty and Duncker with permission, Coronary blood flow and myocardial ischaemia In: Bonow RO, 
Mann DL, Zipes DP, Libby P, eds. Braunwald’s Heart Disease. 10th ed. Philadelphia: Elsevier 2014 	
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Coronary Vascular Resistance (CVR) 
We	have	now	identified	CVR	as	 the	principal	determinant	of	auto-regulation	of	CBF.	Whilst	 the	 principal	 component	 of	 CVR	 relates	 to	 vascular	 tone	 there	 are	other	determinants	of	CVR.	These	include	the	compressive	forces	of	the	cardiac	cycle	as	well	as	the	anatomy	and	distribution	of	subepicardial	and	subendocardial	vessels.	 These	 compressive	 and	 anatomical	 features	 have	 been	 described	extensively	14-17	For	the	purposes	of	this	thesis	I	will	focus	on	vascular	tone	and	its	control	 and	 effect	 on	 CVR	 and	 thus	 CBF	 regulation	 as	 this	 is	 the	 dominant	mechanism,	18	in	this	context	the	thesis	is	focused	on	the	control	mechanisms	of	CVR	with	emphasis	on	nitric	oxide	(NO).	
	
Along	the	course	of	the	epicardial	coronary	artery	there	is	very	little	pressure	drop	in	 the	healthy	heart,	 indicating	negligible	 resistance	 in	 this	 conduit	vessel.	The	dominant	pressure	drop	in	the	coronary	vessels	occurs	in	those	arteriolar	vessels	between	50	to	200μm	in	diameter,	hence	the	term	resistance	vessels	19	There	is	very	 little	 contribution	 from	 capillaries	 and	 coronary	 venules	 to	 CVR,	 indeed	resistance	across	these	structures	remains	constant	during	changes	in	pressure,	flow	 and	 metabolic	 demands.	 20	 (Figure	 2:	 Distribution	 of	 coronary	 vascular	resistance)	
	 29	
	
Figure 2: Distribution of coronary vascular resistance 
Schematic representation of the distribution of coronary vascular resistance and a representation of the 
mechanisms that likely contribute to control of resistance in successive segments of the coronary 
vascular tree. Outlining the complex interaction of different factors controlling CVR. With permission21 	
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The effect of epicardial coronary stenosis 
Prior	 to	 an	 in-depth	 description	 of	 the	 mechanisms	 of	 control	 of	 CVR	 it	 is	important	to	clarify	and	understand	the	effect	of	an	epicardial	stenosis	on	CVR	and	ultimately	CBF.	Unlike	 the	 subepicardial	 vessels	 the	 subendocardial	 vessels	 are	exposed	 disproportionately	 to	 the	 extravascular	 tissue	 pressures	 caused	 by	ventricular	 contraction.	 Minimal	 microvascular	 resistance	 is	 lower	 in	 the	subendocardial	 vessels	 and	 this	 goes	 some	 way	 in	 compensating	 for	 the	susceptibility	 of	 the	 subendocardial	 layer	 to	 ischaemia.	 22	 When	 the	autoregulatory	 mechanisms	 of	 CBF	 are	 intact	 flow	 is	 uniform	 across	 the	myocardium,	however,	with	progressive	narrowing	of	an	epicardial	coronary	the	distal	coronary	pressure	(Pd)	progressively	reduces.	In	response	to	increasingly	severe	stenosis	the	resistance	vessels	will	dilate	and	“auto-regulate”	CBF	through	the	myocardium.	This	compensation	holds	until	Pd	drops	below	the	lower	limit	of	the	auto-regulatory	range	(equating	to	the	exhaustion	of	the	vasodilatory	capacity	of	the	resistance	vessels	and	set	by	both	mechanical	and	metabolic	demands).	As	soon	as	Pd	drops	below	this	lower	auto-regulatory	threshold	CBF	drops	sharply	and	delivery	of	oxygen	is	not	adequate	for	the	myocardial	bed,	11,23,24	the	extrinsic	forces	on	the	subendocardial	layers	of	the	heart	will	lead	to	ischaemia	developing	here	first.25	
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Mechanisms of CVR control: feedback, feedforward, metabolic and non-
metabolic 
Feedback vs feedforward control of CVR 
Many	 decades	 have	 passed	 in	 the	 search	 for	 a	 principal	 signal	 that	 regulates	coronary	 blood	 flow.	 More	 than	 40%	 of	 the	 total	 CVR,	 20,26	 is	 generated	 in	arterioles,	 	 (diameter	 of	 50-200	 μm).	 If	 we	 assume	 the	 majority	 of	 oxygen	delivered	occurs	at	 the	 systemic	 capillary	bed,	 in	any	 feedback	mechanism	 the	control	of	the	resistance	vessels	must	occur	independent	of	direct	oxygen	tension	unless	a	mechanism	exists	utilising	the	close	proximity	of	post-capillary	venules	to	pre-capillary	arterioles.	27	
Indirect	action	of	oxygen	in	feedback	models	has	also	been	proposed	the	principal	model	 being	 the	 adenine	 nucleotide	 model,	 Pradhan	 et	 al	 28	 suggest	 that	haemoglobin	 derived	 ATP	 acts	 on	 purinergic	 receptors	 and	 causes	 upstream	(feedback)	signaling	via	endothelial	gap-junctions	to	release	NO.	Nitrite	is	seen	by	many	 as	 the	 ultimate	 feedback	 molecule	 in	 the	 control	 of	 CVR	 and	 thus	 CBF.	Produced	by	oxidation	of	NO	nitrite	can	also	be	reduced	back	to	NO	under	optimal	conditions	of	low	PO2	and	pH,	29	and	again	assuming	low	pH	and	PO2	will	occur	principally	at	the	point	of	oxygen	delivery	(capillaries)	the	requirement	of	close	proximity	of	venous	to	resistance	arteriole	is	required.		
Subsequently,	the	notion	of	feed-forward	mechanisms	in	the	control	of	CBF	has	emerged.	 Whilst	 feedback	 mechanisms	 rely	 on	 an	 error	 signal	 based	 around	oxygen	consumption	(not	easily	seen	 in	the	cardiac	circulation),	a	 feed-forward	signal	 doesn’t	 need	 a	 local	 oxygen	 error	 signal.	 Rather	 a	metabolite	 produced	
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secondary	to	systemic	oxygen	utilisation	would	(See	ROS	and	H2O2	section	below	page	37),	control	CVR	and	thus	CBF	direct.	This	means	there	is	no	requirement	for	oxygen	mismatch	to	demand.		
	
Feed-forward	 control	 may	 also	 be	 orchestrated	 by	 sensing	 key	 hemodynamic	forces	such	as	shear	stress	(NOS	upregulation)	and	intramural	pressure	changes	(myogenic	control).	20	Oxygen	should	also	not	be	excluded	from	a	 feed-forward	model.	Systemic	and	myocardial	delivery	of	oxygen	to	tissues	is	a	complex	subject	with	some	evidence	that	this	may	occur	to	a	significant	degree	at	the	pre-capillary	arterioles	(resistance	vessels).	However,	this	principally	occurs	in	skeletal	muscle	and	there	is	no	experimental	evidence	of	this	occurring	in	the	mammalian	heart	microcirculation.	30	
	
Below	 each	 of	 the	 major	 potential	 mechanisms	 proposed	 to	 regulate	 CVR	 are	described	 in	 more	 detail.	 These	 are	 the	 major	 examples	 of	 feedforward	 and	feedback	control	systems	and	are	categorised	as	metabolic	or	non-metabolic.	
	
Metabolic control of CVR 
Under	 physiological	 conditions	 CBF	 is	 adjusted	 to	meet	 oxygen	 demand	 in	 an	organ	that	is	extremely	efficient	at	oxygen	extraction	even	at	rest.	The	regulation	of	flow	is	so	tightly	coordinated	that	coronary	venous	pO2	does	not	stray	far	away	from	20mmHg	regardless	of	the	severity	of	exercise.	2		
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Feed-forward	 control	 of	 CVR	 may	 occur	 by	 a	 multitude	 of	 mechanisms;	 from	factors	that	reflect	systemic	oxidative	metabolism	to	localised	changes	in	coronary	flow	velocity	(shear	stress).	Whilst	 it’s	 tempting	to	consider	only	one	signal	 for	control	 of	 CVR	 it’s	 clear	 that	 there	 are	 a	 number	 of	 control	 mechanisms	 that	orchestrate	this	fine-tuned	system.		
	
Oxygen and carbon dioxide 
The	 first	 obvious	 markers	 of	 systemic	 oxidative	 metabolism	 are	 oxygen	 and	carbon	dioxide,	which	have	long	been	proposed	as	the	principal	determinants	of	CVR.	Both	arterial	hypoxia	and	hypercapnia	produce	coronary	vasodilation.	1,31	Broten	 et	 al	 31	 showed	 a	 synergistic	 effect	 of	 both	 hypoxia	 and	 hypercapnia	occurring	simultaneously	with	each	molecule	potentiating	 the	other	beyond	an	additive	affect.	However,	in	vivo	changes	in	these	gases	in	the	arterial	phase	could	only	predict	a	small	component	of	the	change	in	CBF	seen	during	pacing	and	an	even	smaller	part	during	autoregulation,	32	suggesting	that	these	molecules	do	not	exert	a	dominant	role	as	a	feed-forward	mechanism.	
	
Both	lung	and	tissue	capillaries	have	an	enormous	surface	area	and	it	is	this	fact	that	leads	many	to	the	conclusion	that	these	two	networks	are	the	“mirror	images”	of	 each	 other.	 It	 is	 intuitive	 to	 come	 to	 the	 conclusion	 that	 tissue	 (systemic)	capillaries	 yield	 the	oxygen	 absorbed	 by	 the	 lung	 in	 a	 final	 pathway	 of	oxygen	delivery	 to	 the	 tissues.	 33	 This	 process	 became	 a	 fundamental	 principal	 in	physiology	 following	the	work	of	Krogh	and	Erlangen	 in	developing	the	“Krogh	cylinder	model”	in	1918.	34	The	work	describes	a	mathematical	model	of	oxygen	
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delivery	 to	 skeletal	 muscle	 by	 an	 array	 of	 capillaries	 to	 a	 surrounding	 tissue	cylinder.	At	the	time	of	this	work	there	was	no	method	enabling	the	measurement	of	oxygen	levels	in	microcirculatory	vessels,	therefore	the	model	assumed	that	all	oxygen	exchange	at	the	tissue	level	takes	place	in	the	capillary.	By	the	1970s	this	assumption	 was	 being	 questioned,	 Duling	 &	 Berne	 using	 new	 (for	 that	 time)	techniques	with	micro-oxygen	cathodes	found	that	significant	longitudinal	oxygen	gradients	 occurred	 in	 arterioles	 of	 80	 to	 150	 μm	 in	 diameter	 to	 the	 terminal	arterioles	(42	±	3	to	21	±	3	mmHg).	35	These	observations	were	confirmed	by	a	multitude	of	investigators	using	a	large	array	of	evolving	techniques.	36-38		
	
The	release	of	oxygen	to	-	and	its	consumption	by	-	the	tissues	is	clearly	highly	complex,	changing	 in	different	 tissues	with	widely	different	characteristics.	The	reality	 is	 that	 these	numerous	studies	have	multiple	methodological	difficulties	and	their	interpretation	is	often	complex.	38	Suffice	to	say	that	the	assumption	that	all	oxygen	delivery	occurs	at	the	systemic	capillary	network	(after	the	resistance	arterioles)	is	by	no	means	without	debate;	thus	we	should	not	assume	that	oxygen	tension	has	no	role	as	a	feed-forward	mechanism	in	CVR	control.	
	
Adenine nucleotide / purinergic receptor control of CBF 
In	areas	of	increased	oxygen	demand	(low	PO2	tension),	adenosine	triphosphate	(ATP)	 is	 released	 from	 red	 blood	 cells	 (RBC).	 The	 adenine	 nucleotide	 model	(Figure	3:	Adenine	nucleotide	hypothesis	of	coronary	vascular	resistance	control),	postulates	 that	ATP	and	 its	breakdown	products	adenosine	diphosphate	 (ADP)	and	 adenosine	 monophosphate	 (AMP),	 act	 on	 purinergic	 receptors	 on	 the	
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myocardial	capillary	endothelium.	Via	gap	junctions	this	signal	is	conducted	in	a	retrograde	manner	to	 the	arteriolar	endothelial	cells	where	nitric	oxide	(NO)	is	generated	via	nitric	oxide	 synthetase	 (NOS)	and	 thus	 smooth	muscle	mediated	dilation	®	 reduced	 CVR®	 increased	 coronary	 blood	 flow	 occurs.	 39	 Extensive	evidence	supports	the	release	of	ATP	from	erythrocytes	in	response	to	reduced	oxygen	tension.	40-42	Further	research	has	suggested	a	defined	second	messenger	signaling	 cascade	 controlling	 this	 mechanism	 via	 G-protein	 –	 cAMP	 –	 Protein	kinase	 A	 (PKA)	 pathway	 that	 so	 far	 has	 stopped	 short	 of	 identifying	 a	transmembrane	protein	 that	 releases	ATP.	 39.	 	Beyond	ATP	release	by	RBC	 the	interaction	of	ATP	-	and	its	breakdown	products	ADP	and	AMP	–	with	capillary	endothelial	purinergic	receptors	has	principally	been	studied	in	rodent	cerebral	microcirculation	 in	which	ATP	 (and	 to	a	 lesser	extent	ADP)	 is	 a	 ligand	 to	P2Y1	receptor	on	the	capillary	endothelium	causing	dose	dependent	vasodilation.	In	a	dose	 dependent	 response	 AMP	 is	 also	 a	 ligand	 to	 P1	 receptors	 resulting	 in	vasodilation.	 43,44	 The	 steps	 involved	 in	 gap	 junction	 conduction	 (presumably	hyperpolarizing	factor),	45	and	the	link	to	arteriolar	endothelial	NOS	stimulation	and	NO	release	are	hypothesized	steps	only.		39		
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Figure 3: Adenine nucleotide hypothesis of coronary vascular resistance control 
In myocardial capillaries ATP is released from RBC in areas of high oxygen demand (low PO2 tension), 
this is facilitated by deoxy-haemoglobin. ATP (and its breakdown product ADP) stimulate endothelial 
P2Y1 receptors and AMP also acts via P1 receptor to generate a retrograde signal via gap junctions 
resulting in NO release from the arteriolar endothelium and smooth muscle vasodilation. Abbreviations 
ATP: Adenosine triphosphate, ADP: Adenosine monophosphate, AMP: adenosine monophosphate, HbO2 
oxy-haemoglobin, Hb: desoxy-haemoglobin, NO: nitric oxide. With permission 46 	
Gorman	 et	 al	 tested	 the	 adenine	 /	 purinergic	 model	 in	 a	 canine	 closed	 chest	coronary	 perfusion	 model.	 46	 Using	 P2Y1,	 P1,	 and	 NOS	 inhibitors	 they	 found	 a	stepwise	 depression	 of	 the	 balance	 between	 oxygen	 delivery	 and	 myocardial	oxygen	consumption,	lower	oxygen	tensions	were	required	to	create	equivalent	vasodilation	as	seen	in	baseline	/	control	conditions.		
	
The	adenine	nucleotide	/	purinergic	model	hypothesizes	an	alternate	explanation	for	retrograde	conduction	of	metabolic	signals	back	to	the	resistance	arterioles,	and	thus	a	mechanism	by	which	CBF	regulation	can	occur	in	a	feedback	system.	In	this	model	we	also	have	a	link	between	oxygen	tension	and	the	regulation	of	NOS	as	well	as	 the	standard	shear	stress	model	of	NOS	upregulation.	47	However,	 in	terms	of	basic	mechanistic	science	we	are	some	way	from	joining	the	dots	in	this	system,	even	the	basics	of	ATP	release	from	RBC,	transduction	cascade	across	the	
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capillary	epithelium,	and	gap	junction	retrograde	conduction	are	some	way	from	being	 fully	 understood	 or	 proven.	 Whilst	 Gorman	 et	 al	 went	 some	 way	 in	highlighting	the	role	of	ATP	in	a	canine	model	again	this	is	just	an	indication	of	mechanism	and	does	not	prove	a	causative	link,	particularly	when	trying	to	pick	apart	the	interaction	between	purinergic	receptor	signaling	and	NOS	stimulation.	No	experiment	was	performed	with	NOS	inhibition	blocking	purinergic	receptor	stimulation.		
	
Reactive oxygen species and hydrogen peroxide 
A	vasodilatory	signal	through	reactive	oxygen	species	(ROS),	and	-	in	particular	-hydrogen	peroxide	(H2O2),	has	long	been	proposed	as	a	feed-forward	mechanism	of	 CBF.	 Increased	 myocyte	 contraction	 would	 lead	 to	 greater	 mitochondrial	electron	 transport	 train	 (ETC)	 activity	 and	 resultant	 production	 of	 superoxide	radical	(O2-)	and	conversion	to	H2O2	by	superoxide	dismutase	group	of	enzymes	(SOD).	H2O2	itself	was	identified	as	an	endothelium	derived	hyperpolarising	factor	in	 an	 ex-vivo	 model	 using	 human	 coronary	 arterioles.	 48	 H2O2	 is	 capable	 of	diffusion	 into	 smooth	 muscle	 in	 coronary	 resistance	 vessels	 leading	 to	vasodilation	and	directly	linking	metabolic	rate	to	oxygen	delivery	(CBF).	Yada	et	al	49	 	demonstrated	that	H2O2	in	cooperation	with	NO	and	adenosine	played	an	important	 role	 in	 CBF	 autoregulation	 in	 the	 context	 of	 reducing	 coronary	perfusion	 pressure.	 These	 elegant	 in-vivo	 canine	 experiments	 assessed	 the	Acetylcholine	 induced	 vasodilation	 of	 coronary	 arterioles	 in	 controls,	 NOS	inhibition	 with	 NG-Monomethyl-L-Arginine	 (L-NMMA)	 and	 finally	 with	 NOS	inhibition	plus	catalase	(selectively	dismutases	H2O2)	all	receiving	 ibuprofen	to	
	 38	
inhibit	 cyclooxygenase.	 NOS	 inhibition	 significantly	 attenuated	 vasodilation	 of	large	 arterioles	 (≥100μm),	 with	 further	 attenuation	 once	 catalase	 was	 added.	Medium	and	small	arterioles	(<100μm)	were	relatively	resistant	to	NOS	inhibition	but	markedly	attenuated	by	catalase.	
	
α and β mediated CVR control 
Whilst	sympathetically	mediated	α	and	β	mediated	coronary	blood	flow	changes	are	not	strictly	metabolic	the	activation	of	the	sympathetic	system	increases	heart	rate	 and	 contractility	 resulting	 in	 increased	 (metabolic)	 CBF.	Whilst	 the	 direct	dilating	effect	β	adrenoreceptor	activation	 can	be	 seen	on	 isolated	microvessel	
50,51	 it	 is	much	more	difficult	 to	understand	 the	 role	 in	vivo	during	exercise	or	ischaemia.	 This	 is	 because	 the	 large	 effect	 on	 local	metabolic	 increases	 in	 CBF	makes	studying	the	direct	affect	β	and	certainly	α	adrenoreceptor	activation	on	CBF	challenging.	Duncker	et	al	52	using	a	porcine	treadmill	model	attempted	to	demonstrate	 the	 impact	 of	 	β	 adrenoreceptor	activation	 in	 a	 complex	 series	 of	experiments	that	used	the	alternate	blockade	of	α	and	β	adrenoreceptors.	Later	Gorman	 et	 al	 53	 repeated	 the	 experiments	 in	 dogs	 with	 the	 addition	 of	compensation	 for	 the	 enhanced	 α	 activity	 when	 the	 β	 receptors	 are	 blocked,	finding	that	β-adrenoreceptor	stimulation	by	norepinephrine	can	account	for	up	to	25%	of	the	reduction	in	CVR	during	exercise.	
	
α-adrenoreceptor	 stimulation	 occurs	 simultaneously	 during	 sympathetic	stimulation	and	vasoconstricts	vessels		>100	μm	in	size,	54	whilst	these	two	actions	seem	at	odds	its	clear	that	constriction	of	these	up	stream	larger	vessels	together	
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with	dilation	by	β-adrenoreceptor	of	the	<100	μm	vessels	will	result	in	an	overall	decrease	in	CVR	and	an	increase	in	CBF.	
The	function	of	α	and	β	adrenoreceptor	during	exercise	of	the	healthy	heart	is	well	described.	Much	less	data	exists	in	humans	with	coronary	atherosclerosis,	Hansen	et	al	6	demonstrated	that	 the	myocardial	upregulation	of	noradrenaline	release	was	 preserved	 (aortic	 to	 coronary	 sinus)	 during	 exercise	 in	 patients	 with	significant	stable	coronary	atherosclerosis.	
	
Localised metabolic regulation of CVR, Adenosine 
Proposed	independently	by	Berne	et	al	55	and	Gerlach	et	al	56	as	a	molecule	that	is	released	by	cardiomyocytes	during	times	of	increased	oxygen	consumption	and	thus	 reduced	myocardial	 oxygen	 tension.	 This	mechanism	would	 allow	 for	 the	reduction	in	CVR	and	the	increase	in	CBF	allowing	myocardial	oxygen	to	remain	within	 a	 physiological	 range.	 57Later	 experimentation	 led	 to	 a	 confusing	 set	 of	studies	 supporting	 58,59	 and	 refuting	 60,61	 the	 hypothesis.	 One	 fundamental	observation	indicated	that	adenosine	might	not	be	central	to	the	maintenance	of	myocardial	oxygen	tension;	blockade	of	endogenous	adenosine	receptors	did	not	decrease	coronary	flow	during	increased	oxygen	consumption.	62,63This	led	Tune	et	 al	 60	 to	 carefully	 measure	 coronary	 sinus	 adenosine	 and	 derive	 interstitial	adenosine	 before	 and	 after	 adenosine	 receptor	 blockade,	 confirming	 that	adenosine	 concentration	 changed	 little	 with	 exercise	 and	 remained	 under	 the	threshold	 for	 causing	 localised	 metabolic	 vasodilation	 both	 with	 and	 without	adenosine	receptor	blockade.	
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Adenosine, localised metabolic regulation of CVR during ischaemia 
Whilst	there	is	little	contribution	of	adenosine	in	physiological	regulation	of	CBF,	during	ischaemia	the	adenosine	question	resurfaces.64	If	changes	in	CVR	and	thus	CBF	are	enough	to	compensate	for	epicardial	coronary	disease	without	ischaemia	adenosine	release	is	not	augmented.	However,	when	myocytes	become	ischaemic	they	will	release	adenosine	in	an	attempt	to	augment	CBF	and	oxygen	delivery.	
	
Adenosine	has	also	been	implicated	in	a	number	of	other	protective	mechanisms	including	the	down	regulation	of	myocardial	contractility,65,66	myocardial	pre	and	per-conditioning	,67,68	inhibition	of	platelet	aggregation	69,70	as	well	as	a	myriad	of	other	 proposed	 functions.	 However,	 the	 positive	 impact	 of	 adenosine	within	 a	clinical	 setting	has	been	as	unclear	as	 its	proposed	ubiquitous	 function	shortly	after	its	discovery		
 
Other potential localised metabolic regulators of CVR 
Beyond	the	proposed	headlining	metabolic	mechanisms	of	CVR	regulation	there	are	a	long	list	of	molecules	and	mechanisms	all	of	which	have	their	own	body	of	publications	 behind	 them.	 Prostaglandins,	 71,72	 KATP	 channels,73,74	 endothelium	derived	 hyperpolarising	 factor	 (EDHF),	 59,75	 to	 name	 but	 a	 few.	 All	 of	 these	mechanisms	 have	 considerably	 less	 evidence	 (especially	 in-vivo)	 to	 support	 a	significant	role	in	CBF	regulation.	The	principal	theme	around	this	thesis	is	NO	and	nitrite	 and	 for	 that	 reason	 I	 have	 chosen	 not	 to	 emphasise	 every	 possible	mechanism	of	CBF	regulation	regardless	of	importance.	
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Non-metabolic mediators of CVR  
 Vessel wall stress or myogenic control 
Myogenic	 vasoconstriction	 is	 an	 increase	 in	 vasomotor	 tone	 in	 response	 to	 an	increase	in	arterial	wall	stress,	which	occurs	independently	of	neural	or	humoral	mechanisms.	 In	healthy	 arterioles	myogenic	 control	plays	 an	 important	 role	 in	regulation	of	a	range	of	vascular	beds	including	skeletal	muscle,	brain,	renal	and	splanchnic.	76		
This	response	also	plays	its	role	in	pathology	such	as	hypertension	were	it	reduces	tissue	 perfusion77	 or	 in	 diabetes	 were	 the	 response	 is	 impaired	 resulting	 in	vasculopathy	at	a	microvascular	level.	78	
	
Miller	et	al	79	demonstrated	myogenic	constriction	of	human	coronary	arterioles	ranging	from	44	to	227	μm	with	a	graded	response	to	pressure	that	constricted	vessels	up	to	55	±	4%.	The	confounding	influence	of	shear	stress	was	removed	by	setting	 up	 a	 constant	 pressure	 no	 flow	 system.	 Basal	 tone	 was	 lower	 in	 the	presence	 of	 diltiazem,	 which	 inhibits	 the	 voltage	 dependent	 calcium	 channels	(VDCC).	Inhibition	of	Protein	Kinase	C	also	reduced	basal	tone	and	its	activation	increased	basal	tone.		
	
Myogenic	control	was	found	to	be	independent	of	endothelial	function	by	Kuo	et	al80	in	porcine	arterioles	around	100	μm	in	diameter.	He	again	visualised	arteriole	tone	both	with	and	without	endothelium	at	a	range	of	perfusion	pressures	and	
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found	 no	 effect	 on	 myogenic	 smooth	 muscle	 tone	 when	 endothelium	 was	removed.	
	
Modulation of CVR by shear stress  
The	 localised	and	upstream	control	of	coronary	resistance	vessel	 tone	by	shear	forces	 or	 “flow	 induced”	 dilation	 was	 first	 shown	 by	 Kuo	 et	 al.	 81	 His	 ex-vivo	experiments	 using	 porcine	 arterioles	 demonstrated	 that	 this	 shear-induced	dilation	was	endothelial	dependent	and	mediated	by	NO,	as	well	as	being	inhibited	by	 NO	 synthase	 inhibitors.	 Given	 our	 previous	 description	 of	 adrenergic	 /	purinergic	receptor	mediated	control	 this	section	on	shear	stress	and	NO	could	equally	sit	in	the	metabolic	section	of	this	introduction.	
	
Endothelial	dependent	production	of	nitric	oxide	is	via	the	enzyme	NOS	using	L-arginine	as	a	substrate,	there	are	a	variety	of	analogues	of	L-arginine	that	inhibit	NOS	and	are	used	extensively	to	understand	the	role	of	NO	in	a	variety	of	systems.			
	
In	vitro	work	identifies	NO	as	being	central	to	a	number	of	mechanisms	controlling	CVR.	In	dog	coronary	resistance	vessels,	reductions	of	CVR	with	administration	of	acetylcholine	are	blocked	with	the	addition	of	the	l-arginine	analog	(and	inhibitor	of	NOS)	LNMMA.	82	 In	 isolated	porcine	coronary	resistance	vessels,	blockade	of	NOS	inhibited	bradykinin	induced	relaxation.	80	
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In	vivo	Nω	–nitro-L-arginine	(L-NNA)	another	inhibitor	of	NOS	was	found	to	have	no	effect	on	basal	CVR	in	conscious	dogs	but	significantly	attenuated	the	increased	flow	seen	with	the	administration	of	both	acetylcholine	and	adenosine.	83	Parent	et	al	also	demonstrated	that	inhibition	of	NOS	also	partially	blocked	β-adrenergic	induced	 reductions	 in	 CVR	using	 the	 same	model.	 84	 Reactive	 hyperaemic	 flow	after	brief	coronary	occlusion	(10	to	60	seconds)	conceptually	has	a	number	of	possible	 mechanisms	 including	 adenosine	 mediated,	 myogenic	 tone	 and	potentially	NO.	Yamabe	et	al	85	in	an	anaesthetised	dog	model	used	both	the	NOS	inhibitor	 L-NMMA	 and	 8-phenyltheophylline	 (8-PT)	 a	 selective	 adenosine	antagonist.	 Measurements	 were	 taken	 in	 terms	 of	 peak	 flow	 velocity	 and	repayment	of	flow	debt	(%)	following	10,	20	and	60	seconds	of	LCx	occlusion.	The	group	showed	equivalent	roles	for	inhibition	of	NOS	and	adenosine	antagonism	in	terms	of	%	change	in	flow	repayment	and	an	additive	function	when	both	L-NMMA	and	 8-PT	 were	 used.	 In	 part	 these	 finding	 were	 confirmed	 by	 Kostic	 et	 al	 86	however	they	also	found	significant	reduction	in	baseline	(as	well	as	hyperaemic)	blood	flow	with	NOS	inhibition.		
	
To	add	to	the	somewhat	conflicting	findings	Smith	et	al	87	in	a	conscious	dog	model	showed	no	effect	of	NOS	inhibition	on	basal	CBF	or	throughout	the	autoregulatory	range,	 however,	 at	 pressures	 below	 the	 autoregulatory	 range	 NO	 did	 have	 an	influence	on	trying	to	maintain	CBF	during	what	effectively	amounts	to	ischaemia.		
	
Others	have	studied	in	patients	with	stable	coronary	angina	and	those	undergoing	coronary	 artery	 bypass	 surgery	 (CABG),	 the	 predominant	 influence	 on	 flow-
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induced	dilation	was	 found	 to	be	EDHF,	 rather	 than	NO.	 88	The	mechanisms	of	flow-mediated	 response	 also	 seem	 to	 be	 a	 function	of	 vessel	 size.	 For	 example	Dube	et	al	found	that	EDHF	was	more	influential	in	porcine	epicardial	vessels	and	Kuo	et	al	found	NO	being	dominant	in	the	smaller	arteriole	vessels.	89,90	
	
In	a	series	of	elegant	experiments	using	a	beating	heart	canine	model	Stepp	et	al	
91	 showed	 that	NO	 limits	 coronary	microvascular	 constriction.	 Stepp	 et	 al	 also	demonstrated	that	this	effect	was	more	pronounced	in	smaller	vessels	>120	μm	where	shear	stress	was	increased.	In	order	to	reveal	the	importance	of	flow	(shear	stress)	 in	 the	NO-dependent	dilation	of	 coronary	microvessels	 the	experiments	were	repeated	in	the	absence	of	flow,	here	inhibition	of	NO	synthase	activity	by	L-NMMA	had	no	effect	on	the	constriction	induced	by	endothelin.	
	
A	multitude	of	both	in	vitro	and	in	vivo	experiments	make	up	a	substantial	body	of	work	relating	to	the	role	of	NO	in	control	of	CVR	and	thus	CBF.		Despite	this	body	of	work	a	clear	idea	of	the	influence	of	NO	in	CVR	and	CBF	has	not	been	formulated.	Partly	 this	 is	 secondary	 to	 the	 number	 of	 different	 experimental	 models	 in	different	disease	states	and	using	different	techniques	to	assess	the	influence	of	blocking	NO	synthesis	on	CVR.	
	
The role of NO in human regulation of CVR in health and disease 
In	vivo	studies	in	both	healthy	humans	subjects	and	subjects	with	risk	factors	for	cardiac	disease	seem	to	indicate	a	role	of	NO	in	CBF	regulation.	Quyyumi	et	al	92	
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managed	to	elucidate	some	of	the	importance	of	NO	by		showing	that	the	reduction	in	coronary	vascular	resistance	in	response	to	rapid	cardiac	pacing	was	inhibited	in	healthy	subjects	administered	NO	synthase	inhibitors	L-NMMA.	Quyyumi	made	in-vivo	measurements	of	CVR	using	invasive	doppler	flow	wire	measures	within	the	coronary	artery.	Further	to	this	in	patients	with	increased	cardiac	risk	factors	LNMMA	had	a	negligible	effect	on	increasing	CVR	during	the	same	pacing	protocol	suggesting	 these	 patients	 had	 alternate	 mechanisms	 in	 the	 presence	 of	 likely	endothelial	dysfunction.	
	
Quyyumi	et	al93	went	on	to	describe	the	role	of	NO	in	a	cohort	of	patients	with	stable	 angina	 and	 compared	 them	 to	 a	 healthy	 population	 without	 epicardial	coronary	 disease	 or	 risk	 factors	 for	 coronary	 disease.	 Quyyumi	 used	 the	 same	measures	of	CVR	and	again	 found	a	differential	effect	of	L-NMMA	on	these	two	populations.	With	L-NMMA	healthy	patients	had	a	38%	±	9	(mean	±	SEM)	increase	in	 CVR	 and	 	 a	 15	 ±	 2%	 reduction	 in	 epicardial	 lumen	 whereas	 patients	 with	coronary	risk	factors	had	a	13	±	4%	increase	in	CVR	and	a	4	±	1%	reduction	in	lumen	diameter.	Inhibition	of	nitric	oxide	synthase	also	reduced	the	vasodilatory	effect	of	acetylcholine	in	both	groups	but	the	effect	in	the	atherosclerotic	group	was	much	smaller.	The	reduction	in	CVR	and	the	increase	in	vessel	diameter	was	similar	 in	 both	 groups	 following	 an	 infusion	 of	 sodium	 nitroprusside.	 These	finding	suggest	that	NO	has	a	role	in	defining	CVR	in	healthy	humans	and	that	this	role	 is	 reduced	 in	patients	with	 cardiovascular	 risk	 factors	and	overt	 coronary	atherosclerosis	 (chronic	 or	 stable	 coronary	 disease).	 This	 is	 presumed	 to	 be	
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secondary	 to	 endothelial	 dysfunction,	 which	 is	 expressed	 as	 dysfunctional	 or	reduced	function	of	NO	synthase	within	the	coronary	vasculature.	
	
Does nitrite have a role? 
Whilst	 the	inhibition	of	endothelial	dependent	NO	synthesis	has	been	shown	to	increase	 resistance	 vessel	 tone	 in	 these	 ischaemic	 models	 and	 also	 in	 healthy	humans	 at	 rest	 and	 during	 pacing,	 94-96	 it	 has	 been	 more	 difficult	 to	 directly	measure	net	increases	in	metabolites	of	NO	(Serum	Nitrite,	Total	Red	Blood	Cell	(RBC)	 NOx)	 using	 sensitive	 methods	 in	 similar	 human	 models.	 97	 Part	 of	 the	explanation	for	this	absence	of	a	net	rise	in	direct	measures	of	NO	metabolites	may	be	the	role	of	serum	Nitrite	(NO2-).		
NO2-	is	the	second	most	abundant	metabolite	of	NO	in	blood	after	nitrate	(NO3-).	Using	a	human	forearm	model	Gladwin	et	al	98	found	a	negative	gradient	of	plasma	NO2-from	artery	(540	±	74nM)	to	vein	(466	±	79nM).	The	negative	gradient	of	NO2-	correlated	with	a	positive	gradient	of	HbNO	observed	by	Jia	et	al	(536	±	99nM	to	894	±	126nM,	artery	 to	vein).99	Gladwin	also	reported	 that	 the	negative	A	 to	V	gradient	of	plasma	NO2-	was	enhanced	by	maximal	exercise	and	L-NMMA;	which	both	act	to	decrease	O2	levels.	These	observations	clearly	support	NO2-	acting	as	a	potential	 store	 of	 NO	 that	 could	 be	 released	 and	 targeted	 to	 hypoxic	 tissues.	Although	 no	 mechanism	 was	 investigated	 in	 this	 observational	 study,	 it	 was	proposed	 that	NO2-	was	being	 reduced	 to	NO	 across	 the	vascular	bed	and	as	 a	result	contributing	to	arterial	tone.	
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Doyle	 et	 al	 100	 described	 the	 kinetics	 of	 NO2-	 and	 deoxy-Hb	 in	 1981,	 broadly	speaking	these	describe	the	production	of	NO	suggested	by	Gladwin.	
	
NO2-	+	H+	+	HbFe2+(deoxy)	èHbFe3+	+	OH-	+	NO	èHbFe2+	-NO		
Cosby	et	al	101	demonstrated	that	isolated	aortic	rings	were	more	sensitive	to	the	vasodilator	effect	of	NO2-		-	in	the	presence	of	erythrocytes	-	when	O2	levels	were	reduced.	 In	 the	same	paper	 it	was	reported	that	 the	reduction	of	NO2-	began	to	occur	 at	 an	 O2	 tension	 of	 50mmHg,	 which	 equates	 to	 a	 Hb	 saturation	 of	approximately	50%.		
	
Following	these	observations	Gladwin	proposed	that	the	reduction	of	NO2-		to	NO	occurs	in	hypoxic	tissue	and	the	reductase	for	this	process	is	Deoxy-Hb	occurring	maximally	at	50%	O2	saturations	(Figure	4:	Deoxy-haemoglobin	nitrite	reductase	hypothesis).	Within	this	hypothesis	is	a	potential	mechanism	for	maintenance	of	normal	vessel	tone	and	the	phenomenon	of	hypoxic	vasodilation.	102	
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Figure 4: Deoxy-haemoglobin nitrite reductase hypothesis 
Nitrite	reductase	equilibrium	along	the	A1	to	A5	arterioles.	The	majority	of	resistance	is	generated	at	
A1,	A2	and	A3.	Oxygen	extraction	may	be	higher	at	these	sites	as	described	by	Tsai	et	al.	30Gladwin	et	
al	suggest	as	heme	moves	from	R	state	to	deoxyhaem	more	haem	sites	become	available	for	NO2-	and	
maximal	reductase	activity	with	the	formation	of	NO.	The	theoretical	peak	of	this	process	occurs	at	
60-40%	oxygen	saturation,	making	the	myocardial	circulation	the	perfect	environment	to	investigate	
this	process.	Reproduced	with	permission	102			
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Whilst	it’s	a	very	appealing	mechanism,	the	deoxy-Hb	hypothesis	is	not	entirely	without	its	limitations	and	potential	pitfalls.	The	principal	criticism	is	the	lack	of	an	explanation	as	to	how	the	produced	NO	extracts	itself	from	Hb	(whose	avidity	will	 increase	 the	 lower	 the	 O2),	 and	 further	 how	 it	 leaves	 the	 erythrocyte.	 103	Rather	than	being	a	direct	source	of	NO	there	is	some	evidence	that	the	reaction	of	 Nitrite	 with	 deoxy-Hb	 is	 the	 first	 step	 in	 the	 production	 of	 S-nitrosohaemoglobin	 (SNOHb),	 which	 is	 liberated	 once	 oxygen	 returns.	 104	Alternatively	there	is	the	concept	of	an	intermediate	molecule	that	may	bridge	the	liberation	gap,	however,	substantial	evidence	of	this	is	lacking.	105	
	
When	total	NO	metabolites	are	measured	from	aorta	to	coronary	sinus	Rogers	et	al	97	found	no	net	change	of	total	NO	metabolites	indicating	that	there	was	neither	production	 of	NO	by	NOS	 or	 consumption	 of	nitrite	 once	 all	 components	were	taken	into	account.	It	should	be	noted	this	was	in	healthy	human	subjects	with	no	ischaemic	heart	disease.		
	
There	are	also	other	potential	mechanisms	for	the	reduction	of	nitrite	to	NO.	It	has	been	noted	 that	 in	an	 isolated	vessel	model,	 independent	of	haemoglobin,	NO2-			action	 on	 vasodilation	 is	 enhanced	 by	 hypoxia.	 106	 Xanthine	 oxidase	 is	 one	 of	several	enzymes	present	in	vessel	walls	that	have	the	capacity	to	reduce	NO2-			to	NO	more	efficiently	 in	 the	presence	of	hypoxia.	107Beyond	enzymatic	reduction,	simple	 acid	 disproportionation	 of	NO2-	 	 	 to	NO	 can	 occur;	 obviously	 this	would	require	overt	ischaemia	rather	than	hypoxia.	108	
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Thesis aims 
Principally	this	thesis	investigates	the	role	of	both	endogenous	NO	and	NO2-	in	the	regulation	of	CVR	of	patients	with	both	acutely	decompensated	ischaemia,	non-ST	elevation	myocardial	 infarction	 (NSTEMI)	 and	 chronic	 stable	 ischaemia	 (stable	angina).	There	are	a	number	of	factors	within	this	body	of	work	that	make	it	novel.	NSTEMI	 and	 stable	 angina	 collectively	 represent	 a	 disease	 cohort	 that	 is	responsible	 for	 a	 majority	 of	 the	 cardiovascular	 morbidity	 and	 mortality	throughout	 the	 western	 world.	 This	 work	 aims	 to	 elucidate	 basic	 principal	mechanisms	of	CVR	regulation	within	these	two	disease	cohorts	(with	emphasis	on	NSTEMI).		
1. To	 examine	 the	 influence	 of	 NO	 and	 NO2-	 within	 the	 compensatory	mechanisms	 of	 CVR	 control	 in	 the	 ischaemic	myocardium	 (NSTEMI	 and	stable	angina).	2. Following	 reperfusion	 and	 relief	 of	myocardial	 ischaemia	 to	understand	how,	and	 if,	 these	mechanisms	acutely	adapt	 in	response	to	the	 increase	distal	coronary	pressure	and	increased	flow	in	the	absence	of	an	epicardial	stenosis.	3. In	patients	with	acute	NSTEMI	does	augmentation	of	NO2-	concentration	influence	other	important	factors	in	this	cohort.	Namely,	platelet	function	and	 inflammatory/anti-inflammatory	 cytokines.	 Is	 there	 any	 correlation	between	platelet	function	and	these	cytokines.	4. In	 patients	with	 acute	 NSTEMI	 does	 exogenous	 augmentation	 of	 serum	NO2-	concentration	have	any	influence	on	CVR	either	prior	to	or	following	revascularisation	with	coronary	intervention.	
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Chapter 2: General methods 
Methods structure 
This	 general	methods	 chapter	 is	 supplemented	 by	 chapter	 specific	methods	 in	each	 of	 the	 three	 results	 chapters.	 To	 reduce	 repetition	 the	 general	 methods	section	 highlights	 those	methods	 which	 are	 common	 to	more	 than	 one	 of	 the	following	results	chapters.	Where	a	specific	method	is	found	in	one	of	the	three	supplementary	methods	sections	(and	not	here)	there	is	a	cross	reference	with	a	short	description	and	page	number	to	the	location	of	the	full	method	description.		
Study populations 
NSTEMI, NSTEMIinf and Stable angina 
Two	populations	of	patients	were	studied;	NSTEMI	and	stable	angina.	The	NSTEMI	patients	were	principally	recruited	at	University	Hospital	of	Wales	(UHW)	whilst	stable	angina	patients	were	recruited	at	both	UHW	and	Papworth	hospital	(PH).	The	patients	recruited	at	PH	were	done	so	under	the	auspices	of	another	clinical	project	 that	 was	 designed	 with	 identical	 cardiac	 catheter	 protocols	 (Principal	Investigator	Stephen	Hoole).	UHW	patients	were	recruited	and	consented	by	the	local	 team	and	cathlab	protocols	and	percutaneous	coronary	 intervention	(PCI)	also	 carried	 out	 at	 UHW.	 Sample	 preparation	 and	 analysis	 was	 completed	 at	Cardiff	University.	For	Papworth	patients	recruitment,	consent,	PCI	and	cathlab	protocols	were	carried	out	by	the	team	at	Papworth	Hospital,	analysis	of	results	was	 carried	 out	 in	 Cardiff	 University	 using	 identical	 techniques.	 Sample	
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preparation	 and	 storage	 conditions	 were	 identical	 between	 the	 two	 centres,	storage	 times	were	 similar	 as	 the	 samples	were	 analysed	 in	 batches.	 The	 local	research	 ethics	 committee	 approved	 the	 study	 in	 each	 centre	 and	 written	informed	consent	was	obtained	from	each	patient.	
	
Inclusion	criteria	
• Any	patient	over	the	age	of	18	with	the	capacity	to	consent	for	study	and	who	was	receiving	coronary	angiography	as	a	normal	investigation	and	as	part	of	their	routine	treatment	for	either	stable	angina	or	NSTEMI	
• Normal	left	ventricular	function	ejection	fraction	(EF)	(EF≥50%),	assessed	by	echocardiography	
• Lack	of	contraindication	to	the	use	of	dual	antiplatelet	therapy	(aspirin	and	clopidogrel).	
• Patients	 that	 had	 one	 vessel	 PCI	 following	 coronary	 angiography	 with	lesions	 that	were	 suitable	 to	allow	 fractional	 flow	reserve	and	coronary	flow	reserve	measurements.	
• Patients	with	a	successfully	cannulated	coronary	sinus		
Excluded	criteria	included:	
• Patients	with	ongoing	and	unstable	ischaemic	symptoms		
• Previous	ST	Elevation	Myocardial	Infarction	(STEMI)	
• Significant	left	main	disease	
• Patients	with	chronic	total	occlusions,	index	or	otherwise	
• Patients	with	earlier	coronary	artery	bypass	grafts	
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• Significant	valvular	disease	
• Symptoms	of	heart	failure		
• Recent	intravenous	nitrate	infusion	
• Atrial	fibrillation	
	
Patients	all	had	single	vessel	PCI	of	the	culprit	vessel	only	after	a	period	of	medical	treatment.	The	culprit	vessel	was	selected	based	on	angiographic	appearance,	ECG	changes	and	in	the	stable	cohort	in	conjunction	with	non-invasive	testing	when	indicated.		
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Platelet sub-study 
We	conducted	a	prospective	observational	 study	on	high-risk	NSTEMI	patients	who	received	clopidogrel	at	diagnosis	and	for	a	minimum	period	of	5	days	before	PCI	was	conducted.		
Inclusion	criteria		
• Patients	with	an	 index	admission	 following	an	NSTEMI	(troponin	positive	and	/	or	typical	ECG	changes	with	consistent	clinical	history),	and	a		
• GRACE	score	>140	who	subsequently	went	on	 to	have	 significant	disease	treated	by	PCI	and	stent	implantation.		
Exclusion	criteria		
• Patient	who	received	intravenous	antiplatelet	agents:	glycoprotein	IIb/IIIa	inhibitors	(GPI)	or	other)	and		
• Renal	dysfunction	(eGFR	<40mls/min).		
Local	 research	 ethics	 approval	was	 granted	 and	written	 informed	 consent	was	obtained	from	each	patient.		
	
Cardiac catheterisation laboratory protocol 
Diagnostic angiography and coronary sinus cannulation 
Patients	received	2500	units	heparin	prior	to	a	diagnostic	angiogram.	The	default	route	for	coronary	angiography	was	via	the	radial	artery	with	the	femoral	artery	being	used	when	a	radial	procedure	was	not	possible	or	the	operators	preference.	A	standard	diagnostic	angiogram	was	performed	and	the	index	lesion	was	located.	
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If	PCI	was	indicated	and	the	patient	met	the	inclusion	criteria	the	venous	access	(for	coronary	sinus	sampling)	was	prepared	utilizing	an	earlier	aseptically	placed	venflon	 (VENFLONÔ,	 Becton	 Dickinson,	 New	 Jersey,	 USA)	 to	 guide	 a	 radial	introducer	wire	and	exchanged	with	a	six	french	radial	sheath	(ArrowÒ	Teleflex	medical),	 into	 either	 the	 basilica	 or	 cephalic	 vein	 of	 the	 antecubital	 fossa.	Following	a	further	dose	of	heparin	was	administered	to	a	total	of	70	to	100	IU	/	Kg.		
An	 appropriate	 6	 French	 guiding	 catheter	was	 then	 inserted	 into	 the	 relevant	coronary	ostium.	A	5	French	multipurpose	MPA-2	(Cordis,	Florida,	USA)	catheter	was	also	placed	into	the	coronary	sinus	(CS).	Deep	engagement	into	the	CS	was	confirmed	by	injection	of	contrast.	The	MPA-2	catheter	has	side	holes	which	are	critical	to	allowing	smooth	low	vacuum	extraction	of	blood	from	the	CS	without	this	structure	occluding	the	tip	of	the	catheter.	
	
Baseline (pre-PCI) blood sampling 
Baseline	 blood	 sampling	 was	 taken	 from	 central	 venous,	 coronary	 sinus	 and	proximal	 coronary	 artery	 together	 with	 a	 coronary	 artery	 and	 coronary	 sinus	blood	gas	measurement.	These	samples	were	taken	using	a	s	20ml	syringe	at	low	pressure.	 Samples	 were	 immediately	 transferred	 into	 vacuum	 released	vacutainers	(Becton	Dickinson,	New	Jersey,	USA).	K2	EDTA	for	whole	blood	flow	cytometry,	 Citrate	 for	 serum	 collection.	 For	 whole	 blood	 platelet	 aggregation	samples	were	collected	in	Hirudin	double	walled	tubes	(Diapharma,	Ohio,	USA).	
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Baseline (pre-PCI) coronary physiology measurements 
A	 Certus	 coronary	 temperature	 and	 pressure	 sensing	 wire	 (St	 Jude	 Medical,	Minnesota,	 USA)	 was	 equalised	 to	 the	 guiding	 catheter	 proximal	 coronary	pressure	(Pa),	the	wire	was	then	placed	distal	to	the	epicardial	stenosis	into	the	distal	third	of	the	vessel.	
	
The	index	of	microvascular	resistance	(IMR)	was	measured	at	rest	(IMRrest)	and		during	 hyperaemia	 (IMRhyp).	Microvascular	 resistance	was	measured	using	 the	techniques	 described	 by	 Fearon	 et	 al.	 109	 3ml	 injections	 of	 room	 temperature	saline	were	injected	down	the	coronary	artery	via	the	guiding	catheter	to	produce	three	 consistent	 thermodilution	 curves.	The	average	of	 these	 three	 curves	was	taken	 as	 a	 mean	 baseline	 transit	 time	 (Tm	 rest),	 shown	 to	 have	 a	 very	 close	correlation	 with	 the	 inverse	 of	 absolute	 coronary	 flow.	 110	 The	 calculation	 of		IMRrest	using	the	transit	time	at	rest	(Tm	rest)	reflects	resting	tone	in	the	coronary	microcirculation.111	 Hyperaemia	 was	 then	 induced	 with	 administration	 of	intravenous	adenosine	(140	μg/kg/min)	via	the	side	arm	of	the	6	French	venous	sheath	 in	 the	antecubital	 fossa.	Hyperaemia	was	defined	as	 the	point	after	 two	minutes	of	intravenous	adenosine	infusion	via	the	large	bore	sheath	placed	in	the	antecubital	fosa.	Clinical	effect	of	adenosine	was	seen	very	quickly	when	delivered	through	this	large	bore	venous	route.	The	saline	injections	were	then	repeated	and	the	 hyperaemic	 transit	 time	 (Tm	 hyp)	 was	 derived	 from	 these	 thermodilution	curves.	
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PCI	 was	 then	 performed	 as	 per	 the	 operator’s	 preference	 with	 no	 limitations	dictated	 by	 the	 study	 protocol.	 Prior	 to	 the	 first	 balloon	 or	 stent	 deployment	hyperaemia	was	induced	again	and	the	distal	coronary	pressure	measured	once	the	vessel	was	occluded	(Coronary	wedge	pressure,	Pw).			
Peri and Post PCI blood sampling 
Immediately	prior	to	deployment	of	the	coronary	stent	a	further	coronary	sinus	blood	 sample	 was	 taken	 to	 confirm	 the	 concentrations	 of	 Nitric	 Oxide	 (NO)	metabolites	at	the	point	just	prior	to	revascularisation.	Following	successful	PCI	blood	 sampling	 was	 taken	 from	 central	 venous,	 coronary	 sinus	 and	 proximal	coronary	 artery	 together	with	 a	 coronary	 artery	 and	 coronary	 sinus	 blood	 gas	measurement.	These	samples	were	taken	using	a	20ml	syringe	at	low	pressure.	Samples	were	immediately	transferred	into	vacuum	released	vacutainers	(Becton	Dickinson,	New	Jersey,	USA).	K2	EDTA	for	whole	blood	flow	cytometry	and	nitric	oxide	metabolite	analysis,	Citrate	for	serum	collection.	For	whole	blood	platelet	aggregation	samples	were	collected	in	Hirudin	double	walled	tubes	(Diapharma,	Ohio,	USA).	
	
Post-PCI coronary physiology measurements 
IMR	at	rest	(IMRrest)	and	IMR	with	hyperaemia	(IMRhyp)	microvascular	resistance	was	re-measured	in	an	identical	way	to	the	baseline	measurements,	these	post-PCI	measurements	were	carried	out	at	least	5	minutes	after	stent	deployment.		
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Offline analysis of catheter lab haemodynamic data 
IMR hyperaemic calculation 
In	the	presence	of	significant	epicardial	stenosis	IMRhyp	was	calculated	with	the	incorporation	of	both	coronary	sinus	venous	pressure	(Pv)	and	coronary	wedge	pressure	(Pw),	using	the	equation	below,	described	and	validated	here.	109,112,113	The	IMRhyp	reflects	how	well	preserved	the	microcirculation	 is	and	 its	maximal	capacity	 of	 vasodilation.	 A	 number	 of	 factors	 can	 influence	 hyperaemic	 IMR	including	severe	left	ventricular	hypertrophy	(LVH)	and	myocardial	infarction.	114-
116	
	
IMRhyp	=	(Pa	hyp-Pv)	x	Tm	hyp	(Pd	hyp	–	Pw)	/	(Pa	hyp	–	Pw)		
Pa	 is	 the	 proximal	 aortic	 pressure;	 Pd	 is	 the	 distal	 coronary	 pressure	 both	 at	hyperaemia.	
	
IMR resting calculation 
The	 calculation	 of	 IMR	 resting	 (IMRrest)	 is	 identical	 to	 IMR	 hyp	 (minimal	microvascular	resistance),	the	only	difference	is	the	lack	of	an	adenosine	infusion	to	 induce	 hyperaemia	 and	 uncouple	 autoregulation.	 This	 calculation	 reveals	microvascular	 tone	 at	 rest	 (a	 surrogate	 of	 CVR),	 allowing	 us	 to	 relate	 CVR	simultaneously	to	Ao	and	CS	sampling	and	NO	metabolite	measures.	Principally	
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IMRrest	 gives	 the	 investigator	 an	 impression	 of	 perfusion	 at	 the	 time	 of	 blood	sampling	when	any	auto-regulatory	mechanisms	are	in	place.	111		
	
IMRrest	=	(Pa	rest	–	Pv)	x	Tm	rest(Pd	rest	–	Pw)	/	(Pa	rest	–	Pw)		
Fractional Flow Reserve (FFR) method and calculation 
FFR	was	measured	simultaneously	at	the	point	of	IMRhyp	measurement	(pre	and	post	PCI).	The	distal	pressure	sensor	was	placed	distal	to	the	epicardial	stenosis.	Pressure	proximal	to	the	stenosis	was	measured	from	the	coronary	guide	catheter	and	distal	to	the	epicardial	stenosis	via	the	distal	pressure	sensor	of	the	coronary	temperature	and	pressure	sensing	guide	wire	(St	Jude	Medical	Certus	wire	0.014).		The	 measurement	 is	 taken	 at	 the	 hyperaemia	 phase	 of	 the	 protocol	 during	measurement	of	IMRhyp.	FFR	is	a	highly	validated	method	of	assessing	if	epicardial	coronary	 lesions	 are	 flow	 limiting	 using	 comparisons	 to	 both	 surrogate	 and	clinical	end-points.	117,118	
 Collateral Flow Index 
Collateral	Flow	Index	(CFI)	was	calculated	via	
CFI	=	(Pw	-	Pv)/(	Pa	-	Pv)	
Sodium nitrite infusion 
In	the	NSTEMI	cohort	receiving	pre-PCI	loading	with	sodium	nitrite	(NSTEMIinf),	(page	 102)	 the	 sodium	 nitrite	 infusion	was	 started	 immediately	 after	 the	 first	coronary	 sinus	 sample	was	 taken	 pre-PCI.	 The	 sodium	nitrite	was	 supplied	 by	
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Tayside	Pharmaceuticals,	Ninewells	Hospital	and	infusions	prepared	on	the	day	of	recruitment	by	St	Mary’s	Pharaceutical	Unit	(SMPU),	University	Hospital	of	Wales.	Final	concentration	of	sodium	nitrite	was	confirmed	at	SMPU	using	Griess	Reagent	Kit	(Thermo	Fischer	Scientific).	The	infusion	contained	a	total	dose	of	6.9mg	(99	μmol)	 of	 sodium	 nitrite,	 infused	 over	 30	minutes	 (3.3μmol/min).	 Following	 5	minutes	of	this	infusion	an	additional	coronary	sinus	blood	sample	was	taken	to	confirm	the	nitrite	concentration	at	the	point	of	the	pre-PCI	coronary	physiology	measures.		
Measurement of Nitric Oxide metabolites 
Blood preparation 
Blood	samples	were	 collected	 in	K2	EDTA	vacutainers	 (Becton	Dickinson,	New	Jersey,	USA),	and	processed	in	two	batches	pre-PCI	and	post-PCI.	Each	batch	was	briefly	stored	on	ice	prior	to	centrifugation	at	600	g	for	10	min	at	4oC.	All	reagents	were	 purchased	 from	 Sigma	 (Poole,	 UK),	 unless	 stated	 otherwise.	 The	 red	 cell	fraction	 and	 serum	were	 immediately	 separated,	 aliquoted	 and	 flash	 frozen	 in	liquid	nitrogen.	Samples	were	stored	at			-80oC	for	subsequent	analysis.	Summary	of	analysis	(Figure	5:	NO	metabolite	analysis	overview)	
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Figure	5:	NO	metabolite	analysis	overview	
Overview	of	the	analysis	of	blood	samples	and	total	NOx	measured	in	both	the	plasma	and	erythrocyte	
fractions	
 
Ozone-based chemiluminescence 
The	NO	metabolites	were	assessed	using	ozone-based	chemiluminescence	(OBC),	an	 established	 techniques	 within	 the	 group.	 119	 OBC	 detects	 NO	 liberated	 via	chemical	cleavage.	119	The	chemical	cleavage	for	non-nitrate	quantification	is	split	into	 two	 separate	 techniques	 described	 in	 more	 detail	 below	 (plasma	 and	erythrocytes).	 For	 plasma	 nitrite	 analysis,	 5ml	 of	 tri-iodide	 (I3-)	 was	 used,	 for	erythrocytes	the	addition	of	potassium	hexacyanoferrate	(K3Fe3+(CN)6)	was	made.	Each	cleavage	reagent	was	placed	in	a	glass	purge	vessel	and	heated	at	50°C	via	a	thermostatically	 controlled	 water	 bath.	 A	 constant	 flow	 of	 inert	 gas	 (O2-free	nitrogen)	 was	 bubbled	 through	 the	 reagent	 to	 collect	 the	 NO	 liberated.	 This	gaseous	 mixture	 was	 then	 bubbled	 through	 a	 trap	 containing	 25ml	 sodium	hydroxide	 (NaOH	 1mol/l).	 The	 gas	 was	 then	 analysed	 with	 an	 NO	 analyser	(NOA280i,	Sievers,	Boulder,	USA.).	Ozone	is	mixed	with	the	carrier	gas	and	each	
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molecule	of	ozone	(O3),	reacts	with	a	molecule	of	NO,	liberating	a	photon.		The	NOA	controls	this	reaction	and	quantifies	the	liberation	of	photons	by	converting	this	signal	 via	 a	 photo-multiplier	 tube	 into	 a	 potential	 difference.	 This	 potential	difference	measured	in	mV	is	then	quantified	over	time.		
	
Plasma NOx quantification 
As	 indicated	 above	 acidified	 tri-iodide	 (ATI)	 was	 used	 to	 quantify	 plasma	metabolites	of	nitric	oxide	(NOx).	ATI	solution	was	mixed	on	the	day	of	analysis.	The	reagent	has	been	previously	validated	as	an	efficient	reductive	compound	that	provides	a	reproducible	signal	for	the	quantification	of	blood	NO	metabolites.	120	The	 solution	was	prepared	using	70ml	of	 glacial	 acetic	 acid	mixed	with	650mg	iodine	(I2)	crystals	to	this	solution	1g	of	potassium	iodide	(KI),	dissolved	in	20ml	HPLC	(high	performance	liquid	chromatography)	grade	water,	was	added.		
	
The	 tri-iodide	 reagent	was	 then	added	 to	 the	purge	vessel	 (5ml)	 together	with	30μl	antifoam.	Each	sample	was	prepared	using	a	fresh	solution	of	tri-iodide	and	each	sample	was	measured	 in	duplicate.	Each	 sample	was	thawed	 immediately	prior	to	analysis	and	200μl	was	injected	into	the	side	port	of	the	purge	vessel,	to	generate	a	plasma	total	signal	(comprising	NO2-	and	protein	bound	NO	groups).	This	group	is	also	known	as	plasma	NOx.	
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Erythrocyte associated NO 
The	 original	 tri-iodide	 solution	 was	 modified	 by	 the	 addition	 of	 potassium	hexacyanoferrate	(K3Fe3+(CN)6)	immediately	prior	to	sample	analysis,	(1:10	to	tri-iodide).	 This	 agent	 prevents	 auto-capture	 of	 liberated	 NO	 by	 Hb	whilst	 in	 the	assay.121	8ml	modified	tri-iodide	reagent,	together	with	30μl	antifoam,	was	placed	into	a	purge	vessel.	200μl	of	freshly	thawed	erythrocyte	sample	was	injected	into	the	purge	vessel	to	generate	an	erythrocyte-total	signal:	Haemoglobin	bound	NO	(HbNO),	S-nitrosohaemoglobin	(HbSNO)	and	erythrocyte-associated	NO2-).		
Plasma NO3- 
Total	plasma	inorganic	nitrate	(NO3-)	was	also	quantified	using	OBC,	the	cleavage	reagent	 used	 to	 liberate	 NO	 from	 NO3-	 was	 acidified	 vanadium	 III	 chloride	(VCl3).122	When	VCl3	is	used	at	higher	temperatures	(85°C)	it	is	able	to	liberate	NO	from	all	plasma	sources,	including	NO3-.	A	50mM	reagent	solution	was	prepared	by	the	addition	of	0.785g	VCl3	(dissolved	in	20ml	HPLC	grade	water)	to	80ml	1M	HCl	acid.	30ml	of	acidified	VCl3	was	added	to	a	larger-sized	purge	vessel.	A	Liebig	condenser	 was	 connected	 between	 the	 purge	 vessel	 and	 the	 NaOH	 trap	 but	otherwise	 the	 setup	was	unaltered	 from	 that	previously	 stated.	 20μl	 of	 freshly	thawed	plasma	was	injected	into	the	purge	vessel	to	generate	a	plasma	NO3-	&	NOx	signal.	From	this	concentration	the	plasma	[NOx]	concentration	was	subtracted	to	give	the	plasma	[NO3-]	concentration.		
	 65	
Quantification of data produced by NOA 
The	real	time	continuous	data	produced	by	the	NOA	was	analysed	with		Origin	7.0	(OriginLab	Corps,	Massachusetts,	USA).	This	signal	(in	mV)	was	plotted	vs	time	(in	seconds)	to	give	a	raw	trace	and	then	a	fifty-point	adjacent	averaging	algorithm	was	used	to	smooth	this	trace.	The	peak	analysis	package	for	Origin	was	then	used	to	 calculate	 the	area	under	 curve	 (AUC)	of	 each	peak	 (mV.s).	Using	a	 standard	curve	 (prepared	 every	 day	 to	 limit	 variability)	 the	 AUC	 was	 converted	 to	 a	concentration	of	NO.		(Figure	6:	Example	offline	analsis	of	NO	metabolite	raw	data)	
	
Figure 6: Example offline analsis of NO metabolite raw data 
Example of raw data output (black) and smoothed data using Origin 7.0 (red). The first large peak is the 
signal generated with plasma total injection (plasma NOx), a much smaller second peak is seen (marked 
S), this is the signal after the addition of sulphanilamide to the sample and represents plasma protein 
bound NO (no attempt to quantify this signal was made in this thesis). 
 
Calibration curve for quantification of OBC data 
A	 fresh	 standard	 curve	 was	 produced	 daily	 using	 either	 NaNO2	 or	 NaNO3	standards.	For	example,	a	range	of	5	standards	solutions	of	NaNO2	was	analysed	on	the	OBC	system	and	plotted	(62.5	nM,	125	nM,	250	nM,	500	nM,	1000	nM).	A	
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linear	regression	analysis	of	 this	data	provides	a	multiplication	 factor	by	which	NOA	 reading	 (mV.s)	 could	 be	 converted	 into	 a	 concentration	 (nM).	 (Figure	 7:	Example	standard	curve	used	in	the	quantification	of	NO	metabolite	data)	
	
Figure 7: Example standard curve used in the quantification of NO metabolite data 
Figure xx: A standard curve of known NaNO2 concentrations (62.5 nM, 125 nM, 250 nM, 500 nM, 1000 
nM), left panel, and the linear regression analysis, right panel. In this example the NOA output of 
experimental samples would be divided by 2.68 to convert into a concentration of NO2-. 	
Within	 the	 group	 NOA	 is	 an	 established	 and	 validated	 method	 with	 a	 limit	 of	sensitivity	for	plasma	nitrite	of	>10nmol/l	and	for	plasma	nitrate	of	>500nmol/l,	the	intra-assay	coefficients	of	variation	were	<5	and	<8%,	respectively.123	
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Platelet analysis 
Chapter	5:	Results	3	contains	multi-parametric	analysis	of	platelet	function	and	status	as	well	as	cytokine	quantifcation	
Impedance aggregometry 
Whole	 blood	 impedance	 aggregometry	 (multiplate),	 full	 details	 of	 the	 chapter	specific	method	can	be	seen	on	page	152	
Flow cytometry assessment of platelet bound p-selectin 
Whole	blood	flow	cytometry	with	platelet	markers	and	p-selectin	markers.	Full	details	of	the	chapter	specific	method	can	be	seen	on	page	154	
Soluble p-selectin quantification 
Serum	quantification	of	soluble	p-selectin,	electrochemiluminescence	(Meso	Scale	Discovery).	Full	details	of	the	chapter	specific	method	can	be	seen	on	page	156	
Assessment of 12-HETE by lipid extraction and reverse phase LC/MS/MS 
Quantification	 of	 12-hydroxyeicosatetraenoic	 acid	 (12-HETE)	 was	 made	 via	reverse	phase	liquid	chromatography	and	mass	spectrometry	analysis.	Full	details	of	the	chapter	specific	method	can	be	seen	on	page	157	
Cytokine quantification 
Serum	quantification	of	TH1	and	TH2	specific	cytokines	was	made	via	a	multispot	electrochemiluminescence	 (Meso	 Scale	 Discovery).	 Full	 details	 of	 the	 chapter	specific	method	can	be	seen	on	page	158	
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Statistical Analysis 
Statistical	 analysis	 of	 data	 was	 performed	 using	 the	 software	 package	GraphPad	Prism	10.0	(La	Jolla,	California,	USA).	The	individual	tests	performed	are	identified	within	the	method	section	of	each	of	the	three	results	chapters.	
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Chapter 3: Results 1  
The role of NO in coronary blood flow regulation in the presence 
of epicardial coronary disease 
Abstract  
Background 
As	the	extraction	of	oxygen	at	rest	is	almost	maximal	the	heart	must	increase	CBF	when	metabolic	 demands	 on	 the	 heart	 increase	 (exercise).	 Perfusion	 pressure	remains	constant	with	equivalent	rises	in	aortic	and	diastolic	backpressure.	The	only	remaining	way	to	increase	CBF	is	to	reduce	CVR.	Nitric	oxide	-	synthesised	by	both	endothelial	NOS	and	the	(potential)	reduction	of	its	metabolite	nitrite	-	is	a	potent	 vascular	 dilator.	 Its	 role	 in	 humans	 in	 the	 regulation	of	 CVR	 is	 unclear,	especially	in	the	presence	of	epicardial	coronary	disease.	This	chapter	outlines	the	influence	of	NO	in	humans	with	both	acute	epicardial	coronary	stenosis	(NSTEMI)	and	stable	epicardial	stenosis.	
Methods 
Two	groups	of	patients:	stable	angina	(SA)	n=35	and	NSTEMI	n=38.	Both	were	scheduled	to	have	an	angiogram	+/-	PCI.	Pre-PCI	and	post-PCI	aortic	and	coronary	sinus	 blood	 samples	 were	 taken	 together	 with	 measures	 of	 CVR	 (IMRrest	 and	IMRhyp).	Following	rapid	sample	preparation	both	serum	and	red	blood	cell	NOx	were	measured	using	ozone	based	chemiluminescence.	
	 70	
Results 
A	net	increase	in	total	NO	metabolites	(NOx)	were	found	from	aorta	to	coronary	sinus	(A-V)	in	the	NSTEMI	cohort	pre-PCI	(84.9	nM	CI	9.5	to	160,	pANOVA	<0.05	*)	and	 post-PCI	 this	 gradient	 disappeared.	 The	 formation	 of	 NO	metabolites	was	principally	driven	by	an	increase	in	RBC	NOx	from	A-V	whilst	serum	nitrite	did	not	change.	Post-PCI	RBC	NOx	was	similar	but	nitrite	concentration	fell	from	A-V.	This	flux	 in	NOx	was	accompanied	by	a	 change	 in	 IMRrest	(CVR)	 from	45.7	units	 (SD	21.7)	 to	57.6	units	(SD	37.9),	 indicating	an	 increase	 in	CVR.	Unlike	the	NSTEMI	cohort	 the	stable	cohort	had	a	 fall	 in	nitrite	concentration	 from	A-V	both	pre	(-175nM	p<0.05	****)	and	post-PCI	(-183.8nM	p<0.05****).	This	was	accompanied	by	a	change	in	IMRrest	from	38.9	units	(SD	18.4)	to	38.99	(SD	3.96)	indicating	no	change	in	CVR.	Of	note	the	collateral	flow	index	(an	indicator	of	coronary	collateral	formation)	was	significantly	higher	in	the	stable	cohort.	
Conclusions  
NO	 appears	 to	 be	 important	 in	 the	 regulation	 of	 CVR	 in	 patients	 with	 acute	epicardial	 stenosis	 (NSTEMI).	 We	 observe	 a	 net	 production	 of	 NO	 across	 the	myocardial	 circulation	 (A-V)	 in	 the	 NSTEMI	 cohort.	 Immediately	 post-PCI	 we	measure	an	acute	drop	of	NO	likely	secondary	to	a	the	dilutional	effect	of	increased	flow	and	perhaps	a	reduction	in	shear	force	and	down	regulation	of	NOS.	This	drop	is	 associated	with	 an	 immediate	 increase	 in	 CVR.	 Net	 production	 of	 NO	 is	 not	measured	in	the	stable	cohort	pre+-PCI	and	thus	a	drop	is	not	seen	immediately	post-PCI.	 We	 also	 see	 no	 change	 in	 CVR	 post-PCI.	 Coronary	 wedge	 pressure	indicates	significant	collateral	formation	in	the	stable	cohort	perhaps	indicating	
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an	 alternate	 chronic	 compensation	 mechanism	 that	 negates	 the	 need	 for	 NOS	upregulation.		
Introduction 
Conceptually	 increased	oxygen	demand	by	the	heart	can	be	met	 in	 three	ways:	increased	oxygen	extraction,	increased	perfusion	pressure	or	a	reduction	in	total	coronary	vascular	resistance.	1		
	
Even	 at	 rest	 the	 heart	 extracts	 70	 to	 80%	of	 the	 oxygen	 delivered	 to	 it	 by	 the	coronary	 circulation,	 indeed	 the	extraction	per	gram	of	 tissue	 is	20	 fold	higher	than	 skeletal	muscle.	 1,2	 This	 almost	maximal	 oxygen	 extraction	 at	 rest	means	there	is	almost	no	further	increase	in	arterial-to-venous	(A-V)	oxygen	extraction	during	 light	 exercise	 5	 and	 a	 tendency	 towards	 only	 slightly	 increased	 A-V	 O2	extraction	during	moderate	to	heavy	exercise.	6,7.		
	
The	 gradient	 of	 pressure	 across	 the	 coronary	bed	 (perfusion	 pressure)	 can	 be	measured	from	aortic	pressure	to	diastolic	pressure	(or	backflow	pressure),	the	latter	being	generated	by	a	combination	of	heart	rate,	diastolic	and	systolic	left	ventricular	compressive	forces	which	are	in	turn	proportional	to	aortic	pressure.	During	exercise	the	aortic	inflow	pressure	rises	and	is	matched	with	an	equivalent	rise	in	backflow	pressure,	therefore	perfusion	pressure	remains	constant.	10,11		
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Changes	 in	 CVR	 appear	 to	 be	 the	 principal	mechanism	by	which	 the	heart	 can	regulate	 CBF	 and	 fulfill	 the	 demands	 of	 increased	 myocardial	 oxygen	requirements	during	exercise.	1	Control	and	adaptation	of	CVR	means	that	CBF	can	be	maintained	for	a	number	of	different	perfusion	pressures	or	increased	when	the	myocardium	requires	more	oxygen.	11	The	control	of	CVR	has	many	proposed	components	including	(but	not	limited	to)	the	local	concentration	of	adenosine,	58	NO,	95	and	neural	regulation.	124	This	chapter	focuses	purely	on	the	influence	of	endogenous	NO	production.		
	
The	 role	of	both	NO	and	 its	metabolite	NO2-	have	been	 studied	 in	depth	 in	 the	context	of	relatively	healthy	humans	and	those	with	overt	coronary	disease	risk	factors.	 Most	 of	 the	 clinical	 studies	 involving	 NO2-	 have	 had	 an	 emphasis	 on	augmenting	 its	 concentration	 for	 biological	 effect	 in	 terms	 of	 ischaemia-reperfusion	 injury	 and	 coronary	 blood	 flow	 regulation	 (covered	 in	 Chapter	 4:	Results	2).	This	chapter	will	touch	on	endogenous	NO2-	concentration	principally	as	a	means	of	quantifying	NO	production	but	also	touching	on	NO2-	as	a	bioactive	metabolite	 itself	 as	 outlined	 in	 the	 general	 introduction.	 However,	 Chapter	 4:	Results	2	will	cover	this	in	much	more	detail.	
	
	 73	
Relevant human models to assess the role of NO in the regulation of CVR in 
health and disease 
Quyyumi	et	al	have	described	a	series	of	experiments	outlining	the	role	of	NO	in	both	 CVR	 resting	 tone	 as	 well	 as	 its	 role	 in	 decreasing	 CVR	 during	 increased	demand	(pacing),	 in	healthy	subjects.	Quyyumi	 focused	his	 investigation	on	the	effect	of	blocking	NO	synthesis	using	L-NMMA	 to	 inhibit	NOS	and	carrying	out	challenges	 with	 acetylcholine	 and	 pacing.	 95	 The	 same	 group	 went	 on	 to	demonstrate	 diminishing	 endothelial	 function	 (in	 terms	 of	 NOS	 activity)	 in	patients	with	risk	factors	for	coronary	heart	disease.	92	This	work	then	continued	in	patients	with	overt	epicardial	coronary	disease	(stable	chronic	lesions)	using	a	similar	model	of	 assessing	 the	effect	of	L-NMMA	on	both	 resting	CVR	and	CVR	following	acetylcholine	stimulation.	93	L-NMMA	was	found	to	have	a	smaller	effect	in	patients	with	epicardial	 coronary	 stenosis	 at	both	 rest	 and	after	 stimulation	with	acetylcholine.		
	
These	studies	made	a	valuable	contribution	to	the	field,	however,	there	were	some	issues	with	patient	characteristics	that	make	the	findings	less	clear.	The	principal	issue	lies	with	the	lesion	characteristics	in	the	group	with	atherosclerosis;	patients	were	selected	if	their	lesions	were	less	than	40%	(to	allow	for	the	bulky	doppler	catheters	 to	 make	 accurate	 measurements).	 Significant	 differences	 were	 also	present	between	 the	groups	with	and	without	atherosclerosis;	 control	 subjects	were	more	often	female	(83%	vs	25%)	and	significantly	younger	(40	±	8	vs	56	±	9).	In	terms	of	CVR	and	microvascular	reactivity	there	are	significant	differences	between	men	 and	women	 that	make	 interpretation	 of	 these	 result	 difficult.	 125	
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Specifically,	women	investigated	for	potential	ischaemia	(which	is	true	for	these	control	patients),	with	normal	 coronary	arteries	have	been	 shown	 to	have	 less	reactivity	 to	adenosine;	upregulation	of	NOS	may	occur	 to	 compensate	 for	 this	generalized	disruption	of	 control	of	CVR.	 So,	 in	 reality,	 this	work	 looked	at	 the	impact	 of	 gender	 on	 CVR	 control	 by	 NO	 with	 the	 added	 confounder	 of	 mild	coronary	 lesions	 (that	we	wouldn’t	 typically	associate	with	overt	 ischaemia	by	current	standards)	and	cardiovascular	risk	factors	for	atherosclerosis.		
	
Minamino	 et	 al	 126	 measured	 plasma	 nitrate	 and	 nitrite	 concentrations	 in	 the	coronary	 sinus	 -	 in	 patients	 with	 and	 without	 risk	 factors	 for	 coronary	atherosclerosis,	but	all	with	normal	 coronary	artery	anatomy	–	at	baseline	and	with	 an	 increase	 in	myocardial	 oxygen	 consumption	 induced	 by	 rapid	 pacing.		These	experiments	show	that	those	with	risk	factors	did	not	have	a	net	increase	in	NO	metabolites	 (serum	nitrite	 and	 nitrate)	 in	 response	 to	 pacing	 (12.0±0.9	 vs.	14.9±1.1	μmol/liter,	mean	±	SD	p<0.05);	the	converse	was	true	for	those	without	risk	factors	for	coronary	atherosclerosis	(11.1±1.1	vs.	12.2±1.1	μmol/liter).	This	work	indicates	a	role	of	NO	in	the	regulation	of	CVR	in	a	healthy	population	and	less	so	as	cardiovascular	risk	factors	increase.	This	goes	some	way	in	associating	risk	factors	with	endothelial	dysfunction	but	does	not	tell	us	how	this	relates	to	overt	epicardial	coronary	disease	or	if	NO	has	a	central	role	in	compensating	for	overt	flow	limiting	coronary	disease.	Again,	this	piece	of	work	had	its	limitation,	principally	the	method	of	NO	metabolite	quantification.	No	account	is	taken	of	the	red	cell	metabolites	of	NO	and	we	will	read	in	the	next	paragraph	how	potentially	in	 the	 hypoxic	 /	 ischaemic	 environment	 complete	 quantification	 of	 both	
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compartments	is	central	to	understanding	NO	synthesis.	In	terms	of	quantification	of	total	serum	nitrite	+	nitrate,	the	group	used	the	Griess	reaction	a	technique	that	dates	from	1879.	The	Griess	reaction	is	used	in	combination	with	absorbance	at	540nm	before	 and	 after	 passing	 the	 sample	 through	 a	 copper-plated	 cadmium	column.	 It’s	 μmol	 sensitivity	 is	 not	 sensitive	 enough	 to	 capture	 biologically	significant	 nmol	 changes	 in	NO2-	 concentration,	 and	 there	 are	 also	 issues	with	specificity	and	the	interference	of	other	molecules	in	the	plasma.	127	
	
Rogers	et	al	97	studied	healthy	patients	-	with	normal	epicardial	coronary	arteries	-	undergoing	coronary	angiogram	as	a	routine	 investigation	in	the	treatment	of	palpitations	 (electrophysiology	 study);	 these	 patients	 had	 no	 symptoms	 of	ischaemia.	The	group	measured	both	plasma	and	red	blood	cell	NO	metabolites	(total	NO	metabolites)	 from	 aortic	 root	 to	 coronary	 sinus	with	 and	without	 L-NMMA.	 The	 group	 used	 ozone-based	 chemiluminescence,	 a	 highly	 sensitive	method	 of	 quantification	 that	 allows	 ~	 99%	 recovery	 of	 NO	 added	 across	 a	physiological	 and	 pharmacological	 range	 (nM	 sensitivity).	 121	 In	 terms	 of	sensitivity,	specificity	and	measuring	both	plasma	and	red	cell	components	of	NO	metabolites,	 ozone-based	 chemiluminescence	 is	 far	 superior	 to	methods	 based	around	the	Griess	reagent	outlined	above.	128	Rogers	found	that	there	was	a	net	loss	 of	 NO2-	 from	 aortic	 root	 to	 coronary	 sinus	 (366±39nM	 to	 269±48nM	mean±SEM	p<0.05)	as	reported	by	Gladwin	and	others,	98	however	this	reduction	in	nitrite	was	mirrored	by	a	doubling	of	total	RBC	HbNO	from	aorta	to	coronary	sinus	(107nM	to	189	nM	p<0.05	see	paper	for	component	figures	and	SEM)	as	the	haem	lost	its	oxygen	across	the	myocardial	bed.	These	observations	were	reversed	
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across	 the	 pulmonary	 bed	 as	 the	 NO	 was	 replaced	 by	 oxygen.	 Overall	 this	“shuttling”	of	NO	metabolites	equated	to	no	net	change	 in	total	NO	metabolites	from	aorta	to	coronary	sinus	(and	pulmonary	artery	to	aorta).	The	addition	of	L-NMMA	 increased	 systemic	 blood	 pressure	 and	 reduced	 epicardial	 coronary	diameter	 but	 did	 not	 have	 any	 effect	 on	 the	 distribution	 or	 amount	 of	 any	NO	metabolite.	This	research	demonstrated	that	in	healthy	patients	endothelial	NOS	is	unlikely	to	have	a	significant	role	in	controlling	CVR.	The	net	component	ofNO	metabolites	did	not	change	from	aorta	to	coronary	sinus	(just	their	distribution	from	serum	to	RBC	as	a	function	of	O2),	suggesting	that	there	is	no	consumption	of	nitrite	that	isn’t	explained	by	an	increase	in	total	RBC	NO	components	that	occurs	as	oxygen	saturation	falls.		
	
Each	of	the	studies	described	has	its	limitations	in	terms	of	understanding	the	role	of	both	NO	(and	NO2-)	in	terms	of	compensatory	control	of	CVR	in	patients	with	myocardial	ischaemia.	However,	each	of	the	studies	gives	us	an	insight	into	how	best	to	approach	this	question.	It	is	clear	that	total	NOx	(in	both	serum	and	RBC)	needs	to	be	accurately	quantified.	Ideally	this	NOx	quantification	should	measure	the	 trans-myocardial	 gradients	 from	 aorta	 to	 coronary	 sinus.	 Patients	 selected	should	have	overtly	ischaemic	coronary	territories	whose	epicardial	lesion	can	be	quantified	functionally.	The	addition	of	stable	chronic	ischaemia	(stable	angina)	as	 well	 as	 acute	 decompensated	 ischaemia	 (non-ST	 elevation	 myocardial	infarction,	NSTEMI)	should	be	included	as	separate	groups	as	the	mechanisms	of	compensation	 may	 differ.	 The	 assessment	 of	 CVR	 would	 be	 central	 to	
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understanding	 the	 role	of	NO	and	NO2-	 together	with	the	ability	 to	 reverse	 the	ischaemic	territory.		
	
The	core	aim	of	this	chapter	is	to	understand	the	role	of	NO	production	in	terms	of	regulation	of	CVR	in	patients	with	significant	epicardial	coronary	disease	and	how	this	changes	following	treatment	with	PCI.	Specifically,	we	will	quantify	NO	concentration	across	the	myocardial	circulation	both	before	and	after	PCI.	Two	defined	 populations	 will	 be	 studied;	 acute	 NSTEMI	 cohort	 and	 stable	 angina	cohort	both	with	quantified	and	ischaemic	lesions.	
	
	
Hypotheses		
1/	In	the	NSTEMI	cohort	(pre-PCI)	it	was	hypothesised	patients	will	have	reduced	endothelial	 function	 (NOS	 activity)	 and	 be	 reliant	 on	 NO2-	 reduction	 to	 NO	 to	maintain	low	CVR.	If	this	hypothesis	were	true	we	would	expect	a	negative	trans-myocardial	(Ao	to	CS)	NO2-	gradient	and	overall	consumption	of	NO	metabolites	prior	to	revascularisation.		Critical	to	this	observation	is	the	total	NO	metabolite	pool	in	both	plasma	and	red	blood	cell	(RBC)	compartments.	In	healthy	a	negative	NO2-		gradient	is	seen	but	this	is	balanced	by	a	positive	gradient	of	NOx	in	the	red	cell	compartment	which	equates	to	no	net	change	from	Ao	to	CS.		
2/	 Post-PCI	 following	 revascularisation	we	would	 expect	 a	 correction	 towards	zero	in	the	nitrite	gradients	reflecting	reduced	reliance	on	the	NO2-		reduction	to	NO	mechanism	in	the	(now)	non-ischaemic	and	less	hypoxic	myocardial	bed.		
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3/	The	stable	angina	cohort	will	have	less	reliance	on	nitrite	reduction	and	rely	on	other	chronically	upregulated	mechanisms	of	compensation	such	as	endothelial	(rather	 than	 nitrite)	 production	 of	 NO.	 This	would	 be	 reflected	 in	 a	 total	 NOx	positive	 gradient	 from	 aorta	 to	 coronary	 sinus	 (Serum	 and	RBC,	 but	 excluding	nitrate).	
	
Methods 
Study populations 
Two	populations	of	patients	were	studied;	NSTEMI	and	stable	angina.	The	NSTEMI	patients	were	principally	recruited	at	University	Hospital	of	Wales	(UHW)	whilst	stable	angina	patients	were	recruited	at	both	UHW	and	Papworth	hospital	(PH).	The	patients	recruited	at	PH	were	done	so	under	the	auspices	of	another	clinical	project	 that	 was	 designed	 with	 identical	 cardiac	 catheter	 protocols	 (Principal	Investigator	Stephen	Hoole).	UHW	patients	were	recruited	and	consented	by	the	local	 team	 and	 cathlab	 protocols	 and	 PCI	 also	 carried	 out	 at	 UHW.	 Sample	preparation	 and	 analysis	 was	 completed	 at	 Cardiff	 University.	 For	 Papworth	patients	recruitment,	consent,	PCI	and	cathlab	protocols	were	carried	out	by	the	team	at	Papworth	Hospital,	analysis	of	results	was	carried	out	in	Cardiff	University	using	 identical	 techniques.	 Sample	 preparation	 and	 storage	 conditions	 were	identical	between	the	two	centres,	storage	times	were	similar	as	the	samples	were	analysed	in	batches.	The	local	research	ethics	committee	approved	the	study	in	each	centre	and	written	informed	consent	was	obtained	from	each	patient.	
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Inclusion	criteria	
• Any	patient	over	the	age	of	18	with	the	capacity	to	consent	for	study	and	who	was	receiving	coronary	angiography	as	a	normal	investigation	and	as	part	of	their	routine	treatment	for	either	stable	angina	or	NSTEMI	
• Normal	left	ventricular	function	(EF≥50%),	assessed	by	echocardiography	
• Lack	of	contraindication	to	the	use	of	dual	antiplatelet	therapy	(aspirin	and	clopidogrel).	
• Patients	 that	 had	 one	 vessel	 PCI	 following	 coronary	 angiography	 with	lesions	 that	were	 suitable	 to	allow	 fractional	 flow	reserve	and	coronary	flow	reserve	measurements.	
• Patients	with	a	successfully	cannulated	coronary	sinus		Excluded	criteria	included:	
• Patients	with	ongoing	and	unstable	ischaemic	symptoms		
• Previous	STEMI	
• Significant	left	main	disease	
• Patients	with	chronic	total	occlusions,	index	or	otherwise	
• Patients	with	earlier	coronary	artery	bypass	grafts	
• Significant	valvular	disease	
• Symptoms	of	heart	failure		
• Recent	intravenous	nitrate	infusion	
• Atrial	fibrillation			
In	the	NSTEMI	group	patients	all	had	single	vessel	PCI	of	the	culprit	vessel	only	after	a	period	of	medical	treatment	as	outlined	in	Table	1.	The	culprit	vessel	was	selected	on	the	basis	of	angiographic	appearance,	ECG	changes	and	in	the	stable	
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cohort	in	conjunction	with	non-invasive	testing	when	indicated.	Index	vessels	and	other	baseline	variables	were	well	balanced	between	groups	as	per	Table	1.			
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 NSTEMI 
N=30 
Stable angina 
n=35 
Age 63.8 ± 12 64.4 ± 9.6 
Male (%) 32 (84) 29 (83) 
Creatinine μmol/L 88.5 (71.3 – 99) 91 (81 – 98.3) 
CRP 3 (2 – 6.25)  
Left ventricular function 
(EF) 
55 (50-55) 52 (50-55) 
Index vessel   
 LAD (%) 17 (57) 22 (63) 
 LCx (%) 7 (23) 6 (17) 
 RCA (%) 6 (20) 7 (20) 
Hypertension (%) 24 (80) 20 (58) 
Diabetes (%) 10 (33) 8 (23) 
Hyperlipaedemia (%) 28 (93) 24 (70) 
Smoking (%) 16 (53) 13 (37) 
Previous PCI (%) 5 (17) 14 (40) 
Clopidogrel > 5days (%) 30 (100) 21 (60) 
Beta-blocker (%) 25 (83) 27 (77) 
Calcium channel blocker 
(%) 
4 (13) 7 (20) 
ACE Inhibitor (%) 22 (73) 21 (60) 
Statin (%) 28 (93) 32 (91) 
Table 1: Baseline clinical characteristics of NSTEMI patient population 
Baseline clinical and laboratory characteristics of study population. Both pre-PCI and 24 hr post-PCI 
haemoglobin and total platelet count are included with no significant difference seen between either of 
these values. Abbreviations: PCI - percutaneous coronary intervention, CRP – C reactive protein, NSTEMI 
– non-ST-elevavation myocardial infarction, EF -  ejection fraction, ACE - angiotensin converting enzyme 
inhibitor, LAD – left anterior descending, LCx – Left circumflex, RCA – right coronary artery 	
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Cardiac catheterisation laboratory protocol 
The	cardiac	 catheterisation	protocol	 can	be	 seen	 in	 full	 in	 the	general	methods	page	55	
Measurement of Nitric Oxide metabolites 
As	described	in	general	methods	chapter:	page	61	
Statistical Analysis 
Normally	distributed	data	are	expressed	as	mean	±	SD	unless	otherwise	stated.	Non-gaussian	data	expressed	as	median	(IQR).	When	the	distribution	of	data	was	not	clear	the	Shapiro-Wilk	normality	test	was	used.	Multiple	comparison	between	related	 groups	 of	 means	 were	 made	 with	 paired	 and	 unpaired	 ANOVA	 with	Tukey’s	correction	for	multiple	comparisons.	Single	comparisons	were	made	with	paired	and	unpaired	student’s	t	test	as	appropriate.	Wilcoxon	test	was	used	for	non-parametric	 single	 comparisons	 of	 paired	 data	 and	 Mann-Whitney	 test	 for	unpaired	data.	
Results 
Table	 1	 displays	 the	 baseline	 clinical	 characteristics	 of	 the	 two	 study	 groups	together	with	key	baseline	physiological	measures.	Numerically	baseline	clinical	characteristics	were	well	matched	between	groups.		
Trans-myocardial NO metabolites and oxygen 
NSTEMI and stable cohorts 
The	trans-myocardial	NO	metabolite	profiles	for	these	two	groups	are	outlined	in	Table	2	and	Figure	8.	With	 respect	 to	 the	NSTEMI	cohort	 (n=30)	 there	was	no	
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significant	gradient	of	serum	nitrite	across	the	myocardium	pre	PCI	comparing	Ao	to	CS	levels	204-5	nM	(134.1	–	328.3)	vs	203.4	nM	(1245.3	–	293.9),	respectively	(p	 ANOVA>0.05).	 Absolute	measures	 of	 total	 red	 blood	 cell	NO	metabolites	 (RBC	NOx)	were	164.5	±	99	nM	in	Ao	and	247.2	±		142.8	nM	at	the	CS		(p	ANOVA<0.05**).	As	expected	we	see	increased	total	RBC	NOx	as	the	oxygen	concentration	reduces	from	Ao	to	CS.	(Figure	2)	The	total	NO	species	(excluding	nitrate)	were	403.9	±	192.3	 nM	 in	 Ao	 and	 488.7	 ±	 265.9	 nM	 in	 CS	 showing	 a	 positive	 gradient	 (net	production)	across	the	myocardium	of	84.9	nM	pANOVA	<0.05	*	(CI	9.5	to	160)	in	the	presence	of	a	significant	epicardial	stenosis	with	a	mean	FFR	of	0.62	±	0.03.	(Table	4)	
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NSTEMI Pre PCI NOx (n=30) 
 Aorta Coronary Sinus PANOVA  (CI) 
HbO2 (%) 96.6 ± 1.82 34.8 ± 8.7 -61.8 
 Serum NO2- (nM) 204.5 (134.1 to 
328.3) 
(134.1 to 328.3) 
203.4 
(125.3 to 293.9) 
PANOVA >0.05 
Total RBC (nM) 164.5 ± 99 247.2 ± 142.8 PANOVA <0.05* (13.5 to 152)  
mean diff 82.7nM 
Total NOx (nM) 403.9 ± 192.3 488.7 ± 265.9 PANOVA <0.05 *  (9.5 to 160)  
mean diff 84.9nM 
Table 2: Trans-myocardial NO metabolites (NOx) in NSTEMI patients 
Trans-myocardial nitric oxide metabolite concentration from aorta to coronary sinus Abbreviations: 
NSTEMI – Non-ST-Elevation MI cohort, PCI - percutaneous coronary intervention, NOx – total nitric oxide 
metabolites, HbO2 – haemoglobin oxygen saturation, NO2 – nitrite, CI – confidence intervals, nM – 
nanomolar, NO – nitric oxide  
Statistics: normally distributed data as mean ± SD, multiple comparisons with 1-way ANOVA. Not 
normally distributed median (IQR), multiple comparisons Friedman with Dunn’s correction (marked 
ANOVA) 
 
NSTEMI Post PCI NOx (n=30) 
 Aorta Coronary Sinus PANOVA  (CI) 
HbO2 (%) 96.7 ± 1.85 42.5 ± 12.4  
 Serum NO2- (nM) 240.9 
(135.5 to 
332.0) 
178.5 
(126.9 to 263.2) 
PANOVA >0.05 
Total RBC 167.9 (±91.5) 228.1 (±120.9) PANOVA >0.05  (-1.9 to 122.3)  
Total NO 412.9 ± 170 429.1 ± 185.3 PANOVA >0.05 (-59 to 91)  
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Following	coronary	intervention	(post	PCI)	this	total	NO	species	gradient	from	Ao	to	CS	reduced	from	its	pre	PCI	value	of	84.9	nM	(CI	9.5	to	160)	to	16.2	nM	(CI	-59.1	to	 91.6),	 post	 PCI.	 Principally	 the	 loss	 of	 this	 Ao	 to	 CS	 gradient	 post	 PCI	 was	secondary	to	the	development	of	a	negative	gradient	of	serum	nitrite	from		Ao	to	CS	where	 pre	 PCI	 there	 had	 been	 no	 gradient	 i.e.	 Ao	 [nitrite]	=	 CS	 [nitrite].	 As	expected	the	RBC	NOx	values	continued	to	show	their	reciprocal	relationship	with	oxygen	saturation	and	the	gradient	from	Ao	to	CS	pre	PCI	was	preserved	post	PCI.	(figure	2)	The	sum	of	these	two	NO	metabolites	was	412.9	±	170	nM	in	Ao	and	429.1	±	185.3	nM	in	CS	(again	excluding	nitrate)	giving	a	non-significant	difference	of	+16.2nM	cross	heart	once	the	epicardial	stenosis	had	been	treated	by	PCI.	The	post-PCI	FFR	was	0.92	±	0.06	indicating	that	the	epicardial	stenosis	in	this	group	was	adequately	treated.	(Table	4)	
	
The	stable	cohort	(n=35)	underwent	exactly	the	same	Aortic	and	Coronary	Sinus	sampling	 pre	 and	 post	 PCI.	 From	 the	 perspective	 of	 measured	 serum	 nitrite	concentrations	these	patients	exhibited	results	that	closely	resemble	a	cohort	of	healthy	patients	with	no	coronary	disease	measured	by	our	group	previously.97	(Table	1,	Figure	8)	The	serum	concentration	of	nitrite	in	the	aorta	of	these	stable	patients	 pre	 and	 post	 PCI	 was	 very	 similar	 (pANOVA>0.05),	 436nM	 (132.4)	 and	489.6	 (173.5),	 both	 values	 significantly	 higher	 than	 the	matched	 values	 in	 the	NSTEMI	 group.	 Like	 the	 healthy	 controls	 measured	 previously,	 there	 was	 a	significant	negative	gradient	across	the	myocardium	-175.5nM	PANOVA	<0.05	****.	This	negative	gradient	was	almost	identical	post	PCI	(-183.8nM).	
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	With	 respect	 to	 CS	 saturations	 there	 was	 a	 significant	 increase	 in	 oxygen	saturation	post	PCI.	Pre	to	post	PCI	mean	CS	saturations	were	38.7%	(SD	8.4)	and	50.0%	(SD	12.1),	respectively	(p=0.0094).	(Figure	9)	
	
Table 3: Trans-myocardial NO metabolites Stable Angina cohort 
Trans-myocardial nitric oxide metabolite concentration from aorta to coronary sinus Abbreviations: PCI 
- percutaneous coronary intervention, NOx – nitric oxide metabolites, HbO2 – haemoglobin oxygen 
saturation, NO2 – nitrite, nM – nanomolar, NO – nitric oxide  
Statistics: normally distributed data as mean ± SD 	
Stable Angina Pre-PCI NOx (n=35) 
 Aorta Coronary Sinus Delta PANOVA   
HbO2 (%) 97.1 ± 1.9 40.4 ± 7.2 -56.7 
 Serum NO2- (nM) 436.6 ± 132.4 261.1 ± 109.1 -175.5 PANOVA <0.05 
**** 
-175.5 PANOVA <0.05 
**** 
Stable Angina Post-PCI NOx (n=35) 
 Aorta Coronary Sinus Delta PANOVA   
HbO2 (%) 97.3 ± 2.1 50.4 ± 9.6 -46.9 
 Serum NO2- (nM) 489.6 ± 173.6 305.8 ± 130.9 -183.8 PANOVA <0.05 
**** 
-183.8 PANOVA <0.05 
**** 
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Figure 8: Trans-myocardial NO2- metabolites (NOx) in NSTEMI & Stable angina patients 
Figure 9: Trans-myocardial oxygen saturation (%) in NSTEMI & Stable angina patients 
Abbreviations: NSTEMI – Non-ST-Elevation MI cohort, PCI - percutaneous coronary intervention, 
intervals, nM – nanomolar, NO – nitric oxide  
 
Serum nitrate quantification 
All	three	cohorts	had	nitrate	concentration	measured	at	the	identical	time	points	to	nitrite	and	 total	RBC	measures.	Using	a	one-way	ANOVA	 test	 there	were	no	significant	 differences	 between	 time	 points	 within	 each	 group	 or	 across	 the	different	groups.	Nitrate	 is	present	 in	μM	concentrations	as	opposed	to	the	nM	concentration	 of	 serum	 nitrite	 and	 RBC	NOx.	 Because	 nitrate	 does	 not	 change	between	sampling	points	-	and	there	is	no	evidence	that	humans	are	able	to	reduce	nitrate	 to	 nitrite	 across	 the	 coronary	 circulation	 –	 we	 exclude	 this	 from	 the	calculations	of	total	NO	metabolites.	
	
Coronary physiology measurements (CVR) 
A	summary	of	all	coronary	measures	is	reported	in	Table	4	
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NSTEMI and stable cohorts 
In	the	NSTEMI	cohort	the	mean	FFR	pre	and	post	PCI	was	0.62	(SD	0.18)	and	0.91	(SD	0.06)	confirming	both	significant	ischaemia	in	the	myocardial	territory	being	studied	 and	 adequate	 restoration	 of	 epicardial	 vessel	 luminal	 area	 following	PCI.129	The	stable	cohort	FFR	measures	were	very	similar	Pre-PCI	0.69	(SD	0.16)	and	Post-PCI	0.93	(SD	0.05).		
	
Prior	to	PCI	the	IMRrest	-	a	surrogate	of	CVR	-	in	the	NSTEMI	cohort	pre	PCI	was	45.7	 units	 (SD	 21.7).	 Immediately	 post-	 PCI	 this	 increased	 to	 57.6	 (SD	 37.9),	p=0.027	(Figure	3).	These	values	represent	a	rise	 in	resting	microvascular	 tone	immediately	post	PCI	and	at	the	point	of	aortic	and	coronary	sinus	sampling.		
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 NSTEMI (n=30)  Stable Angina  
(n=35) 
 
 Pre-PCI Post-PCI  Pre-PCI Post-PCI  
FFR 0.62 ± 0.03 0.92 ± 0.06 p<0.05**** 0.73 ± 0.15 0.93 ± 0.06 p<0.05**** 
IMRrest 
units 
46.2 ± 21.6 57.6 ± 37.9 p=0.038 38.9 ± 18.4 38.99 ± 22.1 p=0.97 
IMRhyp 
units 
22.3 ± 12.4 22.5 ± 19.8 p=0.95 16.1 ± 7.6 14.03 ± 7.1 p=0.16 
Collateral 
Flow Index 
(CFI) 
mmHg 
0.09 ± 0.08   0.2 ± 0.13  p=0.0001 
Table 4: Coronary physiology results summary data 
Coronary physiology data pre-PCI and 5 minutes post-PCI 
Abbreviations: NSTEMI – Non-ST-Elevation MI cohort, PCI - percutaneous coronary intervention, FFR – 
Fractional flow reserve, IMRrest – Index of microvascular resistance resting conditions, IMRhyp – Index of 
microvascular resistance at hyperaemia, CFI – Collateral Flow Index. 
Statistics: Normally distributed data presented as mean ± SD with significance calculated with one-way 
ANOVA with tukey’s correction for multiple comparisons or paired t-test were ANOVA not possible. FFR 
is a ratio of Pd/Pa. IMRrest and IMRhyp are dimensionless. 
 	
In	the	stable	cohort	IMRrest	pre-PCI	was	38.9	(SD	18.4)	vs.	post-PCI	38.99	(SD	3.96),	p>0.05.	Whilst	the	pre-PCI	values	were	similar	between	the	two	cohorts	unlike	the	NSTEMI	cohort	the	stable	cohort	did	not	see	a	significant	rise	in	IMRrest	post-PCI.	(Table	4	and	Figure	10)		
	
Minimal	microvascular	tone	(IMRhyp)	in	the	NSTEMI	cohort	pre	and	post-PCI	did	not	change	significantly;	22.3	(SD	12.4)	vs	22.5	(SD	19.8)	p>0.05.	The	same	was	true	 for	 the	 stable	 cohort;	 IMRhyp	 did	 not	 change	 significantly	 pre	 to	 post-PCI;	16.14	(SD	7.55)	vs	14.03	(SD	7.11),	p=0.16.	Overall	IMRhyp	in	the	NSTEMI	group	
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was	significantly	higher	than	the	corresponding	measures	in	the	stable	cohort	as	outlined	in.	(Table	4	and	Figure	11)	
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Figure 10: IMRrest Pre and Post-PCI in both NSTEMI & Stable angina patients 
Figure 11: IMRhyp Pre and Post-PCI in both NSTEMI & Stable angina patients 
Abbreviations: NSTEMI – Non-ST-Elevation MI cohort, PCI - percutaneous coronary intervention, IMRrest 
Index of microvascular resistance at rest, IMRhyp index of microvascular resistance during hyperaemia 
(minimal IMR) 
	
Figure 12: Collateral Flow Index (CFI) in both NSTEMI & Stable angina patients 
Abbreviations: NSTEMI – Non-ST-Elevation MI cohort, Stable – Stable angina pectoris 	
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The	 coronary	wedge	 pressure	was	measured	 in	 all	 groups	 pre-PCI	 in	 order	 to	correct	 for	 collateral	 circulation	 in	 the	 calculation	 of	microvascular	 tone.	 This	wedge	pressure	was	converted	to	the	collateral	flow	index	(CFI),	the	stable	cohort	had	a	significantly	higher	collateral	 flow	index	than	the	NSTEMI	group;	0.2	(SD	0.13)		vs.	0.08	(SD	0.08),	p	<0.0001	(Figure	12).		
	
Discussion 
We	have	clearly	indicated	a	significant	net	NO	production	across	the	myocardial	bed	 in	 NSTEMI	 patients	 with	 significant	 epicardial	 stenosis.	 The	 net	 positive	gradient	 in	 the	NSTEMI	cohort	 is	84.9	nM,	principally	 the	result	of	no	apparent	change	in	nitrite	and	an	increase	in	RBC	NOx	across	the	coronary	bed.	This	is	in	complete	 contrast	 to	 the	 stable	 angina	 cohort	 and	 data	 we	 have	 observed	previously	in	healthy	control	patients.	In	the	presence	of	a	significant	epicardial	stenosis	 -	 and	 reduced	 CBF	 –	 the	 benefits	 of	 increased	 trans-myocardial	 NO	production	are	clear.	With	a	lower	CVR	via	dilation	of	resistance	vessels	by	locally	produced	NO	this	mechanism	increases	the	effective	trans-myocardial	perfusion	pressure,	which	in	turn	increases	CBF.		
	
Pre-PCI	aortic	root	serum	nitrite	is	significantly	lower	in	the	NSTEMI	cohort	(204.5	CI	134.1	to	328.3)	in	comparison	to	the	stable	angina	cohort	(436.6	±	132.4	nM),	this	may	reflect	systemic	rather	than	myocardial	endothelial	function.	If	this	is	the	case	the	NSTEMI	cohort	have	significant	reduction	in	their	systemic	endothelial	function	 /	 health	 in	 comparison	 to	 those	 patients	with	 stable	 angina.	 It	 is	 not	
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understood	how	systemic	NO	production	interacts	with	local	trans-myocardial	NO	production.	 Improved	systemic	endothelial	 function	 in	the	stable	angina	cohort	may	go	in	some	way	to	compensate	for	the	epicardial	stenosis	by	reducing	CVR,	it	may	also	relate	to	the	improved	collateral	formation	indicated	by	the	significantly	higher	CFI.		
	
In	 contrast	 increasingly	dysfunctional	 systemic	endothelial	 function	 in	patients	with	 coronary	 disease	 has	 been	 associated	 with	 negative	 outcomes.	 130	 In	 the	context	of	trans-myocardial	NO	production	(in	NSTEMI	patients)	perhaps	we	are	seeing	 a	 localised	 up	 regulation	 of	 NOS	 in	 response	 to	 a	 highly	 dysfunctional	systemic	 endothelium.	 Almost	 a	 “last-ditch”	 attempt	 to	 reduce	 CVR	 in	 an	increasingly	decompensated	auto-regulatory	system	that	is	on	the	limit	of	being	able	to	adjust	and	compensate	for	a	severe	epicardial	stenosis.	This	data	supports	those	observations	and	indicates	a	mechanism	as	to	why	these	patients	may	have	worsening	 cardiovascular	 outcomes	 as	 the	 endothelium	 loses	 its	 ability	 to	maintain	myocardial	perfusion	acutely.	The	resting	IMR	data	in	the	stable	cohort	certainly	supports	the	idea	of	a	lower	CVR	prior	to	hyperaemia	(Stable	IMRrest	38.9	
±	18.4	U	vs	NSTEMI	IMRrest	46.2	±	21.6	U:	both	pre-PCI). 
	
Supporting	the	trans-myocardial	NOx	observations	in	the	NSTEMI	group	we	see	IMRrest	rise	significantly	from	pre-PCI	to	post-PCI	(46.2	Units	±	21.6	vs.	57.6	Units	±	37.9,	p=0.038)	following	restoration	of	epicardial	calibre.	In	the	same	cohort	we	see	a	sharp	correction	in	trans-myocardial	NO	production	from	85.1nM	down	to	24.5nM.	This	correction	may	partly	reflect	acute	down	regulation	of	endothelial	
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NOS	secondary	to	the	reduction	in	shear	stress	post-PCI,	81	and	perhaps	reduced	RBC	ATP	release	as	oxygen	saturation	improve	locally.	46	Conversely,	this	apparent	reduction	in	NO	production	may	just	reflect	the	increased	flow	following	PCI	and	be	caused	by	a	simple	dilutional	effect	which	leads	to	an	acute	rise	in	resting	CVR	(IMRrest).	The	IMRhyp	reflects	how	well	preserved	the	microcirculation	is	and	its	maximal	capacity	of	vasodilation.	A	number	of	factors	can	influence	hyperaemic	IMR	 including	 severe	 left	 ventricular	 hypertrophy	 (LVH)	 and	 myocardial	infarction.	114-116	In	both	the	stable	angina	population	and	the	NSTEMI	population	we	see	no	significant	difference	in	IMRhyp	pre	to	post	PCI,	we	can	assume	therefore	that	 these	 two	 patients	 groups	 have	 not	 suffered	 significant	 peri-procedural	myocardial	 infarction	 (caused	 by	 the	 coronary	 intervention)	 which	 may	 have	influenced	our	measurements	of	CVR	(IMRrest).131	
	
If	 we	 assume	 that	 NOS	 activity	 remains	 constant	 and	 the	 reduction	 in	 NO2-	concentration	 is	a	dilutional	effect	secondary	to	 increased	flow,	we	can	make	a	rudimentary	calculation	of	how	much	flow	would	need	to	increase	using	the	Fick	principal	(Figure	13).	Using	the	measured	NOx	values	in	the	NSTEMI	population	pre	and	post	PCI	we	calculate	that	flow	would	need	to	increase	5.23	times	in	order	to	 account	 for	 this	 reduction	 in	 NOx	 in	 terms	 of	 a	 pure	 dilutional	 effect	 from	increased	CBF	following	PCI.	
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Figure 13: Fick calculation of change in coronary blood flow in NSTEMI cohort post-PCI  
Panel A: Fick principal for calculating Cardiac output  
Panel B&C: Substituting Fick equation for NOx concentration in Ao and CS, pre to post PCI 
Panel D: Replacing P with pre-PCI Ao – CS concentration of NOx 
Panel E: If pre-PCI flow = 1 then post-PCI flow = 5.23 times pre-PCI 
Abbreviations: VO2: Oxygen consumption, CO:Cardiac output, Ca & Cv: Arterial and venous oxygen 
saturation,  C: concentration (nM), f= flow (dimensionless), NOx: total NO metabolite concentration 
(serum plus red cell excluding, nitrate). 	
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Obviously,	the	calculation	of	increased	flow	is	based	on	several	assumptions	which	cannot	be	proven	and	are	unlikely	to	be	correct.	These	include	the	assumption	that	NO	 synthesis	 by	 NOS	 does	 not	 change	 following	 PCI.	 However,	 it	 is	 certainly	possible	that	there	is	an	acute	regulation	of	NOS	activity	by	either/both	reduced	shear	force	(reduced	velocity	across	the	epicardial	lesion),	and	downregulation	of	NOS	 via	 the	 adenine	 /	 purinergic	 pathway	 (described	 in	 Chapter	 1:	 General	Introduction),	it	is	also	reliant	on	there	being	no	reduction	of	nitrite	to	NO	and	loss	to	myocardial	tissue.		
	
Following	PCI	we	only	see	a	change	in	nitrite	gradient	(A-V),	the	RBC	NOx	content	remains	constant.	The	constant	positive	RBC	NOx	gradient	can	be	explained	by	the	reciprocal	relationship	between	oxygen	saturation	and	RBC	NOx	primarily	caused	by	an	increase	in	Hb-NO	as	the	oxygen	saturation	drops.	97	Whilst	this	study	would	have	benefited	from	the	use	of	NOS	inhibitors	we	see	a	direct	relationship	between	reduced	 total	 NO	 concentration	 (post	 PCI)	 and	 an	 increase	 in	 IMRrest	which	 is	consistent	 with	 the	 role	 of	 NO	 in	 the	 regulation	 of	 CVR.	 This	 CVR	 regulation	compensates	for	severe	epicardial	stenosis	and	helps	to	maintain	CBF.		
	
It	 is	 important	 to	 note	 that	minimal	microvascular	 resistance	 IMRhyp	 does	 not	change	from	pre	to	post-PCI	indicating	that	the	rise	in	resting	microvascular	tone	is	not	secondary	to	peri-procedural	myocardial	infarction	or	other	factors.		
	
In	our	NSTEMI	cohort	we	have	shown	objective	evidence	of	 ischaemia	and	 low	oxygen	saturations	prior	to	PCI,	yet	despite	this	environment	we	see	no	evidence	
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of	the	nitrite	consumption	(reduction	of	nitrite	to	NO)	that	we	would	expect	to	see	if	this	was	the	dominant	mechanism	of	autoregulatory	adaptation.	Overall,	we	see	a	net	increase	in	trans-myocardial	NOx	confirming	net	NO	production	across	the	human	coronary	bed	in	response	to	hypoxia	and	ischaemia.	Of	course,	what	this	data	 cannot	 indicate	 is	 a	 dynamic	 situation	 in	 which	 both	 methods	 of	 NO	production	are	occurring	(NOS	synthesis	and	Nitrite	reduction),	with	competing	influences	 on	 overall	 NO	 metabolite	 concentration.	 	 The	 addition	 of	 a	 NOS	inhibitor	would	help	delineate	the	influence	of	these	competing	systems	however,	this	clearly	would	be	unsafe	in	a	group	of	patients	with	acute	coronary	syndromes	and	impaired	coronary	blood	flow.	Analysis	of	this	dynamic	situation	is	seen	in	the	next	 chapter	 (Chapter	4:	Results	2)	with	 the	 recruitment	of	 a	 further	 cohort	of	NSTEMI	patients	 investigated	 in	an	 identical	manner	but	with	augmentation	of	serum	nitrite	concentrations	prior	to,	during	and	after	revascularisation.		
	
The	findings	in	our	stable	cohort	seem	to	be	at	odds	with	the	observations	made	in	 the	 NSTEMI	 cohort.	 Whilst	 the	 stable	 angina	 cohort	 had	 similar	 baseline	characteristics	and	equivalent	levels	of	ischaemia	(Table	4:	Coronary	physiology	results	summary	data),	there	were	some	fundamental	differences	in	both	trans-myocardial	NO	gradients	and	microvascular	tone.	Pre-PCI	we	saw	a	similar	resting	tone	(IMRrest)	in	comparison	to	the	NSTEMI	patients	(Stable	38.9±18.4	vs.	NSTEMI	46.2±21.6,	 p=0.15),	 however,	 post-PCI	 instead	 of	 this	 rising	 (as	 it	 did	 in	 the	NSTEMI	cohort)	 there	was	no	change	 in	 IMRrest	 (pre-PCI	38.9±18.4	vs.	post-PCI	38.99±22.06,	 p=0.98).	 The	 stable	 cohort	 also	 had	 a	 negative	 trans-myocardial	gradient	of	serum	nitrite,	similar	to	typical	healthy	patients	that	can	be	ascribed	
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completely	 to	 the	 reciprocal	 relationship	 of	 oxygen	with	RBC-NOx	distribution	with	 no	 net	 rise	 in	 total	NO	metabolites.	 97	 A	 key	 observation	was	 the	mature	coronary	 collateral	 circulation	 in	 the	 stable	 population	 as	 reflected	 by	 the	significantly	elevated	CFI	in	comparison	to	the	NSTEMI	cohort	Stable	angina	CFI	0.2	 (SD	 0.13)	 	 vs.	 	 NSTEMI	 CFI	 0.08	 (SD	 0.08),	 p	 <0.0001	 (Figure	 12).	 The	autoregulatory	control	of	blood	flow	in	these	patients	is	more	stable	and	this	may	be	related	to	the	non-acute	nature	of	these	patients	and	specifically	their	coronary	lesions.	We	 suggest	 the	mechanism	of	 compensation	 in	 stable	 patients	may	 be	related	to	the	development	of	a	mature	coronary	collateral	circulation	as	indicated	by	 the	 significantly	 elevated	 CFI	 in	 this	 group.	 This	 collateral	 circulation	represents	a	form	of	chronic	adaptation	that	may	negate	the	need	for	upregulation	of	NOS	 and	may	 explain	 the	mixed	 findings	 of	 the	 role	of	NO	 in	 these	 patients	described	previously.	88,93		
 
Conclusion  
The	 above	 study	 gives	 compelling	 evidence	 that	 in	 acute	 patients	 suffering	NSTEMI,	 upregulation	of	 endogenous	 production	of	NO	 -	 presumably	 by	NOS	 -	plays	a	role	in	autoregulatory	adaptation	of	CVR	to	maintain	myocardial	perfusion.	Patients	with	significant	coronary	atherosclerosis	have	consistently	been	shown	to	have	reduced	endothelial	function,	92,93,130,132	it	is	clear	from	this	data	that	the	remaining	endothelial	function	(in	terms	of	localised	myocardial	NO	production),	still	 has	 a	 role	 to	 play.	 Overall	 the	 ability	 of	 individuals	 to	 compensate	 for	
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significant	 (and	 acute)	 epicardial	 stenosis	 may	 be	 related	 to	 their	 ability	 to	upregulate	NOS	and	reduce	CVR.			
	
Despite	 the	 perfect	 environment,	 we	 failed	 to	 find	 compelling	 evidence	 of	increased	dependence	on	nitrite	consumption.	However,	without	the	use	of	NOS	inhibitors	it’s	difficult	to	get	a	clear	understanding	of	the	potential	competing	and	dynamic	influences	of	NO	production	by	NOS	and	Nitrite	reduction.		
	
In	stable	patients,	we	do	see	a	negative	gradient	of	serum	nitrite	 together	with	preserved	 resting	 microvascular	 tone	 post	 PCI.	 However,	 as	 coronary	 sinus	oxygen	saturations	increase	we	do	not	see	any	reciprocal	changes	in	this	nitrite	gradient.	 	Another	explanation	for	the	preserved	microvascular	tone	post	PCI	is	the	objective	evidence	of	substantial	collateral	vessel	formation	with	significantly	elevated	CFI.	Collateral	vessels	formation	may	represent	a	chronic	compensatory	mechanism	that	negates	the	need	for	up-regulation	of	NOS.	
 
LIMITATIONS 
These	experiments	have	several	limitations	that	are	inherent	in	this	type	of	clinical	research.	The	first	set	of	limitations	are	those	created	by	selecting	compromises	that	allow	this	research	to	be	carried	out	in	humans,	safely	and	in	parallel	to	their	clinical	treatment	following	life	threatening	diagnosis.	Amongst	these	limitations	was	the	time	constraint	and	sampling	constraints	in	terms	of	how	long	and	how	often	 we	 could	 measure	 physiological	 and	 serum	 concentrations	 immediately	
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post-PCI.	 We	 can’t	 exclude	 the	 possibility	 of	 later	 significant	 changes	 in	 CVR	(IMRrest)	 and	 NOx	 concentrations.	 For	 example,	 we	 may	 have	 seen	 a	 time	dependent	 change	 in	 NOx	 formation	 indicating	 “recovery”	 of	 NO	 synthesis	 to	compensate	for	increased	flow	post-PCI	and	a	biphasic	response	in	CVR	(IMRrest)		
Whilst	we	attribute	the	increase	in	CVR	post-PCI	(in	the	NSTEMI	cohort),	to	the	reduction	in	NOx	metabolites	(and	thus	NO	synthesis	by	dilution	or	otherwise),	we	can’t	be	sure	the	process	is	not	a	highly	dynamic	one	between	NO2-	reduction	to	NO	and	NOS	synthesis	of	NO.	Equally,	there	may	be	confounding	influences	on	changes	in	CVR	(IMRrest),	the	likeliest	being	the	intact	myogenic	mechanism	(page	41).	The	use	of	a	NOS	inhibitor	would	have	helped	to	elucidate	these	mechanisms,	however,	 the	 use	 of	 these	 drugs	 in	 acute	 NSTEMI	 patients	 is	 not	 possible.		However,	in	the	following	chapter	we	augment	the	serum	concentration	of	NO2-	to	further	understand	its	role	in	autoregulation	of	myocardial	blood	flow.	
	
Unfortunately,	 because	 of	 geographical	 constraints	 measurement	 of	 total	 red	blood	cell	NO	metabolites	was	not	possible	(stable	cohort	primarily	recruited	in	Papworth,	Cambridge).	Without	 total	RBC	we	can	only	assume	that	 the	 inverse	correlation	of	total	RBC	NOx	to	Oxygen	saturation	exists	as	per	previous	healthy	controls	and	our	groups	here.	
	
The	split	of	recruitment	between	two	centres	potentially	introduces	experimental	bias	in	terms	of	small	differences	in	the	way	experimental	protocols	are	performed	and	samples	are	handled.	
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Chapter 4: Results 2  
Augmentation of serum nitrite in patients with non-ST elevation 
myocardial infarction: effect on coronary vascular resistance before and 
after coronary intervention. 
ABSTRACT 
Background 
Nitrite,	a	metabolite	of	NO	can	itself	be	reduced	to	NO	under	favorable	conditions.	In	the	previous	NSTEMI	cohort	resting	CVR	(IMRrest)	is	significantly	higher	than	in	stable	angina	patients	and	rises	significantly	post-PCI	in	correlation	with	an	acute	drop	in	NO	synthesis.	This	snapshot	does	not	tell	us	if	there	is	both	NOS	activity	and	nitrite	reduction	to	NO	competing	with	each	other	and	shuttling	between	both	NO	and	its	metabolites.	Augmented	serum	nitrite	concentration	would	have	the	effect	of	“pushing”	nitrite	reduction	to	NO	in	favourable	conditions.		
Methods 
15	 patients	 were	 recruited	 following	 an	 NSTEMI	 and	 scheduled	 to	 have	 an	angiogram	+/-	PCI	(NSTEMIinf).	Pre-PCI	aortic	(Ao)	and	coronary	sinus	(CS)	blood	samples	were	 taken	prior	 to	 starting	an	 intravenous	 infusion	of	sodium	nitrite	(3.3μmol/min	for	30	minutes),	a	further	CS	sample	was	taken	5	minutes	after	the	start	of	the	infusion	and	just	prior	to	measurement	of	CVR	(IMRrest	and	IMRhyp).	PCI	was	then	carried	out	and	a	further	Ao	and	CS	blood	sample	was	taken	post-PCI.	Both	serum	and	red	blood	cell	NO	metabolites	(NOx)	were	measured	using	
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ozone	 based	 chemiluminescence.	 The	 control	 group	 (n=30)	 were	 the	 same	patients	recruited	in	the	previous	chapter	and	analysed	with	identical	method.	
Results 
The	NSTEMIinf	cohort	had	a	five	fold	increased	concentration	of	serum	nitrite	in	comparison	to	the	NSTEMI	cohort	without	nitrite	infusion;	pre-PCI	NSTEMI	203.4	nM	(125.	to	293.9)	vs.	pre-PCI	NSTEMIinf		1274nM	(821.5	to	1475).		No	influence	on	IMRrest	(NSTEMIinf	47.1±30.9	vs.	NSTEMI	46.2±21.6	p=0.91)	was	seen.	During	PCI	 median	 serum	 nitrite	 concentrations	 were	 1422	 nM	 (1032	 to	 1842).	 No	influence	was	seen	on	post	PCI	microvascular	 tone	 (IMRrest).	 Indeed,	 an	almost	identical	rise	in	microvascular	tone	to	that	seen	in	NSTEMI	without	nitrite	infusion	(NSTEMIinf	59.63±40.1	vs.	NSTEMI	57.6±37.9,	p=0.87).	
Discussion 
The	NSTEMI	cohort	had	a	net	production	of	NO	from	A	to	V	which	correlated	with	changes	in	CVR.	In	a	second	cohort	NSTEMIinf,	an	infusion	of	intravenous	sodium	nitrite	prior	to	and	during	PCI	was	administered	with	a	5	fold	increase	in	serum	NO2-	 	 concentration.	 Despite	 this	 no	 effect	 was	 seen	 on	 CVR	 pre	 or	 post-PCI.	Synthesis	of	NO	in	the	coronary	circulation	seems	to	have	a	significant	effect	on		CVR	 in	 NSTEMI	 patients,	 nitrite	 reduction	 to	 NO	 does	 not	 appear	 to	 have	 a	significant	role	in	CVR	regulation	of	NSTEMI	patients.		
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INTRODUCTION 
The role of Nitrite in the ischaemic myocardium: the perfect model? 
Whilst	 the	inhibition	of	endothelial	dependent	NO	synthesis	has	been	shown	to	increase	resistance	vessel	tone	in	ischaemic	models	and	also	in	healthy	humans	at	rest	 and	 during	 pacing,	 94-96	 it	 has	 been	more	 difficult	 to	 directly	measure	 net	increases	in	metabolites	of	NO	(Serum	Nitrite,	Total	Red	Blood	Cell	(RBC)	NOx)	using	sensitive	methods	in	similar	human	models.	97	Part	of	the	explanation	for	this	absence	of	a	net	rise	in	direct	measures	of	NO	metabolites	may	be	the	role	of	serum	 nitrite.	 Under	 favourable	 conditions	 (hypoxia,	 acidosis)	 nitrite	 (itself	 a	metabolite	of	NO),	may	be	re-cycled	to	NO	acting	as	a	bioavailable	pool	of	NO	made	available	 to	 hypoxic	 and	 ischaemic	 tissue.	 One	 of	 the	 central	 tenets	 to	 this	mechanism	is	thought	to	be	the	ability	of	deoxy-haemoglobin	to	reduce	nitrite	to	NO	 and	 thus	 describes	 a	 plausible	 mechanism	 for	 hypoxia	 induced	vasodilation.101,102	 Like	 other	 proposed	 mechanisms	 the	 “deoxy-haemoglobin”	hypothesis	has	its	limitations,	the	actual	mechanism	of	nitrite	reduction	to	NO	is	likely	to	be	more	complex	and	involve	multiple	pathways	both	enzymatic	and	non-enzymatic	 (see	 introduction	 page	 46).	 Regardless	 of	 the	 mechanism	 multiple	studies	 have	 reported	 the	 vasodilatory	 action	 of	 intravenous	 or	 oral	 doses	 of	nitrite	in	various	ischaemic	models.	133-138		
	
 Human studies of NO2-   administration in health and disease 
There	 are	 many	 small	 trials	 and	 cohort	 studies	 that	 have	 used	 intravenous	administration	of	NO2-			to	study	its	role	in	control	of	vascular	tone	in	humans.	Here	
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we	will	 look	at	 three	key	studies	and	 in	addition	appraise	the	two	more	recent	clinical	trials	in	patients	with	acute	heart	attacks	(STEMI).		
	
Cosby	et	 al	 101	 infused	sodium	nitrite	NaNO2	into	 the	brachial	 artery	of	healthy	human	subjects	increasing	serum	nitrite	from	a	baseline	of	200nM	to	221μM	at	peak	 in	one	group	and	200nM	 to	2.56	μM	 in	another.	Forearm	blood	 flow	was	measured	with	strain	gauge	plethysmography	(SGP)	and	was	found	to	increase	by	175%	 and	 25%	 respectively.	 Further,	 during	 exercise	 there	was	 a	 decrease	 in	venous	NO2-	and	a	further	increase	in	forearm	blood	flow.	Whilst	the	changes	in	forearm	blood	flow	are	interesting	in	terms	of	NO2-	mechanism	the	reduction	in	serum	NO2-	during	exercise	seems	predictable	given	the	demonstrated	reduction	in	venous	oxygen	content	and	how	this	creates	a	situation	where	the	components	of	NO	metabolism	are	 redistributed	between	serum	and	RBC	compartments	as	described	by	Rogers	et	al.	97		
	
Dejam	et	al139	used	a	similar	model	to	Cosby	-	with	a	brachial	infusion	of	NaNO2	-	but	 this	 time	 looked	 at	 the	 influence	 of	 also	 inhibiting	 xanthine	 oxidase	 with	allopurinol	or	adding	ascorbic	acid	to	promote	acid	disproportionation.	Neither	agent	 further	 enhanced	 forearm	 blood	 flow	 and	 a	 dose	 escalation	 protocol	demonstrated	 the	 decay	 of	 both	HbNO	 and	 plasma	NO2-	 in	 the	 same	direction.	However,	considering	the	avidity	of	deoxy-haem	for	NO	it	is	difficult	to	understand	how	 -	 in	 a	 hypoxic	 environment	 that	 is	 purportedly	 reducing	NO	 –	NO	 can	 be	released	from	deoxy-haem	to	the	surrounding	endothelium	/	tissue	and	how	both	NO2-		and	HbNO	can	decay	at	the	same	rate.	
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Ingram	et	al	140	studied	the	effect	of	an	intravenous	NaNO2	infusion	on	patients	during	 dobutamine	 stress	 echocardiogram	 who	 had	 previously	 had	 a	 clinical	diagnosis	 of	 angina	 confirmed	with	 coronary	 angiography.	 This	was	 a	 blinded	randomised	 placebo	 controlled	 crossover	 study	 in	 which	 ten	 patients	 were	recruited.	He	found	that	NaNO2	infusion	(1.5μmol/min	for	20	mins)	improved	the	functional	 response	 in	 ischaemic	 myocardium	 but	 had	 no	 effect	 in	 normally	perfused	areas	of	myocardium.		
 
Lower dose of NaNO2-: biologically active with minimal systemic arterial side-
effects 
High	 doses	of	NaNO2	may	 not	 be	 safe	 in	 humans	 in	 the	 context	 of	 pre-existing	cardiac	disease.	We	know	that	these	high	doses	may	produce	vascular	collapse	and	syncope.	141	Ingram	demonstrated	in	this	study	and	another	(using	hypoxia	and	measuring	pulmonary	vascular	dilation	with	an	 infusion	of	nitrite)	 that	a	lower	total	dose	of	NaNO2	had	a	significant	effect	on	pulmonary	vasodilation.	135	These	finding	 were	 consistent	 with	 other	 groups	 in	 particular	 Maher	 et	 al	 133	 who	demonstrated	a	progressive	dose	related	effect	of	brachial	artery	NaNO2	infusion.	He	found	biologically	important	effects	on	forearm	blood	flow	(during	hypoxia	and	normoxia)	at	doses	from	314nmol/min	(incremental	steps	of	40nmol/min)	with	maximal	effect	at	7.84μmol/min.	Its	important	to	note	that	the	arterial	flow	was	enhanced	by	the	addition	of	hypoxia	with	the	NaNO2	infusion.			
These	 studies	 confirm	 that	 lower	 doses	 than	previously	 described	 102	 are	 both	biologically	active	and	importantly	safe	in	healthy	and	non-healthy	patients.	
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Nitrite and its role in patients with acute myocardial infarction 
To	 date	 per-conditioning	 with	 sodium	 nitrite	 in	 patients	 with	 ST-elevation	myocardial	 infarction	 has	 been	 carried	 out	 in	 two	 clinical	 trials.	 The	 first	was	“Intravenous	 sodium	 nitrite	 in	 acute	 ST-elevation	 myocardial	 infarction:	 a	randomized	controlled	trial”	(NIAMI).	NIAMI	was	a	trial	carried	out	by	Siddiqi	et	al,	142	a	multi-centre,	double-blind,	placebo	controlled	trial	in	patients	presenting	with	acute	ST-elevation	myocardial	infarction	(STEMI).	An	intravenous	infusion	of	NaNO2	was	administered	(totaling	70μmol)	in	the	5	minutes	prior	to	reperfusion	via	 primary-percutaneous	 coronary	 intervention	 (PCI).	 A	 total	 of	 228	 patients	were	studied	(almost	equal	split)	the	outcomes	were	all	surrogate	and	included	infarct	 size	 assessed	 by	 cardiac	 enzyme	 release	 (Creatinine	 Kinase	 (CK)	 and	Troponin	I	(TnI)),	as	well	as	infarct	size	measured	by	cardiac	magnetic	resonance	imaging	(CMR)	and	adjusted	for	area	at	risk	(salvage	index).		The	trial	did	not	show	any	benefit	of	NaNO2	infusion	in	terms	of	infarct	size	reduction	as	measured	by	cardiac	enzyme	or	CMR	salvage	index.	
	
Following	on	from	NIAMI	was	a	single	centre,	double-blind,	randomised	control	trial	comparing	placebo	to	an	intra-coronary	bolus	of	sodium	nitrite	(1.8µmol	over	30	 seconds),	 or	 placebo	 (10mL	 of	 0.9%	 NaCl).	 Carried	 out	 by	 Jones	 et	 al143	surrogate	infarct	size	end	points	were	used	with	the	primary	specified	as	serum	creatinine	kinase	 (CK),	 area	under	 the	 curve	 (AUC).	 Secondary	endpoints	were	troponin	T	AUC,	and	infarct	size	assessed	by	late	gadolinium	enhancement	(LGE)	via	 CMR.	 Perhaps	 surprisingly	 salvage	 index	 was	 not	 used	 as	 a	 pre-specified	
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outcome	which	considering	the	trial	is	somewhat	limiting.	It	should	also	be	noted	that	no	pre-specified	subgroup	analysis	was	 identified	at	 the	outset	of	 the	trial.	
144,145	The	trial	was	also	highly	selective	with	430	patients	considered	eligible	and	82	going	on	to	be	randomised,	the	mean	age	of	which	was	57	years.	Despite	being	labelled	 as	 an	 intention	 to	 treat	 analysis	 2	 patients	 were	 excluded	 after	randomization	from	the	placebo	group.	In	a	clear	evolution	from	NIAMI	this	trial	introduced	 a	 high	 dose	 bolus	 of	 sodium	 nitrite	 intracoronary	 rather	 than	intravenous,	further	this	bolus	was	delivered	distal	to	the	coronary	occlusion	via	an	over	the	wire	balloon	and	distal	port	injection.	No	difference	was	seen	in	the	primary	outcome	(CK	AUC),	or	both	secondary	outcomes	(troponin	T	AUC	and	LGE	infarct	size).	A	further	post-hoc	subgroup	analysis	using	salvage	index,	ratio	of	LGE	vs	myocardia	oedema	/	T2	STIR	(area	at	risk);	again	this	showed	no	significant	difference	between	groups	despite	 the	group	showing	their	 techniques	were	of	high	quality	with	a	positive	association	between	LGE	and	CK	AUC.	A	further	post-hoc	sub-group	analysis	looked	at	both	the	primary	and	secondary	outcomes	and	found	a	 significant	difference	between	 the	groups	 (in	 favour	of	 sodium	nitrite)	when	patients	with	either	profoundly	restricted	flow	or	complete	absence	of	flow	(TIMI	 ≤	 1)	 were	 analysed	 and	 the	 rest	 excluded.	 Here	 the	 authors	 found	 a	significant	 difference	 in	 infarct	 size	 via	 LGE	 (%):	 15.31	 (12.36-18.27)	 vs	 20.08	(16.72-23.43),	p=0.03.	This	was	also	 reflected	 in	 the	 salvage	 index	 calculations	with	a	salvage	index	of	0.56	(0.50-0.62)	vs	0.43	(0.37-0.49),	p=0.002.	CK	AUC	(but	not	troponin	T)	was	also	in	favour	of	sodium	nitrite;	44,608	AU	(27,535-64,848)	vs	55,666	AU	(41,591-93,659),	p=0.030.	The	CMR	findings	at	baseline	were	not	carried	 through	 to	 the	 six	 month	 CMR	 with	 no	 difference	 between	 groups	regardless	of	sub-group	analysis.		
	 109	
	
Somewhat	surprisingly	at	6	months	the	group	receiving	sodium	nitrite	with	TIMI	flow	>	1	appeared	to	have	a	larger	infarct	size	than	the	whole	(unselected)	cohort	at	6	months;	 (TIMI	≤	1	vs	TIMI	>	1	LGE	%)	11.88	 (9.52-14.24)	vs	16.33	 (-9.4-42.06).	This	difference	was	not	seen	in	the	placebo	group;	in	fact,	it	was	reversed	(TIMI	≤	1	vs	TIMI	>	1	LGE	%)	13.15	(10.75-15.56)	vs	10.59	(0.24-20.93).		
	
Overall,	 this	 negative	 clinical	 trial	 generates	 some	 potentially	 interesting	hypothesis	with	the	post-hoc	analysis	but	overall	the	trial	suffers	with	its	initial	power	calculation	that	has	probably	excluded	the	possibility	of	detecting	smaller	(clinically	significant)	infarct	sizes.		Part	of	the	problem	may	be	the	low	frequency	of	 left	 anterior	 descending	 (LAD)	 artery	 occlusions	 21	 (26.25%)	 in	 the	whole	study	 population,	 this	 leads	 to	 a	 number	of	 patients	 (non	 LAD)	with	 relatively	small	 infarct	 sizes,	 making	 it	 statistically	 more	 difficult	 to	 prove	 a	 difference	between	groups	as	the	change	in	infarct	size	will	be	much	smaller.		
	
Also,	noted	by	the	authors	is	the	absence	of	correction	for	multiple	comparisons	and/or	the	use	of	ANOVA	in	this	analysis,	important	because	small	studies	like	this	are	at	even	greater	risk	of	a	type	I	error.	Even	looking	beyond	the	limitations	of	unspecified	post-hoc	analysis,	statistically	we	cannot	really	say	with	any	certainty	that	there	are	differences	between	the	two	groups	and	this	data	should	only	be	considered	preliminary	hypothesis	generating	 in	preparation	 for	an	adequately	designed	and	controlled	trial.146	
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Certainly	 the	 impressive	 protection	 of	 NO2-	 in	 ex-vivo	 animal	 has	 not	 been	repeated	thus	far	in	terms	of	IR	protection	in	the	human	heart.	147-150	
	
Coronary blood flow autoregulation and its relationship to ischaemic 
reperfusion injury 
Principally	this	thesis	investigates	the	role	of	NO	and	NO2-	in	the	autoregulation	of	CBF	in	patient	with	severe	epicardial	stenosis	(stable	angina	and	NSTEMI).	In	the	previous	section	on	STEMI	we	have	read	about	the	potential	role	of	NO2-		in	terms	of	reducing	ischaemia	reperfusion	injury	(IRI).	Whilst	IRI	is	not	the	topic	of	this	thesis	 in	 the	 following	 section	 we	 clarify	 the	 potential	 mechanisms	 of	 NO2-	 in	reducing	 IRI	 and	 how	 this	 relates	 to	 CBF	 autoregulation	 in	 the	 context	 of	 this	thesis.		
	
Beyond	limited	evidence	that	NO2-	may	have	a	direct	effect	on	complex	II	of	the	mitochondrial	respiratory	chain	(and	thus	protect	against	IRI),	151 the	beneficial	effects	of	NO2-	are	focused	(but	not	limited	to)	its	conversion	to	NO.	As	described	in	the	general	introduction	(page	46)	the	mechanism	of	this	conversion	has	many	potential	 candidates:	 deoxy-haemoglobin	 reductase,	 101,102	 Xanthine	 oxidase,	
107,152	 acid	 disproportionation	 108(as	 well	 as	 others).	 Fundamentally	 these	mechanisms	rely	on	the	production	of	NO	which	in	turn	offers	cardio	protection	via	a	multitude	of	well	documented	pathways.	The	presence	of	NO	in	the	coronary	circulation	 has	 been	 shown	 to	 contribute	 to	 the	 maintenance	 of	 regional	myocardial	blood	flow	in	a	canine	model,	153	and	in	the	research	outlined	in	the	previous	 chapter	 of	 this	 thesis,	 both	 models	 required	 a	 significant	 epicardial	
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stenosis.	Beyond	direct	maintenance	of	CBF,	NO	inhibits	platelet	aggregation	and	adherence	to	the	vascular	endothelium	which	is	also	likely	to	have	a	positive	effect	on	 microvascular	 flow	 (see	 Chapter	 5:	 Results	 3,	 page	 137).	 133,154	 During	reperfusion	 NO	 augmentation	 in	 various	 ex-vivo	 and	 in-vivo	 models	 has	 been	shown	 to	 have	 a	 beneficial	 effect	 on	 CBF	 and	 infarct	 size.	 155-158	 NO	 is	 also	implicated	 in	 reducing	 mononuclear	 infiltration	 into	 the	 myocardium	 and	reducing	 infarct	 size.	 159	 Beyond	mononuclear	 infiltration	 NO	 also	 inhibits	 the	release	 of	 TNFa	 (tumour	 necrosis	 factor	a),	 itself	 associated	 with	 IRI.	 160	 NO	interacts	with	mitochondrial	 respiration	via	 the	electron	 transfer	 chain.	At	 low	concentration	NO	donors	like	SNAP	enhance	mitochondrial	membrane	potentials	and	 thus	mitochondrial	 calcium	uptake	 reducing	 IRI	 by	 reduced	mitochondrial	calcium	overload.	 161,162	 Conversely,	 at	 high	 concentration	NO	 can	 increase	 the	production	of	peroxynitrite	and	shift	from	ATP	production	to	oxygen	free	radical	production	with	detrimental	effects	on	IRI.	163	
	
It’s	possible	that	all	of	these	mechanisms	are	at	play	when	we	study	the	effect	of	exogenous	NO2-		therapy	in	patients	undergoing	reperfusion	therapy	for	STEMI.	
142,143	 Fundamentally,	 all	 the	described	mechanisms	 (beneficial	or	detrimental)	are	dependent	on	the	reduction	of	NO2-		to	NO	and	in	the	context	of	mammalian	in-vivo	models	one	of	 the	most	predictable	effects	of	 	NO	is	arterial	and	arteriolar	(resistance	arteriolar)	vasodilation	in	multiple	mammalian	organs.	130,164-167	The	previous	chapter	of	this	thesis	outlines	the	importance	of	endogenous	NO	in	terms	of	CVR	in	humans	with	NSTEMI.	Whilst	the	current	chapter	does	not	investigate	the	effect	of	NO2-	on	markers	of	 IRI,	 and	certainly	has	no	 clinical	 (surrogate	or	
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otherwise)	endpoints,	it	does	give	insight	into	how	relevant	NO2-	reduction	to	NO	is	in	terms	of	the	possibility	of	enhancing	local	NO	concentrations	and	reducing	CVR	within	 a	 human	 disease	model	 that	 provides	 the	 perfect	 low	 oxygen	 and	locally	ischaemic	environment.	168	
	
Nitrite a possible role in regulating coronary vascular resistance? 
The	oxygen	gradient	cross	heart	is	one	of	the	largest	in	the	human	circulation	and	locally	 this	 should	 be	 further	 exacerbated	 by	 critical	 epicardial	 stenosis,	 the	perfect	environment	for	hypoxic	vasodilation	mediated	by	nitrite	reduction	to	NO	and	a	reduction	in	CVR	and	increase	in	CBF.	
	
Rogers	et	al	97	found	no	net	change	in	NO	metabolites	in	humans	with	no	epicardial	coronary	disease.	Certainly,	in	terms	of	serum	nitrite	concentration	we	found	an	almost	identical	pattern	in	those	with	stable	coronary	disease	(Trans-myocardial	NO	metabolites	and	oxygen,	page	82),	and	overt	flow	limiting	stenosis.	Unlike	the	NSTEMI	cohort	resting	and	minimal	CVR	(IMRrest,	IMRhyp)	showed	no	change	pre	and	post	PCI	and	both	values	were	significantly	lower	than	their	equivalent	values	in	the	NSTEMI	group	(Table	4	page	89	and	Figure	10).	Despite	these	low	values	for	 CVR	 Ingram	 et	 al	 140	 found	 significant	 relief	 of	 ischaemia	 with	 a	 low	 dose	infusion	of	sodium	nitrite	during	stress	echocardiography	using	pharmacological	stress	(dobutamine).	The	explanation	for	this	is	unclear,	obviously,	it	is	a	different	cohort	of	patients	with	a	multitude	of	potential	variances.	Further,	we	have	no	data	on	the	severity	of	epicardial	lesions	or	a	way	to	compare	it	to	an	invasive	measure	of	epicardial	stenosis	(FFR),	used	in	this	study.	
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In	Chapter	3:	Results	1	we	outlined	evidence	of	a	net	NO	synthesis	in	patients	prior	to	 PCI	 of	 significant	 epicardial	 stenosis	 who	 had	 suffered	 NSTEMI,	 we	 further	outlined	an	 increase	 in	CVR	post	PCI	 in	association	with	a	 reduction	 in	net	NO	metabolites.	 These	 observations	 suggest	 upregulation	 of	 NOS	 is	 an	 important	mechanism	of	compensation	in	these	patients.	The	truth	is	unlikely	to	be	so	black	and	white;	 it	 is	quite	possible	 for	 the	production	of	NO	 to	be	a	balance	of	NOS	synthesis	and	NO2-	reduction.	This	may	help	to	explain	the	results	of	Ingram	et	al,	however,	Rogers	et	al	inhibited	NOS	with	LNMMA	administration	and	found	no	influence	of	 this	on	either	total	NOx	or	on	the	distribution	of	NOx	between	the	serum	and	red	blood	cell	compartments.		From	these	studies,	it	is	evident	that	the	dynamics	 of	 NO	 synthesis	 can	 be	 quite	 different	 when	 using	 different	 human	models	(healthy	vs.	stable	angina	vs.	NSTEMI),	taking	a	snapshot	of	NO	metabolite	concentration	will	not	be	enough	to	indicate	any	shuttling	of	NO	from	both	NOS	and	Nitrite	reduction.	
	
The	observational	study	 in	Chapter	3:	Results	1	 falls	 into	the	same	trap	that	all	other	clinical	observational	studies	suffer	in	this	and	similar	fields,	we	can	outline	an	association	between	two	measures	but	that	doesn’t	equate	to	a	causative	link.	The	perfect	answer	to	this	would	be	the	addition	of	a	NOS	inhibitor,	however,	in	a	cohort	of	acutely	unstable	patients	this	would	not	be	in	their	best	interests.	It	is	impossible	to	pick	apart	the	addition	of	NO	via	endothelial	NOS	versus	the	addition	of	NO	via	reduction	of	NO2-	and	/	or	the	likely	shuttling	of	NO	between	these	two	states	without	changing	the	concentration	of	either	one	of	these	molecules.	
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Whilst	using	NOS	inhibitors	may	be	harmful	in	this	patient	group,	enhancing	[NO2-]	 in	 patients	 following	 acute	myocardial	 infarction	 has	 been	 shown	 to	 be	well	tolerated.	142	Ingram	140	showed	the	potential	of	even	low	dose	nitrite	to	act	as	a	potent	anti-ischaemic	agent.	In	the	context	of	NSTEMI	patients	this	effect	may	be	even	 greater	 as	we	 have	 shown	previously	 this	 cohort	 has	 significantly	 higher	resting	CVR	which	further	increases	post	PCI	(Table	4	page	89).	
	
The	 following	 is	 a	 description	 of	 the	 effect	 of	 augmenting	 the	 serum	concentrations	of	NO2-	in	a	cohort	of	patients	who	have	suffered	an	NSTEMI.	The	preparation	of	these	patients	and	the	cardiac	catheter	protocols	are	identical	to	those	in	the	same	group	described	in	Chapter	3:	Results	1.	We	chose	to	use	a	dose	of	 sodium	 nitrite	 just	 over	 twice	 as	 high	 (3.3μmol/ml	 for	 30	minutes,	 total	 of	99μmol)	than	that	used	by	Ingram.	The	dose	of	sodium	nitrite	was	based	on	the	maximal	dose	used	by	Maher	et	al	133	without	causing	systemic	hypotension	but	with	maximal	arterial	vasodilation.	
	
METHODS 
	
As	 described	 in	 Chapter	 2:	 General	 methods	 (Measurement	 of	 Nitric	 Oxide	metabolites	page	61)	we	used	the	same	methods	of	NOx	quantification	to	confirm	the	increased	concentration	of	serum	nitrite	at	the	key	points	of	measurements	of	
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coronary	 physiology	 indices.	 We	 were	 careful	 to	 measure	 identical	 coronary	physiology	indices	at	identical	time	points	of	those	described	in	Chapter	2:	General	methods	(Cardiac	catheterisation	laboratory	protocol	page	55)	
	
Unless	 stated	 methods	 are	 identical	 to	 those	 in	 Chapter	 3:	 Results	 1,	 major	differences	are	highlighted	(nitrite	infusion	and	coronary	sinus	blood	sampling).	Methods	are	summarised	here	to	allow	quick	reference	within	this	chapter.	
Study population (NSTEMI and NSTEMIinf) 
Patients	were	recruited	from	University	Hospital	of	Wales	following	local	research	ethics	committee	approval	of	the	study,	written	informed	consent	was	obtained	from	each	patient.	
	
Inclusion	criteria	
• Any	patient	over	the	age	of	18	with	the	capacity	to	consent	for	study	and	who	was	receiving	coronary	angiography	as	a	normal	investigation	and	as	part	of	their	routine	treatment	for	either	stable	angina	or	NSTEMI	
• Normal	left	ventricular	function	(EF≥50%),	assessed	by	echocardiography	
• Lack	of	contraindication	to	the	use	of	dual	antiplatelet	therapy	(aspirin	and	clopidogrel).	
• Patients	 that	 had	 one	 vessel	 PCI	 following	 coronary	 angiography	 with	lesions	 that	were	 suitable	 to	allow	 fractional	 flow	reserve	and	coronary	flow	reserve	measurements.	
• Patients	with	a	successfully	cannulated	coronary	sinus	
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Excluded	criteria	included:	
• Patients	with	ongoing	and	unstable	ischaemic	symptoms		
• Previous	ST	Elevation	Myocardial	Infarction	
• Significant	left	main	disease	
• Patients	with	chronic	total	occlusions,	index	or	otherwise	
• Patients	with	earlier	coronary	artery	bypass	grafts	
• Significant	valvular	disease	
• Symptoms	of	heart	failure		
• Recent	intravenous	nitrate	infusion	
• Atrial	fibrillation	
	
Patients	all	had	single	vessel	PCI	of	the	culprit	vessel	only	after	a	period	of	medical	treatment.	 The	 culprit	 vessel	 was	 selected	 based	 on	 angiographic	 appearance,	ECG.		
	
Non-ST	elevation	myocardial	infarction	(NSTEMI)	patients	were	recruited	prior	to	coronary	angiography	and	continued	in	the	study	if	they	required	PCI.	Patients	all	had	single	vessel	PCI	of	the	culprit	vessel,	the	culprit	vessel	was	selected	based	on	angiographic	appearance,	ECG	changes.	Index	vessels	and	other	baseline	clinical	variables	were	well	balanced	between	the	previous	NSTEMI	group	in	Chapter	3:	Results	1	and	this	cohort	as	displayed	in	Table	5.	
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NSTEMI 
n=30 
NSTEMIinf 
n=15 
Age 63.8 ± 12 64.7 ± 9.8 
Male (%) 32 (84) 13 (87) 
Creatinine μmol/L 88.5 (71.3 – 99) 87 (68 – 99) 
CRP 3 (2 – 6.25) 3 (2-4) 
Left ventricular function (EF) 55 (50-55) 55 (55-55) 
Index vessel   
 LAD (%) 8 (53) 23 (61) 
 LCx (%) 2 (13) 6 (15) 
 RCA (%) 5 (33) 9 (24) 
FFR pre-PCI (index vessel) 0.62 ± 0.17 0.58 ± 0.18 
FFR post (index vessel) 0.92 ± 0.06 0.89 ± 0.08 
   
Hypertension (%) 24 (63) 10 (67) 
Diabetes (%) 10 (26) 6 (40) 
Hyperlipaedemia (%) 30 (78) 9 (60) 
Smoking (%) 16 (42) 5 (34) 
Previous PCI (%) 7 (18) 2 (13) 
Clopidogrel > 5days (%) 38 (100) 15 (100) 
Beta-blocker (%) 32 (84) 12 (80) 
Calcium channel blocker (%) 7 (18) 1 (7) 
ACE Inhibitor (%) 29 (75) 11 (73) 
Statin (%) 34 (89) 13 (87) 
Table 5: Baseline clinical characteristics of study populations NSTEMI and NSTEMIinf . 
Abbreviations: PCI - percutaneous coronary intervention, CRP – C reactive protein, NSTEMI – non-ST-
elevation myocardial infarction, NSTEMI – with infusion of sodium nitrite, EF -  ejection fraction, LAD – 
left anterior descending artery, LCx – left circumflex artery, RCA – right coronary artery, FFR – fractional 
flow ratio, ACE - angiotensin converting enzyme inhibitor 
 
 
Cardiac Catheterisation laboratory Protocol 
The	 cardiac	 catheterisation	 protocol	 was	 identical	 to	 that	 used	 in	 Chapter	 3:	Results	1	with	the	addition	of	sodium	nitrite	infusion	in	the	NSTEMIinf	cohort.	A	
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full	description	of	this	method	can	be	seen	in	general	methods	chapter:	Cardiac	catheterisation	laboratory	protocol	page	55	and	Sodium	nitrite	infusion	page	60.	
	
Sodium nitrite infusion 
In	the	NSTEMI	cohort	receiving	pre-PCI	loading	with	sodium	nitrite	(NSTEMIinf),	the	sodium	nitrite	infusion	was	started	immediately	after	the	first	coronary	sinus	sample	 was	 taken	 pre-PCI.	 The	 sodium	 nitrite	 was	 supplied	 by	 Tayside	Pharmaceuticals,	 Ninewells	 Hospital	 and	 infusions	 prepared	 on	 the	 day	 of	recruitment	by	St	Mary’s	Pharaceutical	Unit	(SMPU),	University	Hospital	of	Wales.	Final	concentration	of	sodium	nitrite	was	confirmed	at	SMPU	using	Griess	Reagent	Kit	(Thermo	Fischer	Scientific).	The	infusion	contained	a	total	dose	of	6.9mg	(99	μmol)	 of	 sodium	 nitrite,	 infused	 over	 30	minutes	 (3.3μmol/min).	 Following	 5	minutes	of	this	infusion	an	additional	coronary	sinus	blood	sample	was	taken	to	confirm	the	nitrite	concentration	at	the	point	of	the	pre-PCI	coronary	physiology	measures.		
	
Offline analysis of catheter lab haemodynamic data 
Again,	this	method	is	identical	to	the	previous	chapter,	full	details	of	the	method	can	be	seen	in	the	general	methods	(Offline	analysis	of	catheter	lab	haemodynamic	data	page	59).	
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Measurement of Nitric Oxide metabolites 
Again,	this	method	is	identical	to	the	previous	chapter,	full	details	of	the	method	can	 be	 seen	 in	 the	 general	methods	 (Measurement	 of	Nitric	Oxide	metabolites	page	61)	
 
Statistical Analysis 
Normally	distributed	data	are	expressed	as	mean	±	SD	unless	otherwise	stated.	Non-gaussian	data	expressed	as	median	(IQR).	When	the	distribution	of	data	was	not	clear	the	Shapiro-Wilk	normality	test	was	used.	Multiple	comparison	between	related	 groups	 of	 means	 were	 made	 with	 paired	 and	 unpaired	 ANOVA	 with	Tukey’s	correction	for	multiple	comparisons.	Single	comparisons	were	made	with	paired	and	unpaired	student’s	t	test	as	appropriate.	Wilcoxon	test	was	used	for	non-parametric	 single	 comparisons	 of	 paired	 data	 and	 Mann-Whitney	 test	 for	unpaired	data.	
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RESULTS 
Transmyocardial NO metabolites and oxygen 
NSTEMI with Sodium Nitrite pre-loading (n=15)  
15	 NSTEMI	 patients	 had	 a	 pre-PCI	 infusion	 of	 intravenous	 sodium	 nitrite	 as	outlined	in	the	methods.	A	total	of	6.9	mg	(99	μmol)	in	a	total	volume	of	30mls	was	infused	over	30	minutes;	this	infusion	was	started	following	the	first	set	of	blood	sampling	(“baseline”)	and	5	minutes	prior	to	coronary	physiology	measures	(FFR,	IMRrest,	 IMRhyp)	 and	 the	 simultaneous	 second	 “pre-PCI”	 coronary	 sinus	 sample.	The	 large	 elevation	 of	 serum	 nitrite	 concentration	 makes	 detection	 of	 small	variations	of	NO	metabolites	 from	aorta	to	coronary	sinus	both	 impossible	and	somewhat	 irrelevant.	 Serum	 nitrite	 measures	 here	 confirm	 the	 similarity	 at	baseline	 to	 the	 NSTEMI	 group	 in	 Chapter	 3:	 Results	 1	 (Table	 2	 page	 84),	 and	quantify	 the	 rise	 in	 serum	 nitrite	 at	 key	 points	 during	 the	 protocol	 (namely,	coronary	physiology	measures	at	baseline	and	post-PCI).	Figure	14	
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Figure 14: Trans-myocardial nitrite gradients (median with IQR) 
Trans-myocardial NO2- nM in NSTEMI and NSTEMI with nitrite infusion (NSTEMIinf). In the NSTEMIinf 
cohort aorta PRE – represents sample taken prior to nitrite infusion (baseline), Cor Sin PRE sample is 
taken at the point of pre PCI coronary physiology measures and 5 minutes after nitrite infusion was 
commenced. Cor POST is taken 5 minutes after stent deployment. Within groups there are no significant 
differences excluding any comparison with Aorta PRE. Statisitcs: not normally distributed data as 
median and IQR. Abbreviations: NSTEMI – Non-ST-Elevation MI cohort, NSTEMI + Nitrite Inf – NSTEMI 
with nitrite infusion, PCI - percutaneous coronary intervention, Pre – pre-PCI, Post – post-PCI, Cor – 
coronary sinus, nM – nanomolar.  	
At	baseline	the	median	aortic	(pre-PCI)	nitrite	concentration	was	210.9	nM	(150.3	–	431.3),	median	CS	pre-PCI	 (and	pre-infusion)	was	192.1	nM	(135.3	–	248.9).	Following	five	minutes	of	sodium	nitrite	infusion	the	CS	nitrite	(pre-PCI)	was	1274	nM	(821.5	-	1475).	Nitrite	concentration	in	the		CS	5	minutes	post	PCI	was	1422nM	(1032	-	1842).	Post	PCI	aortic	sampling	was	slightly	delayed	after	the	CS	samples	and	the	mean	nitrite	concentration	was	1237nM	(931	-	1489),	this	indicated	a	rise	in	nitrite	concentration	across	myocardium	that	in	retrospect	we	consider	to	be	a	sampling	 artifact	 (Figure	 14,	 Table	 6	 and	 Table	 7).	 The	 study	 was	 limited	 by	ensuring	 the	 complexity	and	practice	of	PCI	was	not	hindered,	 and	as	 such	 the	nitrite	 infusion	 had	 finished	 prior	 to	 the	 opportunity	 to	 take	 the	 post	 aortic	
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sample.	Serum	nitrite	concentrations	fall	rapidly	after	the	sodium	nitrite	infusion	stops	(as	we	and	others	have	shown	previously)	with	a	serum	half-life	of	~22min.	
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NSTEMI Pre PCI NOx (n=30) 
 Aorta Coronary Sinus  
HbO2 (%) 96.6 ± 1.82 34.8 ± 8.7 -61.8 
Plasma NO2- (nM) 204.5 
(134.1 to 328.3) 
203.4 
(125.3 to 293.9) 
PANOVA >0.05 
Total RBC (nM) 164.5 ± 99 247.2 ± 142.8 PANOVA <0.05*       (CI 
13.5 to 152) mean 
diff 82.7nM 
Total NOx (nM) 403.9 ± 192.3 488.7 ± 265.9 PANOVA <0.05 *      (CI 
9.5 to 160) mean 
diff 84.9nM 
NSTEMI Post PCI NOx (n=30) 
 Aorta Coronary Sinus  
HbO2 (%) 96.7 ± 1.85 42.5 ± 12.4  
Plasma NO2- (nM) 
240.9 
(135.5 to 332.0) 
178.5 
(126.9 to 263.2) 
PANOVA >0.05 
Total RBC 167.9 (±91.5) 228.1 (±120.9) 
PANOVA >0.05         (CI 
-1.9 to 122.3) mean 
diff 60.1nM 
Total NO 412.9 ± 170 429.1 ± 185.3 
PANOVA >0.05          (CI 
-59 to 91) mean diff 
16.2 nM 
Table 6: Trans-myocardial NO metabolites (NOx) in NSTEMI patients 
Trans-myocardial nitric oxide metabolite concentration from aorta to coronary sinus Abbreviations: 
NSTEMI – Non-ST-Elevation MI cohort, Stable – stable angina cohort, PCI - percutaneous coronary 
intervention, NOx – nitric oxide metabolites, HbO2 – haemoglobin oxygen saturation, NO2 – nitrite, CI – 
confidence intervals, nM – nanomolar, NO – nitric oxide  
Statistics: normally distributed data as mean ± SD, multiple comparisons with 1-way ANOVA. Not 
normally distributed median (IQR), multiple comparisons Friedman with Dunn’s correction (marked 
ANOVA) 	
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NSTEMIinf Pre PCI NOx (n=15) 
 Aorta Coronary Sinus 
HbO2 98.2 ± 1.63 35.1 ± 4.8 
Plasma NO2- (nM) 210.9 
(150.3 to 431.3) 
192.6 
(135.3 to 248.9) 
 PRE INFUSION PRE INFUSION 
NSTEMIinf Post PCI NOx (n=15) 
 Aorta Coronary Sinus 
HbO2 97.7 ± 2.0 42.4 ± 9.5 
Plasma NO2- (nM) 
1237 
(931 to 1489) 
1422 
(1032 to 1842) 
 POST INFUSION POST INFUSION 
 
Table 7: Trans-myocardial NO metabolites NSTEMIinf cohort 
Trans-myocardial nitric oxide metabolite concentration from aorta to coronary sinus Abbreviations: 
NSTEMIinf – Non-ST-Elevation MI cohort with nitrite infusion, PCI - percutaneous coronary intervention, 
NOx – nitric oxide metabolites, HbO2 – haemoglobin oxygen saturation, NO2 – nitrite, CI – confidence 
intervals, nM – nanomolar, NO – nitric oxide  
Statistics: normally distributed data as mean ± SD. Not normally distributed median (IQR). 	
CS	oxygen	saturation	followed	a	very	similar	profile	to	the	other	NSTEMI	group	with	mean	Pre-PCI	saturation	of	35.1%	(SD	4.8)	and	Post-PCI	saturation	of	42.4%	(SD	9.5),	p=0.0078.	Figure	15	
Serum nitrate quantification 
Nitrate	concentration	was	measured	at	the	identical	time	points	to	nitrite	and	total	RBC	measures.	Using	a	one-way	ANOVA	test	there	were	no	significant	differences	between	time	points	within	this	group	or	across	the	different	groups	(comparison	
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to	Chapter	3:	Results	1).	Nitrate	is	present	in	μM	concentrations	as	opposed	to	the	nM	concentration	of	serum	nitrite	and	RBC	NOx.	Because	nitrate	does	not	change	between	sampling	points	-	and	there	is	no	evidence	that	humans	are	able	to	reduce	nitrate	to	nitrite	across	the	coronary	circulation	–	we	have	excluded	this	from	the	calculations	of	total	NO	metabolites.	
	
	
Figure 15:Aortic and coronary sinus haemoglobin oxygen saturation pre and post PCI 
NSTEMI cohort left panel and NSTEMIinf cohort right panel.  
* NSTEMI cohort Cor Sin PRE to Cor POST mean difference 7.7% (paired t, p=0.0034). 
**NSTEMIinf  cohort Cor Sin PRE to POST mean difference 5.4% (paired t,p=0.0078).  
Abbreviations Aorta PRE: Aortic root sample pre-PCI, Cor Sin PRE: coronary sinus sample pre-PCI, Aorta 
POST: Aortic root sample post-PCI, Cor POST: coronary sinus sample post-PCI, NSTEMIinf is NSTEMI cohort 
with sodium nitrite infusion 
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Coronary physiology measures 
NSTEMI with Sodium Nitrite pre-loading (n=15) 
The	 cohort	 of	 NSTEMI	 patients	 receiving	 an	 infusion	 of	 sodium	 nitrite	 had	 no	significant	difference	in	baseline	characteristics	to	the	NSTEMI	cohort	in	Chapter	3:	Results	1.	Blood	sampling	at	baseline	occurred	prior	to	the	start	of	the	infusion.	A	further	coronary	sinus	sample	was	taken	5	minutes	following	the	start	of	the	infusion	 and	 just	 before	measuring	 the	pre-PCI	 coronary	 physiology	measures.	FFR	measures	pre	and	post-PCI	reveal	a	similar	population	to	the	NSTEMI	cohort;	0.58	 (SD	0.18)	 to	 0.89	 (SD	0.08).	The	measured	 coronary	wedge	pressure	 also	revealed	a	similar	low	degree	of	collateral	vessel	formation	to	the	NSTEMI	group;	CFI	was	0.10	(SD	0.11)	(SD	5.17)	with	no	significant	difference	between	the	two	groups.	Table	8	and	Figure	18		
	
Resting	 microvascular	 tone	 was	 very	 similar	 to	 the	 NSTEMI	 (without	 nitrite	infusion)	 both	 pre	 and	 post	 PCI;	 47.13	 (SD	 30.9)	 vs.	 59.6	 (SD	 40.1)	 with	 a	significant	rise	immediately	post	PCI	of	12.5	units	(SD	15.5),	p=0.017,	matching	almost	 identically	 the	 rise	 seen	 in	 the	 NSTEMI	 cohort	 without	 sodium	 nitrite	infusion.	Table	8	and	Figure	16	
	
Minimal	 (hyperaemic)	 microvascular	 tone	 was	 again	 almost	 identical	 to	 the	NSTEMI	group	without	nitrite	infusion;	23.7	(SD	11.4)	vs.	21.9	(SD	13.2)	with	no	significant	change	from	pre	to	post-PCI.	Table	8	and	Figure	17	
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Figure	16:	IMR	resting	pre	and	post	PCI	
Index of microvascular resistance during resting conditions, a surrogate of coronary vascular resistance 
in both cohorts: NSTEMI and NSTEMIinf. 
	
Figure	17:	IMR	hyperaemic	pre	and	post	PCI	
Index of microvascular resistance during hyperaemic conditions (minimal microvascular resistance in all 
three experimental cohorts -  NSTEMI, NSTEMIinf, stable angina cohorts.  
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Figure 18: Collateral Flow Index 
Coronary wedge pressure measured and converted to collateral flow index (CFI) at hyperaemia and prior 
to PCI in the NSTEMI and NSTEMIinf  cohorts 
Fig 16, 17 & 18 Statistics: normally distributed data presented as mean with standard error of mean. 
Statistical significance where marked with * = < 0.05, Paired ANOVA and unpaired t-test (CFI) 
Abbreviations: IMR – index of microvascular resistance, hyp – hyperaemia, NSTEMI – Non-ST-Elevation 
MI cohort, NSTEMIinf – NSTEMI + nitrite infusion, Stable – stable angina cohort, PCI - percutaneous 
coronary intervention, Pre – pre-PCI, Post – post-PCI, Cor Sin  – coronary sinus 	
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 NSTEMI (n=30) NSTEMIinf (n=15) 
 Pre-PCI Post-PCI Pre-PCI Post-PCI 
FFR 0.62 ± 0.03 0.92 ± 0.06 0.58 ± 0.05 0.89 ± 0.02 
IMRrest 
units 
46.2 ± 21.6 57.6 ± 37.9 47.1 ± 30.9 59.6 ± 40.1 
IMRhyp 
units 
22.3 ± 12.4 22.5 ± 19.8 23.7 ± 11.4 21.9 ± 13.2 
CFI 
 
0.08 ± 0.08  0.1 ± 0.1 
ns difference between 
cohorts 
for CFI 
p=0.59  (95% CI -0.04-to 
0.08) 
	
Table 8: Coronary physiology summary data 
Coronary physiology data pre-PCI and 5 minutes post-PCI  
Abbreviations: NSTEMIinf – Non-ST-Elevation MI cohort with nitrite infusion, NSTEMI – Non-ST-Elevation 
MI cohort, PCI - percutaneous coronary intervention, FFR – Fractional flow reserve, IMRrest – Index of 
microvascular resistance resting conditions, IMRhyp – Index of microvascular resistance at hyperaemia, 
CFI – Collateral Flow Index (CFI). 
Statistics: Normally distributed data presented as mean ± SD, for significance see graphical 
representations of data in figure 16, 17 & 18 above 
 
DISCUSSION 
In	 Chapter	 3:	 Results	1	we	 demonstrated	 net	NO	metabolite	 (NOx)	 production	from	Aorta	to	coronary	sinus	(trans-myocardial)	in	the	NSTEMI	cohort.	This	net	production	 disappeared	 post-PCI	 with	 an	 associated	 increase	 in	 CVR.	 The	apparent	net	drop	in	NOx	from	pre	to	post	PCI	was	driven	primarily	by	a	reduction	in	 the	 trans-myocardial	 gradient	of	 serum	NO2-	 (NO2-	 gradient	pre-PCI	A	 to	V	-1.1nM,	 post-PCI	 -52.4nM).	 If	 this	 trans-myocardial	 drop	 in	 serum	 nitrite	represents	 reduction	 to	 NO	 (which	 permeates	 into	 the	 endothelium	 and	
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myocardium)	then	we	would	expect	to	see	a	reduction	in	CVR.	However,	from	pre	to	post-PCI	CVR	(IMRrest)	rose	from	46.2±21.6	to	57.6±37.9,	p=0.038	(mean	±	SD).			
By	 taking	 a	 snapshot	 of	NO	metabolites	we	 have	 no	 idea	 of	 the	 potential	 (and	likely)	 dynamic	 shuttling	 that	 may	 occur	 in	 NO	 and	 its	 metabolite	 nitrite.	 For	instance,	 it	 is	 entirely	 plausible	 to	 imagine	 an	 acute	 down	 regulation	 in	 NOS	(secondary	to	reduced	CBF	velocity	and	shear	stress,	47	or	adenine	/	purinergic	receptor	stimulation	by	ATP,	39	post-PCI),	or	a	dilutional	reduction	in	NO	post-PCI	(Figure	13:	Fick	calculation	of	change	in	coronary	blood	flow	in	NSTEMI	cohort	post-PCI	 page	 95)	 partially	 compensated	 by	 reduction	 of	 nitrite	 to	 NO.	 To	understand	this	relationship,	we	hoped	to	see	a	clear	effect	on	CVR	by	augmenting	serum	nitrite	concentrations	by	up	to	five-fold.		
	
Despite	a	5-fold	augmentation	of	NO2-	concentration	no	effect	is	seen	on	resting	CVR	 (IMRrest)	 pre-PCI,	 pre-PCI	 the	 resting	 CVR	 is	 almost	 identical	 to	 the	 value	observed	in	the	NSTEMI	cohort.	The	resting	CVR	post-PCI	was	almost	identical	to	the	NSTEMI	cohort	without	nitrite	infusion.	Comparing	the	groups	and	as	outlined	in	Table	5	there	was	no	significant	variance	in	baseline	clinical	characteristics	and	haemodynamic	 aspects	 of	 the	 epicardial	 lesions.	 Revascularisation	 outcomes	measured	objectively	with	FFR	were	also	well	matched	between	the	groups.	The	collateral	 flow	 index	 was	 similar	 between	 groups	 indicating	 the	 same	 (poor)	development	of	 collateral	 vessels.	 Finally,	 from	an	oxygen	gradient	perspective	pre-PCI	coronary	sinus	oxygen	saturations	were	almost	identical	between	the	two	NSTEMI	cohorts	(NSTEMI:	34.8%±8.7,	NSTEMIinf	:35.1%±4.8).	
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Gladwin	 et	 al	 168	 and	 colleagues	 have	 made	 a	 strong	 case	 for	 a	 role	 of	 nitrite	reduction	 in	 hypoxic	 vasodilation.	 If	 one	 could	 select	 any	 organ	 system	 or	circulation	 in	 mammals,	 then	 the	 coronary	 circulation	 would	 be	 the	 perfect	environment	 to	 test	 this	 hypothesis,	 principally	 due	 to	 the	 extreme	 oxygen	gradient	from	A	to	V	(~99%	to	~35%	oxygen	saturation).	This	takes	us	straight	into	 the	 range	 at	 which	 it	 is	 proposed	 haemoglobin	 acts	 maximally	 as	 an	allosterically	 regulated	 deoxy-haem	 based	 nitrite	 reductase	 producing	 NO.	 102	Indeed	from	the	perspective	of	a	potential	treatment	in	patients	undergoing	PCI	for	acute	coronary	syndromes	this	is	a	highly	attractive	targeted	way	to	reduce	CVR	 and	 potentially	 treat	 a	 common	 complication	 after	 PCI	 in	 these	 patients	(coronary	slow	or	no	flow)	following	treatment	of	the	stenosed	epicardial	vessel.	
169	
	
This	biological	plausible,	simple	and	effective	hypothesis	of	the	deoxy-haem	model	does	have	its	shortcomings.	The	principal	criticism	is	centered	around	a	plausible	mechanism	by	which	the	NO	produced	is	able	to	extract	itself	from	deoxy-haem,	this	in	an	hypoxic	environment	that	will	increase	the	avidity	of	deoxy-haem	for	NO.	Once	the	NO	has	separated	itself	from	deoxy-haem	the	next	hurdle	is	to	escape	the	erythrocyte	(which	is	packed	full	of	dexoy-haem	with	a	high	avidity	for	NO).	To	 counter	 this	 argument	 some	believe	 that	 rather	 than	 a	 direct	 source	 of	NO	nitrite	 reduction	 with	 deoxy-haem	 is	 the	 first	 step	 in	 the	 production	 of	 S-nitrosohaemoglobin	(SNOHb),	which	is	liberated	once	the	RBC	encounter		normal	oxygen	conditions.	104		
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Secondly,	others	have	shown	that	whilst	a	negative	A	to	V	gradient	of	nitrite	 is	present	 in	 the	 coronary	 circulation	 of	 healthy	 humans,	 this	 is	 balanced	 by	 an	increase	in	RBC	NO	metabolite	species	(Hb-NO,	Hb-SNO,	nitrite)	which	increase	inversely	and	proportionately	to	oxygen	saturation.	The	net	result	of	this	results	in	 no	 gradient	 of	 total	 NO	 metabolites	 and	 likely	 signifies	 shuttling	 of	 NO	metabolites	(which	is	reversed	in	the	pulmonary	vasculature).	97	
	
Thirdly,	 the	 vasodilator	 action	 of	 nitrite	 is	 seen	 in	 hypoxia	 in	 isolated	 vessel	models	 both	 with	 haemoglobin,	 170	 and	 without.	 106.	 However,	 in	 both	 these	models	 rather	 than	 physiological	 activity	 of	 nitrite	 at	 300nM,	 105	 we	 only	 see	activity	at	pharmacological	concentration	(both	NO	dependent	and	independent),	around	10	μM	and	above.	
	
	
Conclusion 
Despite	an	optimal	environment	for	nitrite	reduction	to	NO	we	failed	to	see	any	evidence	that	nitrite	had	a	role	in	hypoxic	dilation	or	regulation	of	CVR.	The	human	NSTEMI	 model	 we	 chose	 and	 the	 methods	 we	 developed	 have	 clear	 clinical	importance	 with	 key	 questions	 being	 asked	 and	 answered	 in	 a	 relevant	pathological	situation.		
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Using	sensitive	NO	assays	and	interrogating	both	serum	and	RBC	NO	metabolites	we	 could	 show	 a	 net	 increase	 in	 NO	metabolites	 that	 suggests	 NOS	 synthesis	across	 the	 coronary	 circulation.	 This	 cohort	 have	 defined	 themselves	 as	 being	different	to	healthy	humans	in	this	regard	who	don’t	seem	to	rely	on	NO	synthesis	to	 regulate	 CVR	 and	 thus	 coronary	 blood	 flow.	 121	 Further,	 it’s	 important	 to	recognise	that	NSTEMI	patients	do	not	display	the	negative	gradient	of	nitrite	seen	in	so	many	other	animal	and	healthy	human	studies.	
	
The	5-fold	increase	in	serum	nitrite	concentrations	observed	in	this	study	and	the	results	 obtained	 seem	 to	 suggest	 that	 any	 dynamic	 shuttling	 between	 nitrite	production	from	NO	and	nitrite	reduction	to	NO	does	not	occur.		
	
Limitations 
As	 with	 any	 study	 -	 and	 in	 particular	 -	 clinical	 studies,	 any	 method	 will	 have	limitations.	The	first	and	most	obvious	here	is	the	dose	of	sodium	nitrite	used	and	the	 serum	concentrations	achieved.	Others	have	previously	 shown	much	 lower	doses	 of	 nitrite	 have	 biological	 effect.	 133,140	 We	 chose	 this	 dose	 principally	 to	ensure	we	had	maximal	vasodilation	effect	with	minimal	systemic	blood	pressure	drop	(potentially	dangerous	in	patients	with	NSTEMI).	Indeed,	the	selected	dose	highlights	the	practical	limitations	of	using	sodium	nitrite	in	this	clinical	context,	higher	doses	as	well	as	being	potentially	dangerous	also	become	progressively	less	relevant	in	the	clinical	context.	
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The	method	we	chose	to	measure	microvascular	function	is	limited	in	a	number	of	ways.	 IMR	 is	 a	 complex	method	 in	an	already	complicated	 situation	where	 the	emphasis	is	always	the	patient	and	their	treatment	and	safety,	limiting	the	number	of	times	we	can	repeat	the	measures	(for	instance	IMR	pre	and	post	nitrite	infusion	would	have	been	very	useful).	IMR	is	also	dimensionless	and	therefore	only	semi-quantitative,	very	good	for	making	intra-patient	or	relative	comparisons	but	less	so	 across	 cohorts.	 We	 limited	 this	 by	 always	 placing	 the	 distal	 pressure	 and	temperature	sensor	in	the	distal	third	of	the	artery.	IMR	also	doesn’t	confirm	the	diagnosis	of	the	patient,	it	is	possible	that	some	of	our	patients	had	suffered	full	thickness	infarcts	(ST	elevation	myocardial	infarction)	and	this	explains	the	lack	of	response	to	nitrite	although	there	was	no	indication	of	this	on	echo.		
	
In	Chapter	5:	Results	3	we	further	evaluate	the	potential	action	of	nitrite	in	this	cohort	and	its	effect	on	platelet	inhibition	and	inflammation.	
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Chapter 5: Results 3  
Platelet function and inflammation in NSTEMI patients and the influence 
of augmented serum nitrite concentration 
ABSTRACT 
Background 
Measuring	platelet	function	around	the	time	of	an	acute	coronary	syndrome	is	an	unproven	technique	that	does	not	correlate	well	with	clinical	outcomes.	Despite	this	we	continue	to	see	these	assays	used	(often	in	isolation),	as	surrogate	markers	of	clinical	effectiveness	of	compounds	in	the	research	setting.	This	chapter	starts	with	a	methodological	assessment	of	platelet	function	assays	in	this	setting	and	is	followed	by	an	analysis	of	 the	association	between	pro-	and	anti-inflammatory	cytokine	 (TH1	 /	 TH2)	 on	 platelet	 function	 and	 an	 analysis	 sodium	 nitrite	augmentation	and	its	effect	on	platelet	function	and	inflammation.		
Methods Platelet	function	was	measured	in	several	ways	for	both	peripheral	venous	and	coronary	sinus	blood.	Platelet	aggregation	was	performed	using	both	adenosine	diphosphate	(ADP)	and	thrombin	receptor	activating	peptide	(TRAP)	as	agonists	using	a	multiplate	analyser.	Flow	cytometry	was	used	to	identify	platelets	that	expressed	p-selectin	on	their	surface.	Soluble	p-selectin	and	Th1/Th2	cytokines	were	quantified	with	a	MSD	multiplex	assay.	Finally,	mass	spectrometry	was	performed	to	quantify	the	eicosanoid	12-HETE.	
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Results 
Platelet	 sub-study	 (PSS),	 n=42.	 Aggregation	 in	 response	 to	 ADP	 and	 TRAP	significantly	 reduced	 peri-procedurally.	 	 Soluble	 p-selectin	 concentration	remained	constant	and	p-selectin	surface	expression	also	continued	throughout.		
Platelet	 function	at	both	baseline	and	24	hrs	was	almost	 identical	between	 the	NSTEMI	and	the	NSTEMIinf	cohorts.	Th1	/	Th2	cytokines	and	the	effect	of	nitrite.	Nitrite	infusion	had	no	effect	on	any	TH1	or	Th2	cytokine	at	24	hours,	numerical	differences	could	usually	be	explained	by	the	differences	seen	at	baseline	concentration	between	the	two	groups.		
Discussion 
Platelet	function	assessment	in	acute	coronary	syndrome	patients	is	complex	with	several	competing	and	 important	 factors	 including	acute	activation	of	platelets,	pharmacological	dynamics	of	powerful	antiplatelet	drug	usage	and	the	influence	of	invasive	cardiovascular	treatments	that	may	also	activate	platelets.	Outlined	in	these	results	we	see	the	dangers	of	interpreting	results	based	on	just	one	assay	(aggregation).		
Nitrite	 had	 no	 effect	 on	 platelet	 function	 in	 terms	 of	 reducing	 this	 ongoing	activation	 of	 platelets.	 These	 observations,	 interpretation	 and	 description	 of	platelet	 function	 changes	 acutely	 are	 novel	 and	 may	 explain	 both	 the	 lack	 of	clinical	 effect	 of	 nitrite	 in	 other	 studies	 and	 the	 poor	 performance	 of	 platelet	function	 testing	 in	 randomised	 controlled	 trials	 aimed	 at	 tailoring	 antiplatelet	pharmacology.	The	lack	of	an	effect	on	platelet	function	was	also	reflected	in	the	
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lack	of	any	effect	of	nitrite	on	the	Th1	or	Th2	cytokines,	whilst	we	could	quantify	these	cytokines	in	the	pg/ml	range.		
	
INTRODUCTION 
Nitric oxide and its role in platelet inhibition  
Nitric	oxide	leads	to	vasodilation	in	mammals	via	its	activation	of	guanylyl	cyclase	and	production	of	cGMP.	171	As	well	as	the	endothelial	production	of	NO	there	is	evidence	of	nitrite	reduction	to	NO	by	a	number	of	mechanisms.	101	In	this	thesis	we	 have	 discussed	 deoxy-haem	 reductase	 activity	 and	 a	 number	 of	 other	mechanisms	proposed	such	as	acid	disproportionation	150	and	xanthine-oxidase	reduction.	138	
	
NO	has	a	well-documented	role	in	inhibiting	platelet	reactivity	via	the	same	cGMP	mediated	mechanism	central	to	many	of	its	actions.	172,173	A	significant	limitation	to	NO	and	its	direct	role	in	serum	is	its	very	short	half-life	which	can	be	measured	in	ms	(1	to	2	ms),	secondary	to	its	rapid	inactivation	by	free	radicals	(superoxide	and	lipid	peroxyl	radicals)	and	metalloproteins	(in	particular	haemoglobin).	174	
NO	complexes	with	thiol	groups	(to	form	RSNO)	which	protects	NO	from	this	rapid	inactivation	 /	 decay	 in	 biological	 activity.	 RSNO	 can	 then	 release	 its	 NO	 and	activate	the	guanylyl	cyclase	/	cGMP	dependent	pathways	and	cGMP	independent	pathway	 giving	 rise	 to	 post-translational	 modification	 of	 proteins.	 175-178	 A	convincing	 role	 for	 NO	 via	 S-nitrosothiols	 (RSNO)	 is	 seen	 in	 terms	 of	 platelet	
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function	via	direct	inhibition	of	platelets,	179,180	and	platelet-leukocyte	binding	to	the	vascular	endothelium.	181-183		
	
Serum	 nitrite	 may	 have	 a	 role	 in	 platelet	 inhibition	 via	 its	 reduction	 to	 NO	regardless	of	which	mechanism	this	occurs	through.		Srihirun	et	al,	154	reported	an	effect	of	nitrite	ex-vivo	on	inhibiting	platelet	reactivity	using	an	LTA	assay	which	was	dependent	on	erythrocytes	and	deoxygenation;	an	effect	abrogated	with	the	addition	of	the	NO	scavenger	C-PTIO.		
	
Velmurugan	et	al,	184	also	showed	ex-vivo	that	nitrite	itself	has	no	direct	effect	on	platelet	 reactivity.	Whilst	 a	multitude	 of	 in-vitro	 (NO	 and	 nitrite	 added	 to	 the	platelet	 assay	 directly)	 studies	 have	 shown	 an	 effect	 of	 NO	 or	 nitrite	 (with	intermediary	metabolism),	there	is	very	little	data	on	the	in-vivo	/	ex-vivo	action	of	NO	or	nitrite,	particularly	in	pathological	states.	In	the	same	paper	Velmurugan	et	al	used	a	dietary	nitrate	supplement	in	healthy	volunteers	to	augment	serum	nitrite	concentrations.	A	small	rise	 in	serum	nitrite	concentration	was	achieved	(baseline	 ~200nM,	 post	 nitrate	 dose	 ~	 350nM),	 this	 was	 associated	 with	 a	significant	 reduction	 in	 platelet	 reactivity	 measured	 using	 light	 transmission	aggregometry	(LTA)	with	a	range	of	agonists.	A	selection	of	human	nitrite	infusion	studies	is	outlined	in	Table	9.	
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Table 9: Summary table of contemporary studies focusing on the effect of augmented nitrite 
concentration and the effect on platelet function in humans 
Summary table of contemporary studies focusing on the effect of augmented nitrite concentration and 
the effect on platelet function in humans. Abbreviations: LTA - light transmission aggregometry, C-PTIO 
– Carboxy-PTIO potassium salt (NO scavenger), ADP – Adenosine diphosphate, P-PCI – Primary 
percutaneous coronary intervention 	
There	are	a	limited	number	of	animal	studies	looking	at	nitrite	supplementation	and	its	effect	on	platelet	reactivity.	188	Until	recently	the	literature	did	not	contain	any	trials	looking	at	the	effect	of	nitrite	infusions	on	platelet	function	in	patient	populations	with	acute	coronary	syndromes	(NSTEMI	/	STEMI),	recently	Jones	et	al,	 189	 published	some	platelet	 function	data	 in	a	 study	 that	used	 intracoronary	
Author / Year Number patients Intervention 
Patient / 
Disease 
type 
Platelet function 
analysis Main result 
Srihirun et al 
2012 185 
15 
Ex-vivo 
Nitrite 0.01 to 
10µM +/- 
deoxygenated 
erythrcytes +/- C-
PTIO 
Healthy 
LTA and 
impedencd 
aggregometry 
(chrono-log), 
Flow cytometry. 
Using ADP as 
platelet agonist 
Nitrite alone had no effect on 
platelet function, the addition 
of erythrocytes reduced 
platelet aggregation and 
reduced expression of 
platelet bound p-selectin. C-
PTIO reversed both these 
actions 
Kadan 
et al 2015 186 
7 
Ex-vivo 
Nitrite 10µM to 
5mM 
Healthy 
LTA with ADP, 
collagen, 
epinephrine 
agonists 
Significant platelet inhibition 
with nitrite alone (no 
erythrocytes), seen at doses 
of nitrite above 500µM 
Akrawinthawong 
et al 2014 187 
42 
Ex-vivo Nitrite 0.01 
to 10µM +/- 
deoxygenated and 
oxygenated 
erythrocytes +/- C-
PTIO 
Healthy 
Flow cytometry 
with ADP, collagen 
and thrombin 
agonists 
Nitrite alone had no effect on 
platelet p-selectin expression. 
The addition of deoxygenated 
erythrocytes significantly 
reduced the expression of p-
selectin after stimulation with 
ADP, Collagen and thrombin. 
Jones et al 
2014143  
Patients received 
1.8µM sodium 
nitrite or placebo 
via intra-coronary 
injection at the time 
of P-PCI, ex-vivo 
platelet function 
STEMI 
patients 
undergoing 
P-PCI 
Whole blood 
aggregometry 
(Multiplate, Roche 
diagnostics), flow 
cytometry 
assessment of  p-
selectin expression 
Reduced p-selectin platelet 
expression and whole blood 
aggregation in response to 
ADP (10µmol/L). At 30 mins, 
4 hrs, 24 hrs and 6 months 
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sodium	nitrite	treatment	in	patients	receiving	P-PCI	in	STEMI	(Table	9),	This	study	did	not	reach	its	primary	or	secondary	endpoints	in	terms	of	reperfusion	injury	protection	but	did	show	some	effects	on	platelet	function	in	the	period	after	P-PCI.	Principally	the	authors	published	a	reduction	in	both	ADP	mediated	aggregation	and	ADP	mediated	P-selectin	expression	on	platelets.	As	will	become	evident	in	this	 chapter,	 the	 use	 of,	 and	 interpretation	 of	 these	 platelets	 assays	 has	many	pitfalls	 (Page	 159:	 Platelet	 sub-study).	 Sensitive	 platelet	 assays	 should	 be	interpreted	 with	 caution	 in	 a	 population	 undergoing	 super-acute	 coronary	intervention	 during	 a	 disease	 process	which	has	 a	 strong	 influence	 on	 platelet	activation	/	aggregation,	whilst	having	acute	and	large	doses	of	potent	antiplatelet	drugs.	 We	 will	 discuss	 the	 Jones	 et	 al	 paper	 in	 the	 discussion	 section	 of	 this	chapter.		
Platelet inhibition in NSTEMI patients 
Platelet	 inhibition	 in	 NSTEMI	 patients	 is	 a	 fundamental	 aspect	 of	 the	 initial	medical	 management.	 Up	 until	 very	 recently	 this	 has	 been	 achieved	 with	 a	combination	 of	 aspirin	 and	 clopidogrel.	 Aspirin	 is	 an	 irreversible	 inhibitor	 of	cyclo-oxygenase-dependent	 platelet	 aggregation,	 its	 efficacy	 within	 acute	coronary	syndrome	patients	was	proven	in	one	of	the	first	large	scale	clinical	trials	within	 cardiology,	 ISIS-2.	 190	 	 Clopidogrel	 is	 an	 irreversible	 antagonist	 of	 the	platelet	 P2Y12	 receptor	 that	 is	 activated	 by	 ADP	 in	 a	 positive	 feedback	 loop	following	degranulation	of	platelets.		
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Figure 19: Platelet activation: A,B and C depict thromboxane A 2 (TXA2), Adenosine diphosphate (ADP) 
and thrombin respectively. A/ Both TXA2 and 12-HETE (Page 157) are synthesised from arachidonic acid 
(AA) via cyclooxygenase (COX). It causes a rise in intracellular Ca2+ via inositol triphosphate. TXA2 can 
diffuse across the membrane to activate other platelets. B/ Activated platelets release ADP via α-granule 
release, it stimulates P2Y12 and P2Y1 receptors on platelets causing further intracellular calcium increase 
via cAMP. ADP and its key receptor P2Y12 amplify and sustain platelet activation. C/ Thrombin release 
at sites of vascular injury mediates both fibrin generation and is the most potent platelet activator. It 
acts via the G-protein linked protease activated receptors (PAR1 to PAR4) which are activated following 
peptide cleavage off thrombin. Via 3 key G-proteins, thrombin initiates shape change (G12/G13 – Rho), 
increase intracellular Ca2+ (Gq and Gi). D/ Depicts inside out platelet activation; specific emphasis on 
initial activation causing reduction in cAMP and increased Ca2+ as described in A,B and C. This then leads 
to a number of changes including further release of ADP and TXA2 leading to a positive feedback loop 
and further activation. Glycoprotein IIb/IIIa also undergoes conformational changes allowing cross 
linkage within fibrin. With permission Davi et al 191 	
Clopidogrel	has	been	 shown	 to	 confer	a	 significant	morbidity	and/or	mortality	benefit	in	the	prevention	of	ischaemic	complications	in	patients	with	NSTEMI	192	
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and/or	after	PCI.	193	Principally	clopidogrel	reduces	clot	formation	(and	occlusion	of	 the	 vessel)	 following	 plaque	 rupture,	 this	 reduces	 ischaemic	 complications	(recurrent	 ischaemia	 and	 /	 or	 STEMI).	 	 A	 significant	 proportion	 of	 NSTEMI	patients	have	clinically	important	incomplete	inhibition	of	P2Y12	mediated	platelet	activation	(up	to	50%).	High	on	treatment	platelet	reactivity	(HTPR)	in	patients	receiving	clopidogrel	has	been	identified	as	a	risk	factor	for	stent	thrombosis	and	myocardial	 infarction	 and	 is	 inversely	 related	 to	 bleeding	 risk.	 194,195	 For	 this	reason	more	potent	and	predictable	platelet	 inhibition	using	newer	antiplatelet	agents	(prasugrel	and	ticagrelor)	in	NSTEMI	patients	have	shown	clinical	benefit	at	the	expense	of	increased	rate	of	bleeding.	196,197	Targeted	release	of	NO	from	nitrite	leading	to	further	platelet	inhibition	is	a	very	attractive	target	particularly	in	patients	who	may	have	a	reduced	response	(secondary	to	a	multitude	of	host	factors)	to	clopidogrel.		
Measuring platelet function  
Platelet	function	testing	(PFT)	and	in	particular	light	transmission	aggregometry	(LTA)	is	notorious	for	producing	a	high	degree	of	variability	in	results	due	largely	to	the	need	for	conditions	to	be	kept	strictly	constant	in	the	context	of	multiple	steps	which	all	have	the	ability	to	“upset”	platelets.	198	In	a	cohort	of	patients	with	variable	clinical	characteristics	and	receiving	PCI	at	different	 times	this	 is	even	more	evident.	199	This	variability	of	testing	conditions	and	timing	is	no	doubt	part	of	 the	 reason	 why	 multiple	 large	 scale	 clinical	 trials	 looking	 at	 tailored	 anti-platelet	therapy	have	thus	far	failed	to	show	any	advantage	of	routine	PFT	in	these	patients	in	order	to	predict	and	treat	partial	response	to	clopidogrel.	200-203	All	of	the	large-scale	clinical	trials	are	defined	by	their	variability	in	method.	Specifically	
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there	is	no	consistency	between	the	type	of	PFT	assay	used	and	the	timing	of	PFT	in	relation	to	antiplatelet	drug	therapy	and	timing	of	testing	around	the	time	of	PCI.		
	
Based	on	a	small	pilot	study	in	preparation	for	this	thesis	it	was	found	that	the	greatest	variability	in	PFT	results	was	according	to	the	timing	of	this	test	around	the	PCI	itself,	with	large	variability	in	platelet	aggregation	in	response	to	ADP.	This	variability	was	similar	to	that	seen	and	reported	in	patients	undergoing	CABG	by	Rinder	 et	 al.	 204	 Rinder	 found	 overt	 platelet	 activation	 confirmed	 with	quantification	of	granule	membrane	protein	140	(gp140)	by	flow	cytometry.	The	circulation	of	these	“spent”	platelets	was	associated	with	reduced	aggregation	in	response	to	ADP	(ex-vivo).	Patients	who	have	been	on	cardio-pulmonary	bypass	at	the	time	of	CABG	appeared	to	have	had	a	large	activation	of	platelets	secondary	no	 doubt	 to	 the	 combination	 of	 no	 antiplatelet	 pharmacotherapy,	 and	 the	mechanical	 insult	 secondary	 to	 cardio-pulmonary	 bypass	 itself.	 Pilot	 data	collected	during	the	initial	preparation	for	this	thesis	indicated	a	significant	shift	in	platelet	 function	 in	NSTEMI	patients,	similar	 to	 that	 found	by	Rinder	et	al	 in	CABG	patients.		
Inflammation and platelet function 
In	 coronary	 disease,	 platelets	 are	 central	 to	 the	 relationship	 between	inflammation,	 thrombosis	 and	 atherogenesis	 (Figure	 20).	 	 The	 focus	 of	 this	relationship	is	the	way	in	which	platelets	interact	with	both	endothelial	cells	and	leukocytes	 (in	 particular	 monocytes).	 These	 interactions	 trigger	 a	 cascade	 of	
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autocrine	and	paracrine	actions	 that	promote	development	of	 coronary	plaque	and	may	have	a	role	in	plaque	susceptibility	to	rupture.	205	
	
At	points	of	endothelial	damage	and	vascular	lesions	two	key	proteins	are	exposed	to	the	blood;	von	Willibrand	factor	(vWF)	and	collagen.	Platelets	will	then	adhere	to	vWF	via	glycoprotein	Ib/IX/V	(GPIb/IX/V),	206	and	collagen	binding	occurs	via	glycoprotein	VI.	207	This	is	the	first	step	in	clot	formation	which	is	quickly	followed	by	further	recruitment	of	platelets	and	formation	of	fibrinogen	bridges	between	pairs	of	platelet	αIIbβ3	receptors.		
Increasingly	 it	 is	 becoming	 evident	 that	 overt	 endothelial	 damage	 is	 not	 an	absolute	in	terms	of	the	ability	of	platelets	to	bind	to	the	endothelium.	The	healthy	endothelium	has	a	number	of	anti-adhesive	mechanisms	principally	these	consist	of	the	ecto-ADPase	which	metabolises	local	ADP	(a	platelet	agonist	released	from	α-granules),	 the	 arachidonic	 acid/prostacyclin	 pathway	 (PGI2)	 and	 the	 NO	pathway.	208	All	three	of	these	mechanisms	have	the	potential	to	be	disrupted;	we	have	already	described	the	association	between	endothelial	dysfunction	in	terms	of	reduced	NO	production	in	patients	with	cardiovascular	risk	factors.	130	Further	to	 this,	 inflammatory	 stimuli	 are	 capable	 of	 both	 down-regulating	 these	 anti-adhesive	 mechanisms	 and	 also	 upregulating	 the	 expression	 of	 adhesion	molecules.	 209	 Inflammatory	 insults	 and	 expression	 of	 adhesive	 ligands	 are	promoted	 by	 hyperlipidaemia	 and	 the	 accumulation	 of	 oxidised	 lipoprotein	fractions.210	The	adhesive	ligands	expressed	in	this	situation	are	p-	and	e-selectin	as	well	as	further	expression	of	vWF.	211	Endothelial	p-selectin-selectin	binds	to	
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the	 GPIbα	 receptor	 and	 the	 p-selectin	 glycoprotein-1	 (PSGL-1),	 both	 of	 which	enhance	tethering	and	rolling	of	the	platelet	along	the	inflamed	endothelium.	The	mechanisms	 of	 firm	 adhesion	 to	 the	 inflamed	 endothelium	 are	 not	 fully	understood	 in-vivo,	but	may	 involve	αIIBβ3	binding	 to	 fibrinogen,	which	 is	 itself	bound	to	the	endothelium	via	ICAM-1	and	other	mechanisms.	211	
	
Platelets	bound	to	endothelium	are	known	to	secrete	IL-1β	which	appears	to	be	the	central	mediator	of	platelet	induced	endothelial	activation	via	increased	IL-6	and	 IL-8	 expression	 which	 in	 turn	 increases	 the	 expression	 of	 ICAM-1	 and	adhesion	of	monocytes	to	the	endothelium.	209,212	
	
	
Figure 20: Interaction between the platelet and endothelium A/ Healthy endothelium and anti-adhesive 
mechanisms: ecto-ADPase reducing localised ADP concentrations, NO and PGI2 which stimulate cGMP 
and cAMP production and thus reduce intracellular Ca2+ and reduce activation. B/ Hyperlipidaemia 
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induced endothelial activation via the action of lipoprotein particles and reactive oxygen species (ROS), 
leading to C/ e, p-selectin and von-Willebrand factor (vWF) expression, which supports platelet tethering 
and rolling. Ultimately this allows platelet adhesion to endothelium via fibrinogen complexes.   Once 
adherent platelets secrete a number of chemokines and cytokines including IL-1β which stimulates 
endothelial synthesis of IL-6, IL-8 and MCP-1 via NFκB. Ecto-ADPase: ecto-adenosine diphosphatase, NO: 
nitric oxide, MCP-1:  monocyte chemoattractant protein-1. With permission213 	
Platelet leukocytes interaction 
Platelets	adherent	to	the	endothelium	have	a	central	role	in	leukocyte	recruitment	and	activation,	this	is	particularly	true	for	monocytes	and	T	lymphocytes	whose	role	in	atherosclerosis	is	clear-cut.	205,214	A	complex	series	of	membrane	receptor	interactions	 are	 involved	 in	 monocyte	 and	 lymphocyte	 adhesion	 to	 the	endothelium,	a	complex	subject	and	one	in	which	the	reader	can	gain	a	brief	and	limited	overview	in	this	chapter	but	can	gain	a	deeper	insight	by	referring	to	the	review	of	Hansson	et	al.	205		
Platelet, monocyte, and endothelial cell interaction 
Once	the	platelet	is	adherent	to	the	endothelium	they	also	provide	the	initial	steps	of	a	complex	multistep	process	to	allow	monocytes	to	be	recruited	to	the	vessel	wall	and	ultimately	differentiate	into	macrophages.	The	key	steps	involve	selectin	mediated	 rolling,	 monocyte	 activation,	 firm	 integrin-mediated	 adhesion	 and	diapedesis.	 As	 seen	 in	 Figure	 21	 selectin	 mediated	 rolling	 occurs	 via	 the	interaction	of	platelet	bound	p-selectin	binding	to	the	monocyte	receptor	PSGL-1	(p-selectin	glycoprotein	 ligand-1).	 215,216	This	 interaction	 secures	 the	 release	of	both	IL-8	and	TNFα	by	the	monocyte	and	further	firm	adherence	occurs	via	the	MAC-1	(macrophage-1	antigen)	to	ICAM	/	GP	interactions	(intercellular	adhesion	molecules	/	Glycoprotein).	
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Figure 21: platelet monocyte interaction. Platelets adherent to the endothelium bind to monocytes via 
p-selectin glycoprotein ligand-1 (PSGL-1) and macrophage-1 antigen (MAC-1). This stimulates 
monocytes to release key chemokines, cytokines, tissue factor and further increased expression of 
adhesion molecules. This combination of activation is also accompanied by the monocyte differentiating 
into a macrophage. This outlines the central role of the platelet and monocyte in the atherogenic process 
and ultimately plaque formation. With permission from Gawaz et al 209 	
Lymphocyte role in vascular inflammation 
Lymphocytes	 and	 in	 particular	 T-cell	 lymphocytes	 are	 commonly	 found	within	atherosclerotic	plaques,	 typically	 these	are	CD4+	(T	helper)	cells.	On	activation	these	CD4+	cells	reveal	themselves	in	two	distinct	populations;	type	1	(Th1)	and	type	2	(Th2).	Th1	cells	activate	macrophages	and	initiate	a	pro-inflammatory	(and	atherosclerotic)	response	whereas	Th2	tend	to	promote	a	cytokine	profile	that	is	anti-inflammatory.	 210	 These	 populations	 are	 themselves	 controlled	 by	 a	
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regulatory	T-cell	population	(Treg),	via	 the	secretion	of	 IL-10	and	transforming	growth	factor	β	(TGF-β),	pro-inflammatory	Th1	CD4+	cells	are	suppressed.	See	Table	10	for	a	list	of	TH1	and	Th2	Interleukins	and	their	actions.	
Th1	Induced	by	IL-1b	and	IL-12	Suppressed	by	IL-6,	IL-10	and	TGF-b	
Th2	
	Suppressed	by	IFN-g	Cytokine	 Action	 Cytokine	 Action	Interferon	g	(IFN-g)	 Stimulate	macrophages	and	vascular	endothelial	cells,	inhibits	Th2210		
Interleukin-4	(IL-4)	 Reduces	atherosclerotic	progression	and	plaque	formation.	Reduces	tissue	factor	release.	217	
Interleukin-2	IL-2	 	 Interleukin-5	(IL-5)	 Effective	marker	of	Th2	activity		Tumour	Necrosis	Factor	
a	(TNF-a)	 Stimulate	macrophages	and	vascular	endothelial	cells210		
Interleukin-6	(IL-6)	 Secreted	from	monocytes,	less	when	platelet	activation	occurs.	Suppresses	Th1	activated	via	Treg	218,219	
IL-8	 Not	a	classic	Th1	cytokine	but	a	chemokine	produced	by	epithelial	cells	which	triggers	firm	adhesion	of	monocytes	to	the	endothelium	
Interleukin-10	(IL-10)	 Released	by	activated	platelets	and	associated	with	favourable	outcome	in	ACS	
218	Inhibits	Th1	via	downregulation	of	NF-kB	220	
	 	 Interleukin-13	(IL-13)	 Reduces	tissue	factor	release.	217	
	 	 	 	
Table 10:Th1 and Th2 associated cytokines and their actions in the context of acute coronary syndromes. 
The Th1 / Th2 balance is itself regulated by Treg cells (CD28+ FoxP3+) principally through the release of 
IL-6,10 and TGF-b. Abbreviations: IL-interleukin, IFN-g-interferon g, TNF-a tumour necrosis factor b, 
Treg- T-cell regulatory. 	
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Platelet metabolism of arachidonic acid   
Metabolites	of	arachidonic	acid	play	a	key	role	in	mediating	thrombus	formation	and	 vessel	 tone	 in-vivo.	 221	 When	 the	 platelet	 is	 activated	 arachidonic	 acid	concentration	 rises	 steeply	 as	 phospholipid	 hydrolysis	 occurs.	 222	 Arachidonic	acid	 (AA)	 itself	 is	 metabolised	 via	 two	 distinct	 pathways;	 the	 first	 is	cyclooxygenase	 which	 forms	 thromboxane	 A2	 	 (TXA2)	 and	 the	 second	 is	 12-lipoxygenase	 which	 produces	 12-hydroperoxyeicosatetrenoic	 acid	 (12-HPETE)	which	 then	 forms	 12-hydroxyeicosatetraenoic	 acid	 (12-HETE).	 223	 Both	 TXA2	
224,225	and	12-HETE	226,227	have	proven	roles	in	mediating	thrombus	formation	via	platelet	activation.	During	a	pilot	run	we	were	unable	to	detect	and	measure	free	TXA2	 in	 serum	 samples,	 however,	 we	were	 able	 to	 consistently	 quantify	 small	quantities	of	12-HETE.	We	chose	to	measure	serum	12-HETE	in	our	cohorts	as	a	further	platelet	activation	marker.	
	
Chapter aims 
This	 chapter	 contains	 three	main	 sections;	 the	 first	 is	 a	methodological	section	(platelet	sub-study)	in	a	separate	cohort	of	patients	created	to	first	establish	the	PFT	assay	in	terms	of	limitations	and	optimisation	in	NSTEMI	patients	around	the	time	of	PCI.		
	
The	 second	 section	 is	 a	 further	 study	 of	 the	 NSTEMI	 and	 NSTEMIinf	 cohorts	specifically	looking	at	baseline	endogenous	NO	synthesis	and	the	augmentation	of	nitrite	and	the	influence	on	platelet	function.	
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The	 third	 section	 analyses	 the	 cytokine	 profiles	 of	 the	 NSTEMI	 and	 NSTEMIinf	cohorts	 and	 the	 association	 between	 pro-inflammatory	 status,	 endothelial	function	and	platelet	reactivity.	
	
METHODS 
Two	principal	studies	on	3	different	cohorts	of	similar	patients	are	described	in	this	 chapter.	 Cohort	 1	 is	 the	 platelet	 sub-study	 of	 high	 risk	 NSTEMI	 patients.	Cohorts	2	and	3	are	the	NSTEMI	and	NSTEMIinf	population	described	in	Chapter	3:	Results	1	and	Chapter	4:	Results	2.		
Platelet sub-study 
Study patients 
We	conducted	a	prospective	observational	 study	on	high-risk	NSTEMI	patients	who	received	clopidogrel	at	diagnosis	and	for	a	minimum	period	of	5	days	before	PCI	was	conducted.		
Inclusion	criteria		
• Patients	with	an	 index	admission	 following	an	NSTEMI	(troponin	positive	and	/	or	typical	ECG	changes	with	consistent	clinical	history),	and	a		
• GRACE	score	 	>140	who	subsequently	went	on	to	have	significant	disease	treated	by	PCI	and	stent	implantation.		
Exclusion	criteria		
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• Patient	who	received	intravenous	antiplatelet	agents	(glycoprotein	IIb/IIIa	inhibitors	(GPI)	or	other)	and		
• Renal	dysfunction	(eGFR	<40mls/min).		
Local	 research	 ethics	 approval	was	 granted	 and	written	 informed	 consent	was	obtained	from	each	patient.		
Platelet sub-study protocol 
All	patients	received	a	loading	dose	of	aspirin	(300mg)	and	a	maintenance	dose	of	75mg	 once	 daily	 initiated	 at	 the	 same	 time	 as	 the	 clopidogrel	 unless	 this	was	already	 taken	 prior	 to	 their	 hospital	 admission.	 To	 exclude	 any	 influence	 of	variable	clopidogrel	loading	only	patients	that	had	received	a	600mg	loading-dose	followed	 by	 a	 minimum	 of	 5	 days	 of	 maintenance	 therapy	 (75mg	 OD)	 were	recruited.	228	Timing	of	dose	was	also	corrected	for	by	ensuring	the	third	sampling	point	was	exactly	(+/-	1hr)	24	hours	after	the	baseline	measurement	and	drugs	received	at	the	same	time	each	day.	
	
All	 patients	 received	 a	 weight-adjusted	 dose	 of	 intravenous	 unfractionated	heparin	70	–	100	Units/kg	bolus	pre-procedurally.	All	blood	samples	were	taken	from	the	same	large	calibre	venous	sheath	in	the	antecubital	fossa	and	3	samples	collected	in	the	24-hour	period	(immediately	pre-	and	post-PCI	and	24hrs	post-PCI).	Samples	were	collected	 into	a	depressurised	vacutainer	(hirudin	 for	MEA,	citrate	for	flow	cytometry,	EDTA	for	mass	spectrometry	and	ELISA).	The	24	hour	sample	was	taken	at	24	hours	(+/-	1	hour)	and	the	morning	dose	of	clopidogrel	was	administered	at	8am	on	both	days	to	ensure	there	a	was	no	influence	of	dose	timing	on	test	results.	The	PCI	itself	was	carried	out	with	no	restrictions	and	as	
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per	the	operator	preference.	Operators	were	blinded	to	the	results	of	the	platelet	function	testing.	
NSTEMI and NSTEMIinf study protocol (platelet function and cytokine analysis) 
The	second	part	of	the	study	describes	platelet	function	and	cytokine	analysis	of	the	NSTEMI	and	NSTEMIinf		populations	from	Chapter	4:	Results	2.		
Study populations 
Selection	 of	 patients,	 inclusion	 and	 exclusion	 criteria	 can	 be	 seen	 in	 general	methods	Page	52.	
Cardiac catheterisation laboratory protocol 
Full	method	details	are	seen	in	the	general	methods	Page		55.	
Measurement of Nitric Oxide metabolites 
Full	method	details	are	seen	in	the	general	methods	Page	61.	
Impedance aggregometry 
Whole	blood	aggregation	was	determined	using	Multiple	Electrode	Aggregometry	(MEA),	 Multiplate	 Analyzer	 Figure	 22	 (Roche	 Diagnostics),	 which	 detects	 the	change	in	electrical	impedance	due	to	the	adhesion	and	aggregation	of	platelets	on	two	 independent	 electrode-set	 surfaces	 in	 the	 test	 cuvette.	 As	 per	 the	manufacturer’s	 recommendations,	 hirudin	 and	 Adenosine	 Diphosphate	 (ADP)	were	used	as	the	sample	anticoagulant	and	agonist	respectively.	A	1:2	dilution	of	whole	blood	and	0.9%	NaCl	was	stirred	at	37	°C	for	3	min	in	the	test	cuvettes,	ADP	was	 added	 (final	 concentration	 6.5	 μM)	 and	 the	 increase	 in	 impedance	 was	recorded	 continuously	 for	 6	 min.	 The	 process	 was	 repeated	 using	 Thrombin	
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Receptor	Activating	Peptide	6	(TRAP-6),	(final	concentration	32	μM),	in	order	to	assess	platelet	aggregation	independently	of	clopidogrel.	Each	test	cell	generates	two	independent	values,	which	are	averaged	and	expressed	as	the	area	under	the	curve	 of	 the	 aggregation	 tracing	 (AUC).	 Consequently,	manufacturer’s	 software	performs	a	Pearson’s	 correlation	 coefficient	on	 the	 two	measurements	and	 the	result	is	rejected	if	the	coefficient	is	<98%	or	the	difference	to	the	mean	curve	is	>20%.	AUC	was	reported	as	arbitrary	units	and	a	cutoff	of	500	U	was	defined	as	the	 threshold	 above	which	 a	 patient	was	 characterised	 as	 having	HTPR	 (“non-responder”),	 according	 to	 the	 mean	 of	 two	 previously	 proposed	 cut-offs.	
195,229Following	 a	 resting	 period	 of	 20	 minutes	 trained	 laboratory	 technicians	processed	the	samples.	
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Figure 22: Multiplate platelet analyser.  (Roche diagnostics). A five channel impedance analyzer, (inset) 
disposable cuvettes with electrodes and stir bar. 
 
Flow cytometry assessment of Platelet bound p-selectin  
Sample preparation: 
20μl	of	whole	blood	was	 initially	diluted	 in	50μl	Tyrodes	buffer	 (137mM	NaCl,	2.68mM	KCl,	1mM	MgCl2,	1.8mM	CaCl2,	0.2mM	Na2HPO4,	12mM	NaHCO3,	pH7.4)	and	 subsequently	 incubated	 in	 10μl	 fluoresceine-isothiocyanate-(FITC)-mount-Anti-Human	 CD61,	 20μl	 of	 allophycocyanin-(APC)-Mount-Anti-Human	 CD62P	antibody	or	(APC)-Mount-IgG1	isotype	control	(BD	Biosciences,	Pharmigen™)	and	incubated	at	room	temperature	for	15	min.	Incubation	was	terminated	by	fixation	of	20μl	of	 the	reaction	mixture	to	1%	paraformaldehyde.	Samples	were	diluted	four-fold	in	Tyrodes	buffer	prior	to	analysis.	The	Anti-CD61	antibody	is	targeted	against	 the	 constitutively	 expressed	 IIIa	 domain	 of	 the	GpIIb/IIIa	 receptor	 and	identifies	resting	and	activated	platelets	230,231.	
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Sample analysis:  
The	samples	were	analysed	by	CyAn™	ADP-Analyzer	(Beckman	Coulter),	Figure	23	on	the	same	or	the	following	day.	Platelets	were	initially	identified	and	gated	at	50,000	 events	 according	 to	 their	 side	 and	 forward	 scatter	 characteristics	 and	consequently	gated	for	CD61	positivity.	Samples	containing	non-specific	IgG1-APC	antibodies	were	used	as	a	negative	control	and	to	set	an	analysis	marker	so	that	99.9%	of	the	total	population	of	platelets	to	be	defined	as	negative.	Platelets	with	fluorescence	 intensity	higher	that	 this	value	 for	anti-CD62P-APC	antibody	were	defined	 as	 p-selectin	 positive	 and	 were	 expressed	 as	 a	 percentage	 of	 positive	platelets	 compared	 to	 the	 total	 CD61	 positive	 population.	 To	 correct	 for	fluctuations	of	total	platelet	count	at	the	different	time-points,	the	ratio	of	platelet	to	 total	 cells	 in	 the	 pre-PCI	 sample	 was	 used	 to	 correct	 the	 number	 of	 CD61	positive	platelets	in	the	subsequent	time-point	measurements.	
	 156	
	
Figure 23: CyAn flow cytometer. (Beckman Coulter), with Summit software. Capable of 11 simultaneous 
parameters (forward and side scatter with 7-9 colours and simultaneous width, peak, area and log on 
each). 	
Soluble p-selectin quantification 
MSD	 Human	 Ultra-Sensitive	 p-selectin	 ECL	 assay	 (Electrochemiluminescence	technique.	 MSD:	 Meso	 Scale	 Discovery,	 Gaithersburg,	 MD)	 was	 used	 as	 per	manufacturers	recommendations.	A	human	anti-p-selectin	coated	MULTI-ARRAY	96-well	small	spot	plates	was	initially	blocked	with	bovine	albumin	followed	by	addition	 of	 serum	 samples	 and	 detection	 antibody.	 p-selectin	 calibration	standards	were	 run	 in	duplicate	on	 the	 same	plate	under	 the	 same	conditions.	Following	incubation	and	washing	the	read	buffer	was	added	and	the	96	well	plate	was	 analysed	 on	 an	 ImageSector	 6000.	 Results	 were	 analysed	 using	 MSD	workbench	 software.	 Samples	were	 run	 as	 duplicates,	 and	measurements	with	coefficient	of	variation	less	than	15%	were	considered	acceptable.		
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Assessment of 12-HETE by lipid extraction and reverse phase LC/MS/MS 
Lipid Extraction 
For	analysis	of	 lipids	 in	human	plasma,	5	ng	of	12-HETE-d8	were	added	to	the	samples	 before	 extraction,	 as	 an	 internal	 standard.	 Lipids	 were	 extracted	 by	adding	a	solvent	mixture	(1	mol/L	acetic	acid,	isopropyl	alcohol,	hexane	(2:20:30,	v/v/v))	to	the	sample	at	a	ratio	of	2.5	ml	to	1	ml	sample,	vortexing,	and	then	adding	2.5	ml	 of	 hexane.	 232	 After	 vortexing	 and	 centrifugation,	 lipids	were	 recovered	from	the	upper	hexane	layer.	The	samples	were	then	re-extracted	by	addition	of	an	 equal	 volume	 of	 hexane.	 The	 combined	 hexane	 layers	 were	 dried	 and	 the	aqueous	layer	was	re-extracted	by	adding	3.75	ml	of	a	chloroform	and	methanol	mixture	 (1:2,	 v/v),	 vortexing,	 then	 adding	 1.25	ml	 chloroform.	After	 vortexing,	1.25	ml	water	was	added	and	the	mixture	was	vortexed	again	and	centrifuged.	Lipids	were	recovered	in	the	chloroform	layer,	233	and	dried;	the	combined	lipid	extracts	 were	 consequently	 analysed	 for	 free	 12-HETE	 using	 LC-MS/MS	 as	described	below.	
Reversed phase LC/MS/MS of free HETE.   
For	12-HETE	quantitation	lipids	were	separated	on	a	C18	Spherisorb	ODS2,	5	μm-1,	 150	 x	 4.6	 mm	 column	 (Waters,	 Hertfordshire,	 UK).	 The	 mobile	 phase	 was	composed	of	water:	acetonitrile:	acetic	acid	(75:35:0.1,	solvent	A)	and	methanol:	acetonitrile:	acetic	acid	(60:40:0.1,	solvent	B),	with	flow	rate	1	ml.min-1.	Solvent	B	was	increased	from	50	%	to	90	%	over	10	min,	held	for	20	min,	then	returned	to	50	%.232	MS	was	performed	using	a	Sciex	4000	Q-Trap,	using	DP	-85V,	CE	-20V	and	a	dynamic	fill	time	monitoring	the	parent	to	daughter	m/z	(m/z	319.2	to	179.1,	m/z	 327.2	 to	 184.1	 for	 12-HETE	 or	 12-HETE-d8,	 respectively).	 12-HETE	 was	
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identified	 and	 quantified	 using	 12-HETE	 and	 12-HETE-d8	 standards	 run	 in	parallel	under	the	same	conditions.	
Cytokine quantification 
MSD	 Human	 Ultra-Sensitive	 TH1/TH2	 10-plex	 assay	 kit	 (MSD:	 Meso	 Scale	Discovery,	Gaithersburg,	MD)	was	used	as	per	manufacturers	recommendations.	This	 10-plex	 96-well	 plate	 allowed	 the	 quantification	 of	 Interferon-γ	 (IFN-γ),	Interleukin	(IL)-1β,	IL-4,	IL-8,	IL-10,	IL-13	and	tumor	necrosis	factor-α	(TNF-α).	25μL	of	diluent	2	was	dispensed	into	each	well	and	incubated	for	30minutes.	25μL	of	the	serum	sample	or	calibration	standard	was	then	pipetted	into	each	well	and	incubated	with	shaking	at	800rpm	for	2	hours.	The	plate	was	then	washed	3	times	with	PBS-T.	25μL	of	detection	antibody	was	added	to	each	well	and	incubated	for	2	hours.	The	plate	was	then	washed	again	3	times	with	PBS-T.	150μL	of	2	x	Read	buffer	was	then	added	to	each	well	and	the	plate	was	analysed	on	an	ImageSector	6000.	Results	were	analysed	using	MSD	workbench	software.	Samples	were	run	as	duplicates,	and	measurements	with	coefficient	of	variation	less	than	15%	were	considered	acceptable.		
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RESULTS 
 
Platelet sub-study 
A	 total	 of	 74	 ACS	 patients	 were	 consented	 for	 the	 study;	 however	 30	 were	excluded	 as	 they	 did	 not	 undergo	 PCI	 following	 coronary	 angiography.	 Two	patients	 were	 further	 excluded	 due	 to	 peri-procedural	 glycoprotein	 IIb/IIIa	inhibitor	(GPI)	use.	The	remaining	42	patients	completed	the	study	in	full	with	no	peri-procedural	major	complications.		
	
The	complete	group	of	patients	(42),	showed	a	consistent	and	significant	decrease	in	platelet	reactivity	in	the	first	24	hours	after	PCI	as	measured	by	MEA	(Figure	24).	Using	ADP	as	an	agonist	the	mean	value	of	platelet	aggregation	pre-PCI	was	499.1	AU	(±	46.3),	with	40.5%	(17	patients)	exhibiting	HTPR.	Immediately	post	PCI,	this	value	decreased	to	407.6	AU	(±37.7)	translating	to	26.2%	(11	patients)	with	HTPR	(p	>0.05).	At	24	hours	post-procedure,	platelet	aggregation	decreased	to	269.1	AU	(±24.6)	further	reducing	the	number	of	patients	who	appeared	to	have	HTPR	to	4.7%	(2	patients).	The	mean	change	in	platelet	aggregation	from	Pre-PCI	to	24	hrs	Post-PCI	was	230.0	AU	(CI	104.5	to	355.6,	p=0.	0002ANOVA).	(Table	11)	
	
When	the	population	was	split	between	those	with	and	without	HTPR,	the	group	with	HTPR	had	a	mean	reduction	in	ADP	induced	aggregation	from	Pre-PCI	to	24	hrs	Post-PCI	of		379.1	AU	(52%)	(CI	255.9	to	502.2,	p=0.0001ANOVA).	In	comparison,	
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patients	 without	 HTPR	 had	 a	 proportionately	 smaller	 reduction	 of	 98.6	 AU	(33.5%)	over	24hours	(CI	23.04	to	174.1,	p=0.0028ANOVA).	
	
Baseline	pre-PCI	samples	were	collected	before	heparin	administration	in	32	out	of	 the	 42	 patients.	 There	 was	 no	 significant	 difference	 between	 pre-PCI	measurements	 collected	 before	 and	 after	 heparin	 administration;	 thereby	demonstrating	that	heparin	did	not	confound	ADP-induced	platelet	aggregation	as	measured	by	MEA	 (Pre	heparin	mean	476.2	AU	SEM	68.08,	Post	heparin	mean	520.3	AU	SEM	66.49.	p=0.1795	CI	-22.6	to	110.1).	
	
The	 changes	 in	ADP-induced	 platelet	 aggregation	 illustrated	 in	 Figure	 24	were	reflected	 to	 a	 lesser	 extent	 (and	 in	 proportion)	 with	 TRAP	 as	 the	 agonist	 for	aggregation.	For	the	total	population	the	mean	value	of	aggregation	pre-PCI	was	1000	AU	 (±51.6)	 reducing	 to	 843.8	AU	 (±42.1)	 post-PCI	 (p	 <	 0.05ANOVA).	 At	 24	hours	post-PCI,	aggregation	further	decreased	to	792.0	(±41.0)	equating	to	a	mean	reduction	from	Pre-PCI	to	24	hrs	Post-PCI	of	208.4	AU	(20.8%)	(CI	114.1	to	302.6,	p=0.0002ANOVA),	Figure	24.	
	
TRAP	induced	platelet	aggregation	pre-	and	post-PCI	changed	to	a	greater	extent	in	patients	with	HTPR	compared	to	those	without	HTPR.	Notably,	in	patients	with	HTPR,	 TRAP-induced	 aggregation	 had	 a	 larger	 mean	 numerical	 reduction	 in	comparison	 to	 patients	 without	 HTPR	 (214.1	 AU	 vs	 203.9	 AU	 respectively).	Individually	 these	 reductions	 were	 both	 statistically	 significant.	 However,	
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between	groups,	comparisons	did	not	differ	significantly	in	relation	to	the	initial	absolute	pre-PCI	value.	
 
n=42 
Pre-PCI 
(SEM) 
Post-PCI 
(SEM) 
24hrs post 
PCI (SEM) 
P ANOVA 
 
a/ Pre vs Post PCI 
b/ Pre vs 24 hr 
PCI 
c/ Post vs 24 hr 
PCI 
95% CI of 
diff 
 
 
ADP aggregation 
(AUC) 
 
499.1 ± 
46.3 
407.6 ± 
37.7 
269.1 ± 
24.6 
a/ p>0.05 
b/ p=0.0002* 
c/ p<0.05* 
a/ -34.1 to 217 
b/ 104.5 to 
355.6 
c/ 13 to 264.1 
TRAP 
aggregation 
(AUC) 
 
1000 ± 
51.6 
869.2 ± 
42.1 
792.0 ± 
41.0 
a/ p<0.05* 
b/ p=0.0002* 
c/ p>0.05 
a/ 0.74 vs 
261.4 
b/ 114.1 to 
302.6 
c/ -29.5 to 
184.1 
Soluble p-
selectin (ng/ml) 
 
32.1 ± 1.7 31.8 ± 1.9 36.1 ± 3.0 a/ p>0.05 
b/ p=0.0225 
c/ p>0.05 
a/ -3.7 to 3.7 
b/  0.82 to 10.0 
c/ -0.9 to 12.0 
% p-selectin +ve 
plts 
n=16 
2.7 (1.4-
5.0) 
2.5 (2.1-
3.6) 
2.6 (2.0-
5.5) 
a/ ns 
b/ ns 
c/ ns 
 
 
Table 11: Summary table of key findings for aggregometry, soluble and platelet bound p-selectin (ALL 
patients). 
 Row 1 and 2 ADP and TRAP induced aggregation (AU), Row 3 soluble p-selectin (ng), row 4 percentage 
of platelets expressing p-selectin. Mean ± SD or median (IQR). PANOVA values with Tukey’s multiple 
comparison (a= Pre-PCI vs Post-PCI, b=Pre-PCI vs Post-PCI). Except were not normally distributed or 
missing values prevent (Soluble p-selectin). Abbreviations: HTPR: High on treatment platelet reactivity, 
PCI: percutaneous coronary intervention, ADP: adenosine diphosphate, TRAP: thrombin receptor agonist 
peptide, AUC: area under the curve 
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Figure 24: ADP (adenosine diphosphate) and TRAP (thrombin receptor agonist peptide) induced 
aggregation. 
ADP (adenosine diphosphate) and TRAP (thrombin receptor agonist peptide) induced aggregation as 
measured by MEA (multi electrode aggregometry). Each agonist response in ALL patients those with 
HTPR (high on treatment platelet reactivity) and those without HTPR. Abbreviations: HTPR: High on 
treatment platelet reactivity, PCI: percutaneous coronary intervention, ADP: adenosine diphosphate, 
TRAP: thrombin receptor agonist peptide 
 Despite	a	significant	reduction	in	both	ADP	and	TRAP	induced	aggregation	we	saw	a	consistent	and	significant	rise	in	soluble	p-selectin	(4	ng/ml	increase,	CI	0.82	to	10.0,	p=0.0225)	between	pre-PCI	 and	24hrs	post-PCI	 (Table	11),	mainly	 in	 the	HTPR	group	(Figure	26).	Overall	the	consistent	levels	of	p-selectin	found	across	all	time-points	suggest	ongoing	platelet	activation	in	the	face	of	a	reduction	in	ADP	and	 TRAP	 induced	 aggregation	 ex-vivo.	 In	 addition,	 ADP-induced	 platelet	aggregation	pre-PCI	positively	correlated	with	24	hours	post-PCI	p-selectin	levels	(Pearson	r	0.391,	CI	0.071	to	0.64,	p=0.0185),	(Figure	25),	suggesting	that	high	baseline	 platelet	 reactivity	 pre-procedurally	 predicts	 activation	 after	 24	 hours.	
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There	is	no	correlation	when	we	compare	24hr	post-PCI	ADP	induced	aggregation	to	the	same	24	hr	post-PCI	p-selectin	concentration.		
	
Figure 25: Correlation between pre-PCI ADP induced aggregation and soluble p-selectin. 
 Correlation between pre-PCI ADP induced aggregation and soluble p-selectin measured at 24hrs post-
PCI (left panel), and 24hr post-PCI ADP induced aggregation and p-selectin measured at 24hrs (right 
panel). Pre-PCI ADP correlates with degree of platelet activation as indicated by soluble p-selectin 
concentration at 24hrs (Pearson r 0.391, R2 0.152, p=0.0185). Abbreviations: HTPR: High on treatment 
platelet reactivity, PCI: percutaneous coronary intervention 
 	
Since	soluble	p-selectin	in	plasma	may	be	derived	from	endothelial	cells	as	well	as	platelets,	234	we	measured	platelet	bound	p-selectin	in	a	random	population	of	the	study’s	cohort	(n=16).	An	overall	 increase	 in	platelet	bound	p-selectin	between	pre-PCI	and	24	hours	post-PCI	suggests	that	the	soluble	p-selectin	measured	may	originate	from	platelets	(Figure	28).	Overall,	median	(IQR)	percentage	of	platelets	that	were	CD62P	positive	were	pre-PCI,	2.7%	(3.6)	of	platelets	express	p-selectin,	2.5%	(1.5)	immediately	post-PCI	and	at	24	hours	post	PCI	2.6%	(3.5)	of	platelets	continue	 to	 express	 p-selectin.	 Whilst	 these	 numerical	 changes	 do	 not	 reach	significance	the	importance	of	ongoing	expression	of	platelet	bound	p-selectin	in	this	context	should	be	noted.	
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Figure 26: (top panel) Soluble p-selectin concentration pre, post and 24hrs post-PCI  showing ongoing p-
selectin secretion throughout the 24hr period, mean±SEM.   
Figure 27: (bottom panel) Platelet bound p-selectin expressed as percentage of platelets that were 
CD62P positive median (IQR) (bottom row).  
All patients (left column), those with HTPR (middle column) and those without HTPR. 
Abbreviations: HTPR: High on treatment platelet reactivity, PCI: percutaneous coronary intervention, 
CD62P: p-selectin protein present on platelet membrane 	
Specifically,	 in	 patients	 with	 HTPR	 the	 percentage	 of	 platelets	 CD62P	 positive	remained	constant	throughout	the	24-hour	period,	pre-PCI	3.1%	(5.8),	post-PCI	3.2%(5.45)	 and	 24hrs	 post-PCI	 2.8%(7.35).	 Again,	 suggesting	 both	 raised	percentage	at	baseline	and	continued	CD62P	expression	throughout	the	24-hour	period	in	a	cohort	of	patients	with	significant	and	large	reductions	in	ADP	induced	aggregation	 (Table	 11	 and	 Figure	27:	 (bottom	panel)	 Platelet	 bound	p-selectin	expressed	 as	 percentage	 of	 platelets	 that	 were	 CD62P	 positive	 median	 (IQR)	(bottom	row).Figure	27).	
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Figure	28:	Percentage	of	platelets	positive	for	CD62P	at	24	hrs	post-PCI	
	Patients	with	HTPR	and	without	HTPR	(high	on	treatment	platelet	reactivity).	HTPR	patients	had	a	numerically	
higher	percentage	of	CD62P	positive	platelets	that	did	not	reach	significance.	In	the	face	of	large	decreases	in	
ADP	induced	aggregation	any	ongoing	expression	of	CD62P	on	platelets	is	significant.	Expressed	as	median	(IQR),	
Wilcoxin	test	 for	paired	data.	Abbreviations:	HTPR:	High	on	treatment	platelet	reactivity,	PCI:	percutaneous	
coronary	intervention	
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12-HETE	is	produced	by	platelet	12-lipoxygenase	metabolism	of	arachidonic	acid	and	 appears	 to	 be	 both	 a	 marker	 and	mediator	 of	 platelet	 aggregation.	 227	 In	patients	with	HTPR,	median	 levels	of	12-HETE	increased	from	0.13	ng/ml	(IQR	0.88)	 to	 0.92	 ng/ml	 (IQR	 1.3)	 over	 the	 24	 hour	 period	 post-PCI	 (p=0.017),	
	Figure	29.	On	the	other	hand,	in	patients	without	HTPR,	median	levels	of	12-HETE	decreased	 from	0.15	ng/ml	 (IQR	0.15)	to	0.09	ng/ml	 (IQR	0.08)	over	 the	same	period	(p=0.009).	
	
 
Figure 29: Serum 12-HETE concentration 
All patients (left panel), HTPR patients (middle panel) and patients without HTPR (right panel). Data 
points are pre-PCI and 24 hrs post-PCI. Data expressed as median (IQR), ng/ml. Wilcoxin test used 
throughout. Abbreviations: 12-HETE: 12- Hydroxyeicosatetraenoic acid, HTPR: High on treatment 
platelet reactivity, PCI: percutaneous coronary intervention 
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NSTEMI and NSTEMIinf : platelet function 
Platelet aggregation: ADP 
Overall	when	using	ADP	as	an	agonist	there	is	no	significant	difference	between	the	NSTEMI	and	the	NSTEMIinf	cohorts	in	terms	of	ex-vivo	aggregation	using	MEA.	
	
Figure 30: Comparison of NSTEMI vs NSTEMIinf – ADP induced aggregation pre, post and 24 hrs post-
PCI.  
Expressed as mean ± SEM, pANOVA. Panel A: All patients, panel B & C those with and without HTPR (high 
on treatment platelet reactivity). Nitrite augmentation does not appear to influence ADP aggregation. 
We see the same highly significant reduction throughout the 24 hour period as per the platelet sub-
study. Abbreviations: HTPR: High on treatment platelet reactivity, PCI: percutaneous coronary 
intervention 		
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When	comparing	NSTEMI	with	NSTEMIinf			at	each	of	the	three	time-points	there	was	a	very	similar	drop	seen	between	the	groups.	The	reduced	ex-vivo	response	to	ADP	seen	over	this	24	hr	period	mimics	that	seen	in	the	platelet	sub-study.	From	pre	to	24hrs	post-PCI	the	platelet	sub-study	ADP	response	dropped	from	499.1	±	46.3	to	269.1	±24.6	AU	(panova<0.005),	similar	to	both	the	NSTEMI	cohort	466.4	±	266	to	266.7	±	101.6	(panova<0.05).	and	the	NSTEMIinf	cohort	512.9	±	239.4	to	226.7	±	96.5	AU	(panova<0.005),	Figure	30:	Comparison	of	NSTEMI	vs	NSTEMIinf	–	ADP	induced	aggregation	pre,	post	and	24	hrs	post-PCI.Figure	30.	
	
When	both	cohorts	are	split	into	those	with	HTPR	and	those	with	no	HTPR,	again	we	see	no	change	in	ADP	induced	aggregation.	Visually	the	group	with	no	HTPR	(right	panel	Figure	30),	appear	to	have	increased	platelet	aggregation	in	response	to	ADP	(NSTEMIinf	 	cohort).	It	should	be	noted	that	the	pre-PCI	level	(pre	nitrite	infusion)	is	raised	in	comparison	to	the	NSTEMI	cohort.	Whilst	it’s	easy	to	assume	a	pattern	these	variation	are	probably	reflecting	random	variability	given	the	low	n	number		(The	whole	group	was	15	but	this	sub-population	is	only	7).	
	
Trans-coronary platelet activation 
If	nitrite	is	being	reduced	to	NO	the	site	we	would	expect	this	to	happen	is	in	the	coronary	 circulation	where	 haemoglobin	 saturation	 is	 the	 lowest	 and	 localised	ischaemia	is	likely	to	be	present.	Below	is	a	comparison	of	the	two	cohorts	in	terms	of	ADP	 induced	platelet	 aggregation	 from	aortic	 /	 coronary	sinus	 (CS)	 samples	taken	pre	and	post-PCI.		
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Mean	aortic	aggregation	was	502±261	vs	494.3±306	AU	(pANOVA>0.05)	for	NSTEMI	and	 NSTEMIinf	 respectively.	 Pre-PCI	 CS	 was	 also	 very	 similar	 449.7±233	 vs	424.8±205.4	 AU	 (pANOVA>0.05),	 respectively.	 As	 an	 additional	 measure	 in	 the	NSTEMIinf	cohort	a	further	pre-PCI	sample	was	taken	following	5	minutes	of	nitrite	infusion	(mean	CS	nitrite	concentration:	1208±502.7nM),	Figure	31.	Here	we	see	platelet	 aggregation	 in	 the	 CS	 go	 from	 424.8±205.4nM	 pre-infusion	 to	456.4±231.1nM	 post	 infusion,	 pANOVA>0.05.	 Again,	 post-PCI	 there	 is	 very	 little	difference	between	the	two	cohorts	with	a	very	comparable	drop	seen	 in	both;	379.9±203	vs	343.6±181.2	nM	respectively.	
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Figure 31: Comparison of central venous vs coronary sinus platelet aggregation. 
(ADP) paired comparison (NSTEMI vs NSTEMIinf), at anatomically and temporally identical points. No 
difference is seen between the  two cohorts at all points. NSTEMIinf cohort has an additional coronary 
sinus (unpaired) sample pre-PCI and 5 minutes following sodium nitrite infusion. 
 
Platelet aggregation: TRAP 
Using	TRAP	as	an	agonist	can	help	to	indicate	if	the	changes	seen	in	aggregation	to	ADP	 are	 secondary	 to	 a	 platelet	 wide	 reduction	 (systemic)	 in	 aggregation	 or	specific	to	ADP	and	P2Y12	receptor.	Platelet	aggregation	using	TRAP	as	an	agonist	also	 reveals	 a	 similar	 pattern	 to	 the	 platelet	 sub-study	 cohort.	 Between	 the	NSTEMI	and	NSTEMIinf	cohorts	there	is	no	significant	difference	between	each	pair	of	results	along	the	three	time	points.	Pre-PCI	mean±SD	aggregation	by	TRAP	was	998.3±318	vs	1026±313.5	AU	for	NSTEMI	vs	NSTEMIinf	cohorts	respectively.	Post-PCI	 this	 reduced	 to	 857.6±228.4	 vs	 912.9±297.1	 AU,	 and	 24	 hrs	 post-PCI	 this	further	dropped	in	both	groups	to	741.2±202.3	vs	725.6±181.4	AU.		
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Again,	 in	an	 identical	manner	 to	 the	platelet	 sub-study	group	we	see	 the	 same	significant	reduction	in	TRAP	aggregation	from	pre	to	24	hrs	post-PCI	within	the	NSTEMI	cohort	998.3	±	318	vs	741.2	±	202.3	(panova<0.05)	and	a	similar	drop	in	the	NSTEMIinf	cohort	 1026	±	313.5	 vs	725.6	 ±	 181.4	 (not	 reaching	 significance	likely	 secondary	 to	 smaller	 cohort	 size),	 Figure	 32.	 Comparing	 NSTEMI	 to	NSTEMIinf		even	when	we	further	split	the	group	into	those	with	and	without	HTPR	there	is	still	no	effect	of	nitrite	infusion	seen	on	platelet	function.	
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Figure 32: Comparison of NSTEMI vs NSTEMIinf – TRAP induced aggregation pre, post and 24 hrs post-
PCI.  
Expressed as mean ± SEM, pANOVA. Panel A: All patients, panel B & C those with and without HTPR (high 
on treatment platelet reactivity). Nitrite augmentation does not appear to influence ADP aggregation. 
We see the same highly significant reduction throughout the 24 hour period as per the platelet sub-
study.  
 
Soluble p-selectin 
Between	 the	 two	 NSTEMI	 cohorts	 NSTEMIinf	 has	 significantly	 higher	concentrations	of	 soluble	p-selectin	at	baseline	 (baseline	 sample	 taken	prior	 to	nitrite	infusion).	However,	both	cohorts	show	the	same	pattern	of	no	net	change	in	soluble	p-selectin	 from	pre	to	24	hrs	post-PCI,	Figure	33.	Again,	 this	pattern	does	not	 change	 if	 the	 cohorts	are	 split	between	 those	with	and	 those	without	HTPR.	
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Figure 33: Comparison of NSTEMI vs NSTEMIinf – soluble p-selectin concentration pre, post and 24 hrs 
post-PCI. 
Expressed as mean ± SEM, pANOVA. Panel A: All patients, panel B & C those with and without HTPR (high 
on treatment platelet reactivity). Nitrite augmentation does not appear to influence ongoing p-selectin 
secretion from pre to 24 hrs post-PCI. Baseline values (pre-infusion) are higher in the NSTEMIinf cohort, 
this likely represents assay variation or chance (low n number). 
 
Inflammatory and anti-inflammatory cytokines 
NSTEMI vs NSTEMIinf 
As	outlined	a	range	of	both	pro	and	anti-inflammatory	cytokines	were	measured,	specifically	IL-1β,	IL-6,	IL-8	all	have	a	role	in	platelet-endothelial	interaction	with	the	action	of	IL-1β	and	its	NF-κB	mediated	upregulation	of	IL-6	and	8	synthesis.	NO	has	an	anti-inflammatory	role	principally	by	its	anti-adhesive	quality	and	thus	
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influence	 on	 inhibiting	 both	 leukocyte	 and	 platelet	 /	 endothelial	 binding	 and	directly	inhibiting	platelets.	206	
	
	
Figure 34: Quantification of IL-1β, IL-8, TNFα and IL-13. NSTEMI (30) vs NSTEMIinf (15) cohorts. 
Expressed as mean ± SEM. There is a numerical difference between the two cohorts at baseline (pre 
sodium nitrite), this likely represents changing assay conditions or chance.   	
Experimentally	it	should	be	noted	that	the	Pre-PCI	samples	were	taken	prior	to	the	 infusion	 of	 sodium	 nitrite	 and	 act	 as	 a	 baseline	 to	 ensure	 highlight	 any	differences	between	the	cohorts	prior	to	the	effect	of	nitrite.	
	
IL-1β	showed	no	significant	change	from	Pre-PCI	to	24hrs	post-PCI	in	the	NSTEMI	cohort	 (Pre-PCI	 vs	 24hrs	 Post-PCI:	 0.45±0.36	 vs	 0.51±0.57	 pg/ml)	 or	 the	
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NSTEMIinf	 cohort	 (Pre-PCI	 vs	 24hrs	 Post-PCI:	 0.18±0.13	 vs	 0.25±0.16	 pg/ml).	There	was	a	significant	difference	at	baseline	pre-PCI	when	comparing	NSTEMIinf	cohort	vs	NSTEMI	cohort:	Pre-PCI	(NSTEMIinf	vs	NSTEMI	0.18±0.13	vs	0.45±0.36	pg/ml,	p=0.018),	at	24	hrs	Post-PCI	a	numerical	but	not	significant	difference	was	measured	(NSTEMIinf	vs	NSTEMI	0.25±0.16	vs	0.51±0.57	pg/ml,	p=0.19),	Figure	34.	
	
The	chemokine	IL-8	which	plays	a	role	in	monocyte	adhesion	to	the	endothelium	showed	 equivalent	 concentration	 both	within	 and	 between	 groups.	 Pre-PCI	 to	24hrs	 post-PCI	 in	 the	 NSTEMI	 cohort	 (Pre-PCI	 vs	 24hrs	 Post-PCI:	 5.0±2.5	 vs	5.6±3.7	 pg/ml)	 or	 the	 NSTEMIinf	 cohort	 (Pre-PCI	 vs	 24hrs	 Post-PCI:	 5.9±1.7	 vs	5.9±2.1	pg/ml).	Concentrations	of	IL-8	were	almost	identical	when	we	compared	the	 two	 time	 points	 between	 NSTEMIinf	 cohort	 vs	 NSTEMI	 cohort:	 Pre-PCI	(NSTEMIinf	vs	NSTEMI	5.9±1.7	vs	5.0±2.5	pg/ml)	and	24	hrs	Post-PCI	(NSTEMIinf	vs	NSTEMI	5.9±2.1	vs	5.6±3.7	pg/ml),	.Figure	34	
	
TNFα	is	a	pro-inflammatory	cytokine	belonging	to	the	TH1	group.	The	release	of	TNFα	is	stimulated	by	IL-1β,.	A	similar	concentration	was	seen	within	groups	Pre-PCI	 to	 Post-PCI,	NSTEMI	 cohort	 (Pre-PCI	 vs	24hrs	 Post-PCI:	 6.5±2.1	 vs	 6.6±2.2	pg/ml)	and	the	NSTEMIinf	cohort	(Pre-PCI	vs	24hrs	Post-PCI:	4.2±1.2	vs	5.2±2.7	pg/ml).	Concentrations	of	TNFα	were	significantly	different	at	baseline,	pre-PCI	between	 NSTEMIinf	 cohort	 vs	 NSTEMI	 cohort:	 Pre-PCI	 (NSTEMIinf	 vs	 NSTEMI	4.2±1.2	vs	6.5±2.1	pg/ml,	p=0.0021),	this	significant	difference	was	not	sustained	
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24	hrs	Post-PCI	(NSTEMIinf	vs	NSTEMI	5.2±2.7	vs	6.6±2.2	pg/ml,	p=0.16),	Figure	34.	
	
IL-13	 is	an	anti-inflammatory	TH2	cytokine	which	 inhibits	 the	release	of	 tissue	factor.	 Similar	 concentration	 between	 time	 points	 in	 the	 NSTEMI	 cohort	 were	measured	 (Pre-PCI	 vs	 24hrs	 Post-PCI:	 3.1±2.9	 vs	 3.1±2.2	 pg/ml).	 Whilst	 a	numerical	but	not	significant	difference	was	seen	in	the	NSTEMIinf	cohort	(Pre-PCI	vs	24hrs	Post-PCI:	5.1±2.7	vs	3.4±1.8	pg/ml).	When	comparing	between	cohorts	we	see	a	significant	difference	at	baseline	Pre-PCI		(NSTEMIinf	vs	NSTEMI	5.1±2.7	vs	3.1±2.9	pg/ml,	p=0.0443).	This	difference	was	not	maintained	 to	 the	24	hrs	Post-PCI	(NSTEMIinf	vs	NSTEMI	3.4±1.8	vs	3.2±2.2	pg/ml,	p=0.77),	Figure	34.	
	
There	 is	a	consistent	numerical	difference	at	baseline	between	the	two	cohorts	that	may	be	secondary	to	low	n	number	and/or	changing	assay	conditions	(assays	done	on	different	plates	on	different	days	to	reduce	length	of	storage).		
	
Platelet reactivity and inflammation 
Within	the	NSTEMI	cohort	a	further	analysis	was	undertaken	looking	at	associated	changes	in	key	cytokines	between	patient	with	and	without	HTPR.	Following	are	3	panels	of	matched	cytokines	(matched	in	their	function),	the	measurements	are	made	 from	 the	 venous	 sample	 taken	 pre	 and	 24	 hrs	 post-PCI.	 The	 groups	 are	further	split	into	patients	with	HTPR	and	those	without,	using	the	cut-off	of	469	AU	for	ADP	(pre-PCI)	as	per	Sibbing	et	al.	235	
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On	 activation	 platelets	 release	 IL-1β	 to	 the	 endothelium	 with	 resultant	 up	regulation	of	NFκB	and	formation	of	IL-6	and	IL-8.	The	low	concentrations	of	IL-1β	are	at	 the	bottom	end	of	 the	 limits	of	detection.	Whilst	none	of	 the	changes	reach	statistical	significance	there	is	a	clear	numerical	trend	of	increased	IL-8	in	the	group	with	HTPR	both	pre	and	24hrs	post-PCI	(pre-PCI:	no	HTPR	4.4±1.2	vs	HTPR	 6.0±3.5	 pg/ml,	 24hrs	 post-PCI:	 no	 HTPR	 4.1±1.1	 vs	 5.4±2.2	 pg/ml.	Mean±SD),	Figure	35.	IL-8	is	a	chemokine	produced	by	epithelial	cells	and	triggers	firm	adhesion	of	monocytes	to	endothelium.	236	
	
Figure 35: IL-1β and IL-8 quantification in patients with and without HTPR. 
IL-1β (left panel) and IL-8 (right panel). Data split into pairs those with HTPR and those without, further 
expressed as pre and 24 hrs post-PCI. No significant changes between and within groups. Mean±SEM. 
IL: interleukin, pg/ml: picograms / milliliter, HTPR: high on treatment platelet reactivity. N=12 in each 
group from NSTEMI cohort 	
IL-10	is	secreted	by	monocytes	on	binding	to	activated	platelets	via	the	p-selectin	/	PSGL-1	receptor	interaction.	219	IL-10	is	actually	an	anti-inflammatory	cytokine	whose	principal	role	is	as	a	negative	feedback	inhibitor	via	its	inhibitory	action	of	NFκB.	 Monocytes	 will	 also	 release	 TNFα	 in	 this	 interaction	 with	 activated	platelets,	 causing	 further	 endothelial	 inflammation	 and	 leukocyte	 adhesion.	 237	Again,	we	see	a	numerical	trend	that	doesn’t	reach	significance	both	in	the	pairs	
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and	between	groups	 for	 IL-10	and	no	overt	 trend	for	TNFα.	 	 IL-10	(pre-PCI:	no	HTPR	1.99±1.4	vs	HTPR	3.70±3.3	pg/ml,	24hrs	post-PCI:	no	HTPR	2.12±0.66	vs	3.7±4.4	 pg/ml	 Mean±SD).	 TNFα	 (pre-PCI:	 no	 HTPR	 6.0±2.8	 vs	 HTPR	 6.53±1.7	pg/ml,	24hrs	post-PCI:	no	HTPR	5.2±2.7	vs	7.1±1.7	pg/ml	Mean±SD),	Figure	36.	
	
Figure 36: IL-10 and IL-TNFα concentration with and without HTPR 
IL-10 (left panel) and IL-TNFα (right panel). Data split into pairs those with HTPR and those without, 
further expressed as pre and 24 hrs post-PCI. No significant changes between and within groups. 
Mean±SEM. IL: interleukin, pg/ml: picograms / milliliter, HTPR: high on treatment platelet reactivity, 
TNFα: tumor necrosis factor α. N=12 in each group from NSTEMI cohort 	IL-4	and	IL-13	are	both	anti-inflammatory	TH2	cytokines,	certainly	IL-13	appears	to	be	present	in	larger	concentrations	in	patients	without	HTPR.	IL-4	like	IL-1β	is	at	the	bottom	end	of	its	sensitivity	range.	IL-4	(pre-PCI:	no	HTPR	0.7±0.7	vs	HTPR	0.43±0.41	pg/ml,	24hrs	post-PCI:	no	HTPR	0.3±0.25	vs	0.7±0.9	pg/ml	Mean±SD).	IL-13	(pre-PCI:	no	HTPR	3.9±4.4	vs	HTPR	6.0±2.9	pg/ml,	24hrs	post-PCI:	no	HTPR	1.85±1.5	vs	4.0±1.9	pg/ml	Mean±SD).	Figure	37.	
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Figure 37: IL-4 and IL-13 concentration with and without HTPR. 
IL-4 (left panel) and IL-13 (right panel). Data split into pairs those with HTPR and those without, further 
expressed as pre and 24 hrs post-PCI. No significant changes between and within groups. Mean±SEM. 
IL: interleukin, pg/ml: picograms / milliliter, HTPR: high on treatment platelet reactivity. N=12 in each 
group from NSTEMI cohort 	
Coronary vascular resistance: influence of platelets and inflammation 
Conceptually	 patients	 with	 HTPR	 would	 appear	 to	 be	 at	 higher	 risk	 of	microvascular	 disruption	 and	 thrombus	 formation.	 Certainly	 in	 the	 context	 of	patients	 suffering	 with	 an	 acutely	 occluded	 coronary	 artery,	 STEMI,	 increased	platelet	 reactivity	 appears	 to	 play	 a	 role.	 238,239	 The	 effect	 of	 residual	 platelet	reactivity	(HTPR)	is	assessed	in	relation	to	both	resting	and	hyperaemic	IMR.		
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Figure 38: The effect of HTPR and no HTPR on both resting IMR and hyperaemic IMR. 
HTPR (black column) No HTPR (grey columns). Resting IMR seen in the left panel and hyperaemic IMR 
on the right panel. Results for both pre-PCI and post-PCI. No difference is seen in respect of resting (left 
panel) and hyperaemic (right panel) IMR.  
 IMRrest: Index microvascular resistance at rest, IMRhyp: Index microvascular resistance at hyperaemia, 
HTPR: High on treatment platelet reactivity. Statistics: Mean±SEM, multiple comparisons analysed with 
one way ANOVA. 	
HTPR	does	 not	 appear	 to	 influence	 resting	microvascular	 tone	 suggesting	 that	platelet	 function	 has	 little	 influence	 on	 CVR	 and	 CBF	 regulation	 in	 NSTEMI	patients.	IMRrest	HTPR	group	pre	to	post-PCI,	45.3±24.6	units	vs	46.9±31.5	units.	IMRrest	no	HTPR	group	pre	to	post-PCI	43.6±15.4	units	vs	53.1±16.9	units,	Figure	38.	
	
If	 HTPR	 were	 associated	 with	 peri-procedural	 myocardial	 infarction	 or	microvascular	 disruption	 we	 should	 see	 this	 reflected	 in	 the	 minimal	microvascular	 tone	 (IMRhyp).	 116	 There	 was	 no	 significant	 change	 in	 IMRhyp	 in	either	 the	 HTPR	 group	 or	 no	 HTPR	 group	 suggesting	 that	 despite	 the	 high	proportion	 of	 clopidogrel	 resistance	 and	 HTPR,	 this	 has	 little	 influence	 on	microvascular	 insult.	 IMRhyp	 HTPR	 group	 pre	 to	 post-PCI,	 23.2±12.3	 units	 vs	
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20.45±12.95	 units.	 IMRhyp	 no	 HTPR	 group	 pre	 to	 post-PCI	 21.3±10.3	 units	 vs	21.5±11.6	units.	
DISCUSSION 
Platelet sub-study 
The	purpose	of	the	platelet	sub-study	was	to	develop	and	optimise	a	method	to	reproducibly	 measure	 platelet	 function	 that	 would	 allow	 the	 correct	interpretation	of	platelet	function	around	the	time	of	PCI.	The	literature	is	littered	with	both	small	and	large	clinical	and	basic	research	that	make	assumptions	about	platelet	status	(often)	based	on	one	measure	of	platelet	function	/	status	and	in	wildly	different	settings.	This	study	outlines	significant	changes	in	ex-vivo	platelet	aggregation	that	occur	within	24	hours	of	PCI	in	high	risk	NSTEMI	patients	using	bedside	 PFT.	 The	 platelet	 sub-study	 kept	 all	 conditions	 consistent	 between	sampling	points	(pharmacotherapy,	sampling	and	preparation	technique)	except	for	 the	 PCI	 itself.	We	 have	 outlined	 an	 important	 aspect	 of	measuring	 platelet	function	 /	 status	 at	 a	 clinically	 critical	 time.	Whilst	 there	 were	 no	 changes	 in	antiplatelet	pharmacotherapy	during	the	study	period	it	is	clear	from	the	multiple	measurements	 of	 platelet	 status	 that	 a	 large	 flux	 in	 platelet	 activation	 and	clearance	is	occurring	in	this	24-hour	period.		
	
A	consistent	reduction	in	both	ADP	and	TRAP	induced	aggregation	is	seen	post-PCI	and	at	24	hrs.	In	contrast	to	this	reduction	in	ex-vivo	platelet	aggregation	we	have	demonstrated	markers	of	ongoing	platelet	activation	with	increased	soluble	and	platelet	bound	p-selectin.	This	p-selectin	profile	indicates	α-granule	secretion	
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with	expression	of	p-selectin	on	the	platelet	membrane	and	subsequent	cleavage	and	release	in	plasma	as	a	free	molecule.	240	Ongoing	activation	of	platelets	is	also	confirmed	by	the	significant	elevation	of	the	eicosanoid	12-HETE,	which	is	both	secreted	 by	 and	 activates	 platelets	 per	 se.	 227,241	 These	 markers	 of	 platelet	activation	are	seen	to	greatest	extent	in	those	patients	defined	as	having	HTPR	at	baseline	(pre-PCI)	using	ADP	induced	aggregation.		
		
Ongoing	 platelet	 activation	 and	 loss	 of	 ADP	 induced	 aggregation	 is	 well	documented	 in	 patients	 during	 and	 following	 cardiopulmonary	 bypass	 (CPB),	where	recovery	of	platelet	function	has	a	more	acute	onset	and	offset.	204	This	is	the	first	study	that	raises	the	possibility	of	this	phenomenon	being	present	post	coronary	stenting	as	a	potential	stimulus	 for	ongoing	platelet	 activation,	which	may	 reflect	 their	 “near-maximal”	 activation	 in	 situ	 and	 consequent	 inability	 to	contribute	further	to	the	ex	vivo	aggregation	required	by	PFT	assays.	
	
The	data	presented	supports	the	hypothesis	that	the	observed	flux	in	response	to	ADP	–	rather	than	being	related	to	the	type	of	bedside	PFT	device	used	–	is	the	result	 of	 ongoing	 platelet	 activation	 occurring	 during	 the	 PCI	 and	 24	 hours	following	the	procedure.	Indeed,	higher	levels	of	pre-PCI	ADP	induced	aggregation	are	a	very	good	predictor	of	ongoing	platelet	activation	at	24	hours	as	reflected	by	its	 positive	 association	 with	 soluble	 p-selectin	 levels	 at	 24	 hours	 post-PCI,	 a	correlation	that	is	lost	when	using	24hr	Post-PCI	ADP-induced	aggregation.	Figure	25	
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Put	simply	the	data	describes	ongoing	platelet	activation	 in	the	24-hour	period	after	PCI.	When	we	analyse	whole	blood	samples	ex-vivo	in	the	MEA	system	we	are	effectively	measuring	how	much	residual	platelet	aggregation	is	possible	with	the	addition	of	TRAP	or	ADP	rather	than	increasing	platelet	inhibition	over	this	24-hour	period.	
	
Extensive	attempts	were	made	to	exclude	any	confounding	periprocedural	drug	effects	 in	 the	 methodology.	 In	 particular	 we	 have	 enrolled	 patients	 following	loading	 and	 at	 least	 5	 days	 maintenance	 of	 clopidogrel	 in	 order	 to	 exclude	cumulative	clopidogrel	response	that	occurs	with	acute	periprocedural	 loading.	The	influence	of	heparin	on	platelet	aggregation	has	been	quantified	and	shown	to	be	non-significant.		
	
The	 24-hour	 post-PCI	 ADP	 induced	 aggregation	 suggests	 that	 only	 4.7%	 of	patients	had	HTPR,	if	this	is	compared	to	other	studies	using	the	same	bedside	PFT	apparent	HTPR	is	much	lower	in	our	group.	195,242,243	However,	it’s	clear	that	the	first	two	studies	use	pre-PCI	PFT	and	the	degree	of	HTPR	agrees	with	our	data.	The	third	by	Aradi	et	al,	does	indeed	use	post-PCI	PFT	and	the	rates	of	HTPR	are	much	 higher	 post-PCI.	 However,	 it	 should	 be	 noted	 that	 the	 vast	 majority	 of	patients	(97%)	received	an	acute	loading	dose	of	clopidogrel	(600mg)	just	prior	to	 the	 PCI	 and	 a	 further	 unspecified	 number	 also	 received	 the	 glycoprotein	inhibitor	tirofiban	with	further	delay	in	PFT	measurement.	It	is	likely	that	these	two	important	factors	protect	from	the	ongoing	platelet	activation	we	see	at	24	
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hours	as	reflected	in	the	low	ADP	signals	with	corresponding	raised	markers	of	platelet	activation.	
	
This	platelet	sub-study	succeeded	in	providing	both	an	insight	into	platelet	status	and	also	a	way	to	interpret	platelet	status	for	the	rest	of	the	study.	Also	outlined	is	the	importance	of	a	consistent	approach	to	the	timing	for	future	clinical	tailored	therapy	 trials	 where	 antiplatelet	 therapy	 is	 changed	 on	 the	 basis	 of	 peri-procedural	 aggregation	 tests.	 Heterogeneous	 clinical	 protocols	 for	 tailored	therapy	trials	are	no	doubt	part	of	the	reason	why	these	trials	have	failed	to	show	any	advantage	to	a	conceptually	attractive	treatment	strategy.	
	
In	 the	 following	 discussion	 the	 effect	 of	 nitrite	 infusion	 on	 platelet	 function	 is	considered	where	a	smaller	reduction	(or	complete	absence	of	reduction)	in	ADP	and	 TRAP	 induced	 aggregation	 is	 expected	 as	 this	 would	 indicate	 further	inhibition	of	platelet	function	by	nitrite	and	protection	from	the	dramatic	platelet	activation	that	occurs	in	the	24	hr	period	post-PCI.		
	
Nitrite and platelet inhibition 
We	 have	 demonstrated	 in	 the	 previous	 chapter	 that	 nitrite	 concentration	augmentation	(~5	fold)	has	no	influence	on	CVR	and	thus	CBF	regulation.	Whilst	unlikely,	 it	 is	 possible	 this	 may	 have	 been	 secondary	 to	 the	 method	 of	 CVR	assessment	 (despite	 being	 able	 to	 measure	 subtle	 changes	 in	 CVR	 post-PCI).	Therefore	 demonstrating	 a	 significant	 biological	 effect	 on	 platelet	 inhibition	
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would	go	some	way	in	questioning	the	conclusions	made	in	respect	of	nitrite	and	the	lack	of	evidence	of	reduction	to	NO	and	effect	on	CVR.	
	
The	 inhibitory	 action	 of	 NO	 on	 both	 platelet	 function	 and	 adhesion	 to	 the	endothelium	is	well	documented.	244,245	In	terms	of	a	role	of	nitrite	and	its	action	(via	 reduction	 to	 NO),	 the	 evidence	 is	 much	 less	 clear.	 Schafer	 et	 al,	 246	demonstrated	 that	 healthy	 human	 platelets	 ex-vivo	 can	 clearly	 be	 inhibited	 in	terms	 of	 aggregation	 but	 only	 at	 very	 high	 pharmacological	 concentrations	(60μM),	of	nitrite.	A	clear	issue	here	is	not	only	the	high	concentration	of	nitrite	but	 also	 that	 this	 was	 carried	 out	 with	 platelet	 rich	 plasma	 (red	 cell	 and	haemoglobin	free).	In	terms	of	effect	on	systemic	blood	pressure	60μM	is	far	in	excess	of	that	which	would	cause	significant	hypotension	even	in	healthy	subjects.	
133	 In	 rat	platelets	ex-vivo	Bryan	et	 al	 failed	 to	 show	a	 convincing	anti-platelet	effect	in	a	whole	blood	ex-vivo	system	at	nitrite	doses	from	0.1	up	to	10	mg	kg-1.	
247	
	
Other	studies	have	indicated	a	role	for	nitrite	in	the	inhibition	of	platelets	either	following	 a	 nitrite	 infusion	 or	 by	 augmenting	 nitrite	 serum	 concentration	following	oral	nitrate	supplements.	154,172,184	Jones	et	al	143	as	previously	discussed	showed	 some	 effect	 of	 an	 intracoronary	 dose	 of	 sodium	 nitrite	 on	 patients	undergoing	P-PCI	for	STEMI.	In	both	the	main	paper	and	supplementary	material	they	suggest	that	nitrite	also	has	a	beneficial	effect	on	platelet	function.	Central	to	this	finding	is	the	reduced	aggregation	to	collagen	seen	in	the	patients	receiving	nitrite	peri-procedurally,	as	previously	discussed	these	types	of	changes	in	peri-
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procedural	platelet	aggregation	are	difficult	to	interpret	and	may	indicate	platelet	activation	 and	 less	 inhibition.248	 However,	 the	 authors	 also	 performed	 flow	cytometry	 	 to	 quantify	 the	 amount	 of	 P-selectin	 expressed	 on	 platelets,	unfortunately	 only	 data	 after	 stimulation	 with	 collagen	 is	 available	 with	 no	reference	to	baseline	platelet	bound	P-selectin	(which	would	have	helped	us	to	differentiate	between	 true	 inhibition	versus	 true	 stimulation	at	baseline	before	the	addition	of		platelet	agonist).		
	
High	on	treatment	platelet	reactivity	(HTPR)	is	a	common	finding	in	this	patient	group	(with	clopidogrel)	and	the	platelet	sub-study	in	this	chapter	goes	a	long	way	in	answering	how	clinically	applicable	and	useful	nitrite	might	be	in	this	group.	Indeed,	 clinically	 relevant	 HTPR	 in	 both	 cohorts	 of	 patients	 (NSTEMI	 and	NSTEMIinf)	was	 47.6%	and	 46.7%	respectively.	 The	 coronary	 circulation	 is	 the	perfect	environment	to	reduce	nitrite	to	NO	in	a	focused	and	targeted	fashion.	Low	oxy-haemoglobin	 saturations	 and	 localised	 ischaemia	 provide	 the	 optimal	environment	to	deliver	NO	to	the	crux	point	in	the	pathological	process	of	NSTEMI,	namely	ruptured	plaque	and	thrombus	formation.	
	
Despite	this	we	have	seen	no	effect	of	nitrite	in	protecting	the	circulating	platelets	from	the	activation	that	occurs	immediately	post	PCI	and	in	the	following	24-hour	period.	To	further	emphasise	this	we	have	also	split	the	population	into	those	with	and	without	HTPR	as	defined	by	Siller-Matula	et	al.	235	Patients	with	overt	HTPR	with	a	pre-PCI	ADP	induced	aggregation	above	468	AU	still	fail	to	show	any	change	in	platelet	reactivity	following	serum	nitrite	augmentation.	To	confirm	this	we	also	
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see	 the	 same	high	 concentrations	of	 soluble	p-selectin	 throughout	 this	24	hour	period.	
	
The	 lowest	 haemoglobin	 saturation	 in	 this	 experimental	 model	 is	 seen	 at	 the	coronary	 sinus	 samples.	 If	 nitrite	 was	 to	 be	 reduced	 to	 NO	 this	 should	 be	happening	preferentially	from	aorta	to	coronary	sinus	(CS).	Platelet	aggregation	was	measured	at	the	CS	both	pre	and	post-PCI	in	both	cohorts.	A	further	CS	sample	was	 taken	 from	 the	 CS	 5	 minutes	 into	 the	 sodium	 nitrite	 infusion	 (nitrite	concentration	1208±502.7	nM).	There	was	no	difference	between	the	cohorts	in	terms	 of	 ADP	 aggregation	with	 both	 groups	 showing	 the	 same	 decline	 in	 ADP	induced	 aggregation.	 The	 difference	 in	 ADP	 induced	 aggregation	 within	 the	NSTEMIinf	cohort	pre	nitrite	infusion	versus	post	infusion	was	non	significant.	This	further	 suggests	 that	 significant	 nitrite	 reduction	 to	 NO	 is	 unlikely	 and	 is	 in	agreement	with	the	CVR	findings	in	Chapter	4:	Results	2.	
Platelet reactivity and coronary vascular resistance 
An	important	aspect	of	both	resting	and	minimal	CVR	is	platelet	function.	Minimal	CVR	measured	during	an	infusion	of	adenosine	(IMRhyp)	acts	as	a	good	indicator	of	the	overall	health	of	the	microvasculature	and	its	dilatory	reserve.	No	difference	was	seen	when	comparing	patients	with	and	without	HTPR	in	terms	of	 IMRhyp.	This	 indicates	 that	 there	 was	 no	 significant	 peri-procedural	 infarction	 or	disruption	of	the	microvasculature	during	PCI.	116	When	we	look	at	the	influence	of	HTPR	on	resting	CVR	(IMRrest)	we	also	see	no	difference	between	the	groups	indicating	no	role	of	platelet/inflammatory	mediators	on	resting	CVR.	
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Inflammation, platelet reactivity and nitrite 
Coronary	 atherosclerosis	 is	 the	 principal	 cause	 of	 coronary	 thrombosis	 and	myocardial	 infarction.	 Central	 to	 this	 process	 is	 the	 activation	 of	 platelets;	 on	activation	 α-granules	 release	 inflammatory	 chemokines	 and	 cytokines	 that	promote	 endothelial	 adhesion	 of	 both	 platelets	 and	 leukocytes.	 Endothelial	inflammation	 is	 also	 promoted	 by	 platelet-released	 cytokines	 that	may	 have	 a	direct	effect	or	induce	expressions	of	further	cytokines	within	the	endothelium	or	by	the	attracted	leukocytes.	210,249			
	
No	 influence	 of	 nitrite	 augmentation	 is	 detected	 on	 the	 concentration	 of	 the	platelet-associated	cytokines	IL-1β,	IL-8	or	TNFα.	Also,	IL-10	and	13	–	TH2	anti-inflammatory	cytokines	-	do	not	change	significantly	in	concentration	at	24	hours.	These	results	further	underline	a	lack	of	any	influence	of	nitrite	augmentation	on	platelet	inhibition	and	the	secondary	actions	of	platelets	in	terms	of	endothelial	and	leucocyte	interaction.	If	nitrite	had	any	inhibitory	effect	on	platelets	via	NO	we	 would	 expect	 down-regulation	 of	 IL-1β	 and	 a	 follow	 on	 reduction	 in	 IL-8	expression	and	TNFα.	250-252	
HTPR reflected in cytokine markers of endothelial/leukocyte interaction 
When	our	NSTEMI	population	 is	split	between	 those	with	and	without	high	on	treatment	platelet	reactivity	(HTPR)	we	see	some	patterns	emerging	in	terms	of	interleukins	related	to	platelet	aggregation.	Patients	with	HTPR	had	a	numerical	trend	to	 increased	IL-8	and	TNFα	both	upregulated	via	 IL-1β	and	transcription	activation	via	NFκB.	This	 is	 indicated	of	active	platelet	endothelial	and	platelet-monocyte	adhesion	and	binding.	219,231,236,237		
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This	gives	support	 to	the	hypothesis	 in	 the	platelet	sub-study.	The	reduction	 in	ADP	 and	 TRAP	 induced	 aggregation	 does	 not	 reflect	 increased	 inhibition	 of	platelets	but	reflects	ongoing	platelet	activation.	Reduced	ex-vivo	aggregation	at	24	 hours	 reflects	 dysfunctional	 or	 “spent”	 platelets	 that	 have	 less	 ability	 to	aggregate	in	response	to	ADP	or	TRAP.	
CONCLUSIONS 
The	 measurement	 of	 platelet	 aggregation	 in	 the	 24-hour	 period	 starting	 just	before	 PCI	 should	 be	 interpreted	 with	 caution.	 Certainly,	 no	 interpretation	 of	platelet	 function	 and	 /	 or	 treatment	 decisions	 (in	 terms	 of	 pharmacotherapy)	should	be	made	using	bedside	tests	immediately	following	and	at	24	hours	post-PCI.	Reduced	ADP	and	TRAP	induced	aggregation	ex	vivo	reflects	ongoing	and	high	levels	of	platelet	activation	in	vivo.	
Augmentation	 of	 serum	 nitrite	 concentrations	 (~	 5	 fold)	 has	 no	 influence	 on	platelet	function	during	the	same	24	hour	period.	Even	analysing	coronary	sinus	samples	failed	to	show	any	influence	of	nitrite	augmentation.	
No	influence	of	nitrite	augmentation	is	seen	in	terms	of	pro	and	anti-inflammatory	cytokines	(platelet	associated	or	otherwise).		
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Chapter 6: General discussion 
The role of NO and NO2- in patients with NSTEMI and stable angina  
As	we	have	read,	the	principal	element	of	CBF	regulation	is	a	change	in	CVR.	There	is	 no	 single	 mediator	 of	 CVR	 and	 indeed	 the	 emphasis	 of	 different	 mediators	appears	to	change	according	not	just	to	the	species	but	also	to	the	specific	situation	(normal	 physiology,	 pacing,	 exercise,	 acute	 coronary	 syndromes	 and	 stable	angina),	as	outlined	in	the	general	introduction	(Page	44:	The	role	of	NO	in	human	regulation	of	CVR	in	health	and	disease).	Nitric	oxide	is	implicated	in	many	of	these	specific	 conditions	 with	 evidence	 for	 action	 in	 healthy	 humans	 and	 pathology	alike.	80,93,95	
Specifically,	in	relation	to	healthy	patients	and	those	with	stable	angina	Quyyumi	et	 al93	 demonstrated	 that	 inhibition	 of	 nitric	 oxide	 synthetase	 with	 L-NMMA	resulted	in	a	much	larger	elevation	of	CVR	in	healthy	patients	when	compared	to	those	with	stable	angina.	Halcox	et	 al,	 130	went	on	 to	 show	that	 increasing	 risk	factors	for	ischaemic	heart	disease	had	a	stepwise	additive	effect	on	endothelial	function	measured	by	flow	mediated	dilation.	
	
In	the	first	results	(Page	69:	The	role	of	NO	in	coronary	blood	flow	regulation	in	the	presence	of	epicardial	coronary	disease)	we	have	demonstrated	that	stable	angina	and	NSTEMI	patients	appear	to	be	fundamentally	different	in	terms	of	the	dynamics	of	NO	production	and	CVR	 (IMRrest).	 In	 the	presence	of	 an	 epicardial	stenosis	 NSTEMI	 patients	 in	 comparison	 to	 stable	 angina	 patients	 had	 a	
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numerically	higher	CVR:	IMRrest	NSTEMI	46.2	±	21.6	vs	Stable	38.9	±	18.4	(p>0.05).		Some	 of	 this	 difference	 in	 CVR	 at	 baseline	 may	 be	 secondary	 to	 the	 NSTEMI	patients	having	suffered	small	subendocardial	myocardial	infarcts	as	reflected	in	the	 increased	values	of	hyperaemic	minimal	microvascular	resistance	(Table	4:	Coronary	 physiology	 results	 summary	 data).	 The	 NSTEMI	 patients	 had	 clear	evidence	 of	 NO	 synthesis	 from	 coronary	 artery	 to	 coronary	 sinus	with	 no	 net	decrease	 in	serum	NOx	and	a	clear	 increase	 in	red	cell	NOx	giving	rise	 to	a	net	increase	 from	A	to	V	of	84.9	nM.	 In	the	stable	angina	cohort,	we	see	the	typical	pattern	 of	 serum	NOx	 reduction	 from	 A	 to	 V	 (net	 change	 A	 to	 V	 serum	NOx	 -183.8nM	p<0.05),	which	 is	 also	 seen	 in	 healthy	 patients.	 97	 Other	 studies	 have	interpreted	this	reduction	of	serum	NOx	from	A	to	V	as	evidence	of	serum	NO2-	conversion	 (reduction)	 back	 NO,	 101,168	 however	 when	 the	 red	 cell	 NOx	compartment	is	quantified	this	reduction	of	serum	NOx	is	actually	just	secondary	to	the	shuttling	of	these	metabolites	into	red	cells	as	haemoglobin	becomes	more	desaturated	and	its	avidity	for	NO	increases.	97	
	
At	 first	 sight	 these	 observations	 of	 A-V	 NOx	 concentrations	 and	 CVR	measurements	 seem	 at	 odds	 with	 each	 other.	 If	 NSTEMI	 patients	 are	 actively	synthesising	significant	amounts	of	NO	why	would	CVR	be	higher	than	patients	with	stable	angina	and	equivalent	epicardial	 lesions?	Here	our	attention	should	turn	 towards	 the	 differences	 in	 coronary	 collateralisation	 seen	 between	 these	patient	groups.	Our	stable	angina	patients	had	a	significantly	higher	CFI	than	the	NSTEMI	patients	(0.2	±	0.13	vs	0.08	±	0.08	p	0.0001).	Coronary	collateralisation	will	have	the	effect	of	increasing	the	distal	coronary	pressure	(Pd)	particularly	at	
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low	perfusion	pressure	(Pa),	and	reducing	the	impact	of	an	epicardial	stenosis	on	resting	microvascular	resistance	/	IMRrest	(CVR)	by	maintaining	the	patency	of	the	resistance	vessels.	253	Both	 factors	result	 in	 improved	microvascular	 flow.	So,	 it	seems	the	mechanisms	of	regulation	of	microvascular	patency	are	fundamentally	different	in	these	two	pathologies.	Whilst	NSTEMI	patients	seem	to	compensate	for	an	epicardial	stenosis	by	upregulating	NOS	and	thus	NO	synthesis	to	maintain	microvascular	perfusion,	stable	angina	patients	do	not	appear	to	rely	on	NOS	but	more	on	the	(perhaps	chronic)	formation	of	collateral	flow	distal	to	the	epicardial	stenosis.	
	
What happens to NOx and CVR post-PCI? 
In	terms	of	NOx	and	CVR	in	our	two	disease	groups,	we	also	observed	an	increase	in	CVR	from	pre	to	post	PCI	in	the	NSTEMI	group	(IMRrest	(units):	46.2	±	21.6	vs	57.6	±	37.9	p	0.038).	In	association	with	this	rise	in	CVR	we	saw	an	acute	drop	in	total	NOx	synthesis	 (from	A	 to	V),	 from	+85nM	 to	 +16.2nM.	The	 stable	 angina	group	had	no	significant	(A	to	V)	net	changes	in	serum	NOx	from	pre	to	post	PCI	(A	to	V	net	serum	NO2-:	pre-PCI	-175-5nM,	post-PCI	-183.8nM),	in	keeping	with	the	 theory	 that	 stable	 angina	 patients	 do	 not	 rely	 on	 local	 NO	 synthesis	 for	microvascular	perfusion.	The	stable	angina	group	also	had	almost	identical	CVR	from	pre	to	post	PCI	(IMRrest	(units):	38.9	±	18.4	vs	38.99	±	22.1	p	>0.05).			
The	sharp	correction	of	NOx	seen	in	the	NSTEMI	group	together	with	the	sharp	increase	 in	 CVR	 may	 partly	 reflect	 acute	 down	 regulation	 of	 endothelial	 NOS	secondary	to	the	reduction	in	shear	stress	post-PCI,	81	and	perhaps	reduced	RBC	
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ATP	release	as	oxygen	saturation	improve	locally.	46	However,	increased	coronary	flow	 clearly	 has	 a	 role	 in	 this	 mechanism	 but	 is	 unlikely	 to	 be	 the	 whole	explanation.	If	we	assume	that	NOS	activity	remains	constant	and	the	reduction	in	NO2-	concentration	 is	 a	dilutional	 effect	 secondary	 to	 increased	 flow,	we	would	expect	flow	to	increase	by	5.23	tmes	to	account	for	this	reduction	in	net	NOx	(pg	xx).	Whilst	its	entirely	possible	that	flow	could	increase	5	fold	post	PCI	there	may	also	be	an	acute	contribution	to	reduced	NO	synthesis	by	both	reduced	shear	force	(reduced	velocity	across	the	epicardial	lesion),	and	downregulation	of	NOS	via	the	adenine	 /	 purinergic	 pathway	 described	 in	 the	 general	 introduction	 Page	 34:	Adenine	nucleotide	/	purinergic	receptor	control	of	CBF.		
	
NSTEMI and local NO synthesis 
In	 the	 presence	 of	 a	 relatively	 acute	 and	 significant	 epicardial	 stenosis	 -	 and	reduced	CBF	–	the	benefits	of	 increased	trans-myocardial	NO	production	 in	the	NSTEMI	group	are	clear.	An	 increase	(or	maintenance)	of	CBF	will	be	achieved	with	a	relatively	lower	CVR	via	locally	synthesized	NO	and	dilation	of	resistance	vessels.	 The	 mechanism	 of	 acute	 decompensation	 of	 patients	 leading	 to	 an	NSTEMI	event	is	by	no	means	fully	understood,	however,	NO	has	been	implicated	in	 many	 of	 the	 mechanisms	 from	 platelet	 aggregation,	 254-256	 to	 plaque	stability257,258	 	 and	 now	 also	 here	 in	 maintaining	 microvascular	 perfusion.	 Of	course,	it	is	difficult	to	know	if	this	local	synthesis	-	in	the	coronary	circulation	–	of	NO	 is	 in	acute	 response	 to	 the	NSTEMI	event	or	 if	 there	has	been	a	gradual	decline	 in	 this	 synthesis	 that	 has	 led	 to	 the	 acute	 event.	 Much	 of	 the	 data	(referenced	above)	in	relation	to	NO	and	NSTEMI	suggests	that	chronic	reduction	
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in	NO	synthesis	may	led	up	to	these	events.	Although	there	are	very	few	previous	studies	 measuring	 cross	 heart	 A	 to	 V	 and	 none	 that	 do	 this	 in	 patients	 with	NSTEMI.		
	
This	 data	 supports	 the	 role	 of	 NO	 in	 maintaining	 microvascular	 perfusion	 in	NSTEMI	patients	and	indicates	a	mechanism	as	to	why	these	patients	may	have	worsening	 cardiovascular	 outcomes	 as	 the	 endothelium	 loses	 its	 ability	 to	maintain	myocardial	perfusion	acutely.		
 
Nitrite (NO2-) reduction to NO  
In	our	NSTEMI	cohort	we	have	shown	objective	evidence	of	ischaemia	as	well	as	low	 oxygen	 saturations	 prior	 to	 PCI	 (Table	 4:	 Coronary	 physiology	 results	summary	 data,	 Page	 89),	 according	 to	 many,101,168,259	 these	 conditions	 would	appear	to	be	ideal	for	the	reduction	of	NO2-	to	NO	yet	despite	this	environment	we	see	no	evidence	of	nitrite	consumption.	In	fact,	a	net	increase	in	trans-myocardial	NOx	was	measured	suggesting	NOS	synthesis	of	NO	rather	than	reduction	of	NO2-.		
	
Of	course,	it	is	possible	we	are	observing	a	very	dynamic	situation	in	which	both	methods	of	NO	production	are	occurring	(NOS	synthesis	and	nitrite	reduction),	with	competing	influences	on	overall	NO	metabolite	concentration.		The	addition	of	a	NOS	inhibitor	would	help	delineate	the	influence	of	these	competing	systems	however,	this	clearly	would	be	unsafe	in	a	group	of	patients	with	acute	coronary	
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syndromes	and	impaired	coronary	blood	flow.	Cosby	et	al	101	found	that	infusions	of	 sodium	 nitrite	 infused	 into	 the	 brachial	 artery	 of	 healthy	 humans	 caused	significant	 increases	 in	 flow	during	 exercise	 down	 to	 concentrations	 of	 900nM	either	with	or	without	NOS	inhibition	using	L-NMMA.	Similar	observations	have	been	made	by	many	others	in	various	settings.	133,136-140		
	
We	 therefor	 recruited	 a	 virtually	 identical	 cohort	 (in	 terms	 of	 baseline	characteristics),	 using	 identical	methods	 to	 those	 in	 the	 observational	NSTEMI	group	 in	Chapter	3:	Results	1	 (Page69).	 	 	With	 the	addition	of	 a	sodium	nitrite	infusion	 and	 augmentation	 of	 serum	nitrite	 concentrations	 throughout	 the	 PCI	procedure.	 In	 our	 group	 of	 NSTEMI	 patients	 (n=15),	 we	 increased	 the	median	coronary	sinus	NO2-	from	192.6nM	(135.3	to	248.9)	to	1422nM	(1032	to	1842),	well	within	the	physiologically	active	range	reported	by	both	Maher	et	al133	and	Cosby	et	al.	101	
	
As	reported	in	Chapter	4:	Results	2	(Page	102)	we	saw	no	appreciable	effect	of	this	increased	 serum	 NO2-	 on	 CVR	 (IMRrest),	 minimal	 microvascular	 resistance	(IMRhyp),	when	compared	to	the	NSTEMI	patients	without	NO2-	augmentation.	In	fact,	almost	identical	CVR	values	were	seen	both	before	PCI	and	the	infusion	group	also	experienced	an	almost	identical	rise	of	CVR	after	PCI	with	restoration	of	flow.	
	
Why	 then	 do	we	 fail	 to	 see	 any	 appreciable	 effect	 of	NO2-	 augmentation	when	others	have	observed	good	effect?	As	outlined	earlier	the	influence	of	both	NO	and	
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NO2-	 appears	 to	 be	 different	 according	 to	 the	 cohort	 studied.	 Healthy	 human	volunteers	have	mixed	reports	of	the	influence		of	both	NO	and	NO2-	on	coronary	and	peripheral	 flow	which	 is	probably	a	reflection	of	both	the	 interpretation	of	incomplete	 (no	 red	 cell	 component)	of	NOx	 and	 the	way	 clinical	outcomes	 are	measured.	97,101	A	subtle	effect	of	NO2-	augmentation	has	been	seen	on	the	time	to	ischaemia	of	patients	with	stable	angina	undergoing	stress	echocardiography,	140	however,	thus	far	all	of	the	large	RCT	looking	at	the	effect	of	NO2-	augmentation	in	cardiovascular	 disease	 (STEMI)	 have	 failed	 to	 show	 any	 meaningful	 effect	 on	clinical	 endpoints.142,143	Whilst	 STEMI	 and	NSTEMI	 patients	 are	 fundamentally	different	the	data	in	this	thesis	goes	some	way	in	explaining	why	there	may	have	been	no	effect	of	NO2-	augmentation.			
NO and NO2- : platelet function and inflammation  
The	first	part	of	the	last	results	chapter	(Platelet	sub-study,	Page	159)	outlined	the	importance	 of	 careful	 measurement	 of	 platelet	 characteristics	 in	 this	 complex	group	of	patients	with	an	acute	coronary	syndrome	and	concomitant	anti-platelet	drug	 therapy	 and	 invasive	 coronary	 angiography.	 It	 is	 clear	 that	 a	 simple	 one	dimensional	 approach	 to	 measuring	 platelet	 function	 can	 easily	 lead	 to	misinterpretation	of	platelet	 function	analysis.248	The	platelet	sub-study	clearly	demonstrated	that	the	acute	reductions	in	platelet	aggregation	results	during	PCI		actually	reflected	platelets	 that	were	 fully	activated	with	 loss	of	 function	rather	than	acutely	inhibited	by	some	outside	agent.	
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When	 comparing	 NSTEMI	 patients	with	 and	without	 augmentation	 of	 NO2-	 no	difference	in	platelet	aggregation	was	observed	when	using	both	ADP	and	TRAP	as	 agonists.	 Further	 when	 clopidogrel	 responders	 were	 separately	 analysed	against	clopidogrel	non-responders	(potential	for	more	effect	of	NO2-),	no	effect	of	NO2-	augmentation	was	evident.	To	test	the	hypothesis	that	this	platelet	inhibition	may	just	be	occurring	locally	across	the	coronary	bed	with	a	significant	epicardial	stenosis,	measures	of	 trans-coronary	 (aorta	 (A)	 to	 coronary	 sinus	 (V))	 platelet	function	were	taken	and	found	to	be	almost	identical	in	the	two	groups	(Figure	31:	Comparison	of	central	venous	vs	coronary	sinus	platelet	aggregation.	Page	170).	Soluble	p-selectin	was	also	 identical	between	the	two	groups	pre	to	24hrs	post	PCI,	 with	 the	 same	 rises	 in	 p-selectin	 seen	 over	 this	 24	 hr	 period	 reflecting	continuous	platelet	activation	in	this	acute	period.	
	
In	vitro	and	Ex-vivo	studies	have	shown	a	clear	role	for	NO	and	its	role	in	platelet	inhibition	via	the	cGMP	pathway,	173	and	RSNO.	180	There	is	also	in-vivo	evidence	of	impaired	NO	(specifically	platelet	derived	NO),	production	contributing	to	acute	coronary	syndromes	(NSTEMI	and	STEMI).	260,261	
	
In	terms	of	platelet	inhibition	in	acute	coronary	syndromes	NO2-	appears	to	have	the	potential	to	be	a	“magic	bullet”	in	terms	of	its	potential	to	be	reduced	to	NO	in	areas	of	low	oxygen	saturation	or	pH.	This	was	demonstrated	by	Srihirun	et	al	154	who	 demonstrated	 that	 nitrite	 had	 an	 effect	 ex-vivo	 and	 that	 this	 was	 indeed	dependent	on	the	presence	of	both	erythrocytes	and	deoxygenation.	Specifically	in	acute	coronary	syndrome	Jones	et	al	143	demonstrated	some	effect	of	a	nitrite	
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infusion	 on	 STEMI	 patients,	 however,	 the	 results	 were	 somewhat	 selective	 in	terms	 of	what	was	 reported.	 There	was	 also	 the	 suggestion	 of	 a	 long	 term	 (6	month)	 effect	 of	 a	 single	 nitrite	 infusion	 on	 platelet	 function,	 which	 seems	biologically	 implausible	 and	 may	 reflect	 baseline	 differences	 in	 patient	characteristics	rather	than	biological	activity.	
	
However,	the	data	outlined	in	this	thesis	suggests	that	when	careful	consideration	is	 given	 to	 quantification	 of	 platelet	 function	 there	 is	 no	 overt	 effect	 of	augmentation	of	serum	NO2-	on	platelet	inhibition	regardless	of	the	propensity	for	those	platelets	to	activate/aggregate.	
	
Central	 to	 the	 pathophysiology	 of	 epicardial	 plaque	 rupture	 in	 NSTEMI	 is	 the	activation	of	platelets;	this	activation	leads	to	α-granules	release	of	inflammatory	chemokines	 and	 cytokines	 that	 promote	 endothelial	 adhesion	 of	 both	 platelets	and	 leukocytes.	Endothelial	 inflammation	 is	 also	promoted	by	platelet-released	cytokines	that	may	have	a	direct	effect	or	induce	expressions	of	further	cytokines	within	the	endothelium	or	by	the	attracted	leukocytes.	210,249			
	
Again,	 in	 this	 thesis,	 no	 influence	 of	 nitrite	 augmentation	was	 detected	 on	 the	concentration	of	the	platelet-associated	pro-inflammatory	cytokines	IL-1β,	IL-8	or	TNFα.	 Also,	 IL-10	 and	 13	 -	 TH2	 anti-inflammatory	 cytokines	 -	 did	 not	 change	significantly	in	concentration	at	24	hours.	These	results	further	underline	a	lack	of	any	influence	of	nitrite	augmentation	on	platelet	inhibition	and	the	secondary	actions	of	platelets	in	terms	of	endothelial	and	leucocyte	interaction.	If	nitrite	had	
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any	inhibitory	effect	on	platelets	via	NO	we	would	expect	down-regulation	of	IL-1β	and	a	follow	on	reduction	in	IL-8	expression	and	TNFα.	250-252	
Conclusions 
The	 hypothesis	 to	 be	 investigated	 in	 this	 thesis	 are	 listed	 individually	 below	together	with	a	brief	conclusion	for	each	point	
1. To	 examine	 the	 influence	 of	 NO	 and	 NO2-	 within	 the	 compensatory	mechanisms	of	CVR	control	in	the	ischaemic	myocardium.		
Nitric	 oxide	 and	 its	 influence	 on	 CVR	 depends	 on	 the	 specific	 pathology	 being	studied.	There	is	clear	indication	that	NO	has	no	role	in	CVR	regulation	in	stable	angina	patients,	chronic	coronary	collateral	formation	appears	to	have	a	role	in	maintaining	 microvascular	 perfusion.	 NSTEMI	 patients	 have	 a	 relatively	 poor	formation	of	coronary	collaterals	but	appear	to	rely	on	de-novo	synthesis	of	NO	to	maintain	a	low	CVR	and	CBF.	There	is	no	evidence	of	overt	nitrite	consumption	in	either	group.	
2. Following	 reperfusion	 and	 relief	 of	myocardial	 ischaemia	 to	understand	how,	and	 if,	 these	mechanisms	acutely	adapt	 in	response	to	the	 increase	distal	coronary	pressure	and	increased	flow	in	the	absence	of	an	epicardial	stenosis.	
Stable	angina	patients	appear	to	have	no	flux	in	CVR	once	the	epicardial	stenosis	is	treated,	unlike	NSTEMI	group	in	which	a	significant	rise	in	CVR	is	demonstrated	together	 with	 a	 sharp	 drop	 in	 net	 NO	 concentration	 from	 A	 to	 V	 (post-PCI).	Assuming	this	drop	in	concentration	is	related	to	the	increase	in	flow	(secondary	to	the	PCI),	this	equates	to	a	5	fold	increase	in	coronary	flow,	this	large	increase	in	
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flow	may	 be	 possible	 but	 may	 also	 suggest	 an	 acute	 down	 regulation	 in	 NOS	formation	of	NO.	
3. In	 patients	with	 acute	 NSTEMI	 does	 exogenous	 augmentation	 of	 serum	NO2-	concentration	have	any	influence	on	CVR	either	prior	to	or	following	revascularisation	with	coronary	intervention.		
No	effect	of	NO2-	augmentation	was	found	on	CVR	in	patients	with	NSTEMI	pre	or	post	PCI.	The	same	(NO	dependent)	rise	in	CVR	was	seen	in	both	groups	post-PCI	with	no	action	of	NO2-	evident.		4. In	patients	with	acute	NSTEMI	what	effect	does	this	augmentation	of	NO2-	concentration	 have	 on	 other	 important	 factors	 in	 this	 cohort.	 Namely,	platelet	function	and	inflammatory	markers.		
Once	the	complex	nature	of	platelet	function	measures	in	acute	NSTEMI	patients	was	 understood	 no	 influence	 of	 a	 significant	 augmentation	 of	 serum	 nitrite	concentration	was	found	on	platelet	function	regardless	of	the	residual	(baseline)	function	 of	 these	 patients.	 The	 same	 was	 true	 in	 terms	 of	 platelet	 derived	inflammatory	and	ant-inflammatory	cytokines	when	24	hour	concentrations	were	compared	to	baseline.	
	
Limitations 
As	 with	 any	 clinical	 study	 the	 practicalities	 of	 applying	 complex	 methods	 and	protocols	in	a	clinical	situation	will	always	lead	to	some	element	of	compromise,	particularly	in	unusual	and	acute	environments	like	cardiac	catheter	labs.		
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The	first	compromise	we	chose	to	make	was	the	dose	of	sodium	nitrite	used	and	the	serum	concentrations	achieved.	We	chose	this	dose	principally	to	ensure	we	had	 maximal	 vasodilation	 effect	 with	 minimal	 systemic	 blood	 pressure	 drop	(potentially	 dangerous	 in	 patients	 with	 NSTEMI).	 Indeed,	 the	 actual	 median	concentration	achieved	was	1422	nM	(1032	to	1842),	well	above	that	reported	by	Cosby	 et	 al101	 (900nM)	 in	 which	 significant	 increases	 in	 blood	 flow	 were	demonstrated	in	healthy	human	brachial	arteries	with	exercise.		
	
The	assessment	of	CVR	in	patients	undergoing	invasive	cardiac	procedures	is	not	easy	and	requires	time,	patients	and	consistency	to	produce	a	high	standard	of	data	quality.	The	method	we	used	(IMR)	has	its	limitations,	the	principal	one	being	the	fact	that	it	is	a	dimensionless	and	thus	semi-quantitative.	To	account	for	this	we	 always	 made	 relative	 (paired)	 comparisons	 of	 the	 results	 within	 patient	groups.	Comparisons	between	different	patient	groups	(NSTEMI,	NSTEMIinf	and	stable	 angina),	 were	 always	 made	 following	 identical	 method	 in	 terms	 of	delivering	the	pressure/temperature	wire	to	the	distal	3rd	of	the	coronary	artery,	measuring	after	a	standardized	time	after	adenosine	infusion	etc.		
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